
File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\.astro


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\.astro


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\@astrojs\prism\Prism.astro
---
import { runHighlighterWithAstro } from './dist/highlighter';

interface Props {
	class?: string;
	lang?: string;
	code: string;
}

const { class: className, lang, code } = Astro.props as Props;
const { classLanguage, html } = runHighlighterWithAstro(lang, code);
---

<pre
	class={[className, classLanguage]
		.filter(Boolean)
		.join(' ')}><code class={classLanguage} set:html={html} /></pre>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\ClientRouter.astro
---
type Fallback = 'none' | 'animate' | 'swap';

export interface Props {
	fallback?: Fallback;
	/** @deprecated handleForms is enabled by default in Astro 4.0
	 *
	 * Set `data-astro-reload` on your form to opt-out of the default behavior.
	 */
	handleForms?: boolean;
}

const { fallback = 'animate' } = Astro.props;
---

<style is:global>
	/* Route announcer */
	.astro-route-announcer {
		position: absolute;
		left: 0;
		top: 0;
		clip: rect(0 0 0 0);
		clip-path: inset(50%);
		overflow: hidden;
		white-space: nowrap;
		width: 1px;
		height: 1px;
	}
</style>
<meta name="astro-view-transitions-enabled" content="true" />
<meta name="astro-view-transitions-fallback" content={fallback} />
<script>
	import type { Options } from 'astro:transitions/client';
	import { supportsViewTransitions, navigate } from 'astro:transitions/client';
	// NOTE: import from `astro/virtual-modules/prefetch.js` as `astro:prefetch` requires the `prefetch` config to be enabled
	// @ts-ignore
	import { init } from 'astro/virtual-modules/prefetch.js';

	type Fallback = 'none' | 'animate' | 'swap';

	function getFallback(): Fallback {
		const el = document.querySelector('[name="astro-view-transitions-fallback"]');
		if (el) {
			return el.getAttribute('content') as Fallback;
		}
		return 'animate';
	}

	function isReloadEl(el: HTMLElement | SVGAElement): boolean {
		return el.dataset.astroReload !== undefined;
	}

	if (supportsViewTransitions || getFallback() !== 'none') {
		if (import.meta.env.DEV && window.matchMedia('(prefers-reduced-motion)').matches) {
			console.warn(
				`[transitions]: all view transition animations, including fallback animation, are disabled as this device has the prefer-reduced-motion setting enabled.`,
			);
		}
		document.addEventListener('click', (ev) => {
			let link = ev.target;
			if (ev.composed) {
				link = ev.composedPath()[0];
			}
			if (link instanceof Element) {
				link = link.closest('a, area');
			}
			if (
				!(link instanceof HTMLAnchorElement) &&
				!(link instanceof SVGAElement) &&
				!(link instanceof HTMLAreaElement)
			)
				return;
			// This check verifies that the click is happening on an anchor
			// that is going to another page within the same origin. Basically it determines
			// same-origin navigation, but omits special key combos for new tabs, etc.
			const linkTarget = link instanceof HTMLElement ? link.target : link.target.baseVal;
			const href = link instanceof HTMLElement ? link.href : link.href.baseVal;
			const origin = new URL(href, location.href).origin;
			if (
				isReloadEl(link) ||
				link.hasAttribute('download') ||
				!link.href ||
				(linkTarget && linkTarget !== '_self') ||
				origin !== location.origin ||
				ev.button !== 0 || // left clicks only
				ev.metaKey || // new tab (mac)
				ev.ctrlKey || // new tab (windows)
				ev.altKey || // download
				ev.shiftKey || // new window
				ev.defaultPrevented
			) {
				// No page transitions in these cases,
				// Let the browser standard action handle this
				return;
			}
			ev.preventDefault();
			navigate(href, {
				history: link.dataset.astroHistory === 'replace' ? 'replace' : 'auto',
				sourceElement: link,
			});
		});

		document.addEventListener('submit', (ev) => {
			let el = ev.target as HTMLElement;
			if (el.tagName !== 'FORM' || ev.defaultPrevented || isReloadEl(el)) {
				return;
			}
			const form = el as HTMLFormElement;
			const submitter = ev.submitter;
			const formData = new FormData(form, submitter);
			// form.action and form.method can point to an <input name="action"> or <input name="method">
			// in which case should fallback to the form attribute
			const formAction =
				typeof form.action === 'string' ? form.action : form.getAttribute('action');
			const formMethod =
				typeof form.method === 'string' ? form.method : form.getAttribute('method');
			// Use the form action, if defined, otherwise fallback to current path.
			let action = submitter?.getAttribute('formaction') ?? formAction ?? location.pathname;
			// Use the form method, if defined, otherwise fallback to "get"
			const method = submitter?.getAttribute('formmethod') ?? formMethod ?? 'get';

			// the "dialog" method is a special keyword used within <dialog> elements
			// https://html.spec.whatwg.org/multipage/form-control-infrastructure.html#attr-fs-method
			if (method === 'dialog' || location.origin !== new URL(action, location.href).origin) {
				// No page transitions in these cases,
				// Let the browser standard action handle this
				return;
			}

			const options: Options = { sourceElement: submitter ?? form };
			if (method === 'get') {
				const params = new URLSearchParams(formData as any);
				const url = new URL(action);
				url.search = params.toString();
				action = url.toString();
			} else {
				options.formData = formData;
			}

			ev.preventDefault();
			navigate(action, options);
		});

		// @ts-expect-error injected by vite-plugin-transitions for treeshaking
		if (!__PREFETCH_DISABLED__) {
			init({ prefetchAll: true });
		}
	}
</script>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\Code.astro
---
import type { ThemePresets } from '@astrojs/markdown-remark';
import type {
	BuiltinLanguage,
	LanguageRegistration,
	ShikiTransformer,
	SpecialLanguage,
	ThemeRegistration,
	ThemeRegistrationRaw,
} from 'shiki';
import { bundledLanguages } from 'shiki/langs';
import { getCachedHighlighter } from '../dist/core/shiki.js';
import type { HTMLAttributes } from '../types';

interface Props extends Omit<HTMLAttributes<'pre'>, 'lang'> {
	/** The code to highlight. Required. */
	code: string;
	/**
	 * The language of your code.
	 * Supports all languages listed here: https://shiki.style/languages
	 * Instructions for loading a custom language: https://shiki.style/guide/load-lang
	 *
	 * @default "plaintext"
	 */
	lang?: BuiltinLanguage | SpecialLanguage | LanguageRegistration;
	/**
	 * A metastring to pass to the highlighter.
	 * Allows passing information to transformers: https://shiki.style/guide/transformers#meta
	 *
	 * @default undefined
	 */
	meta?: string;
	/**
	 * The styling theme.
	 * Supports all themes listed here: https://shiki.style/themes
	 * Instructions for loading a custom theme: https://shiki.style/guide/load-theme
	 *
	 * @default "github-dark"
	 */
	theme?: ThemePresets | ThemeRegistration | ThemeRegistrationRaw;
	/**
	 * Multiple themes to style with -- alternative to "theme" option.
	 * Supports all themes found above; see https://shiki.style/guide/dual-themes for more information.
	 */
	themes?: Record<string, ThemePresets | ThemeRegistration | ThemeRegistrationRaw>;
	/**
	 * Chooses a theme from the "themes" option that you've defined as the default styling theme.
	 *  - <string>: one of the keys defined in the "themes" option. Will throw an error if the key is not defined.
	 *  - false: disabled. You'll have to apply the styling theme yourself. No effect if the "themes" option is not set.
	 *
	 * See https://shiki.style/guide/dual-themes#without-default-color for more information.
	 *
	 * @default "light"
	 */
	defaultColor?: 'light' | 'dark' | string | false;
	/**
	 * Enable word wrapping.
	 *  - true: enabled.
	 *  - false: disabled.
	 *  - null: All overflow styling removed. Code will overflow the element by default.
	 *
	 * @default false
	 */
	wrap?: boolean | null;
	/**
	 * Generate inline code element only, without the pre element wrapper.
	 *
	 * @default false
	 */
	inline?: boolean;
	/**
	 * Shiki transformers to customize the generated HTML by manipulating the hast tree.
	 * Supports all transformers listed here: https://shiki.style/packages/transformers#transformers
	 * Instructions for custom transformers: https://shiki.style/guide/transformers
	 */
	transformers?: ShikiTransformer[];
}

const {
	code,
	lang = 'plaintext',
	meta,
	theme = 'github-dark',
	themes = {},
	defaultColor = 'light',
	wrap = false,
	inline = false,
	transformers = [],
	...rest
} = Astro.props;

// shiki 1.0 compat
if (typeof lang === 'object') {
	// `id` renamed to `name` (always override)
	if ((lang as any).id) {
		lang.name = (lang as any).id;
	}
	// `grammar` flattened to lang itself
	if ((lang as any).grammar) {
		Object.assign(lang, (lang as any).grammar);
	}
}

const highlighter = await getCachedHighlighter({
	langs: [
		typeof lang === 'string'
			? Object.keys(bundledLanguages).includes(lang)
				? lang
				: 'plaintext'
			: (lang as any),
	],
	theme,
	themes,
});

const html = await highlighter.codeToHtml(code, typeof lang === 'string' ? lang : lang.name, {
	defaultColor,
	wrap,
	inline,
	transformers,
	meta,
	attributes: rest as any,
});
---

<Fragment set:html={html} />


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\Debug.astro
---
import Code from './Code.astro';

const key = Object.keys(Astro.props)[0];
const value = Astro.props[key];
---

<div class="astro-debug">
	<div class="astro-debug-header">
		<h2 class="astro-debug-title">
			<span class="astro-debug-label">Debug</span>
			<span class="astro-debug-name">"{key}"</span>
		</h2>
	</div>

	<Code code={JSON.stringify(value, null, 2)} />
</div>

<style is:inline>
	.astro-debug {
		font-size: 14px;
		padding: 1rem 1.5rem;
		background: white;
		font-family:
			-apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans',
			'Helvetica Neue', sans-serif;
	}

	.astro-debug-header,
	pre.astro-code {
		margin: -1rem -1.5rem 1rem;
		padding: 0.25rem 0.75rem;
	}

	.astro-debug-header {
		background: #ff1639;
		border-radius: 4px;
		border-bottom-left-radius: 0;
		border-bottom-right-radius: 0;
	}

	.astro-debug-title {
		font-size: 1em;
		color: white;
		margin: 0.5em 0;
	}

	.astro-debug-label {
		font-weight: bold;
		text-transform: uppercase;
		margin-right: 0.75em;
	}

	pre.astro-code {
		border: 1px solid #eee;
		padding: 1rem 0.75rem;
		border-radius: 4px;
		border-top-left-radius: 0;
		border-top-right-radius: 0;
		font-size: 14px;
	}
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\Font.astro
---
import { AstroError, AstroErrorData } from '../dist/core/errors/index.js';

// TODO: remove dynamic import when fonts are stabilized
const { fontsData } = await import('virtual:astro:assets/fonts/internal').catch(() => {
	throw new AstroError(AstroErrorData.ExperimentalFontsNotEnabled);
});

interface Props {
	/** The `cssVariable` registered in your Astro configuration. */
	cssVariable: import('astro:assets').FontFamily;
	/** Whether it should output [preload links](https://web.dev/learn/performance/optimize-web-fonts#preload) or not. */
	preload?: boolean;
}

const { cssVariable, preload = false } = Astro.props;
const data = fontsData.get(cssVariable);
if (!data) {
	throw new AstroError({
		...AstroErrorData.FontFamilyNotFound,
		message: AstroErrorData.FontFamilyNotFound.message(cssVariable),
	});
}
---

{
	preload &&
		data.preloadData.map(({ url, type }) => (
			<link rel="preload" href={url} as="font" type={`font/${type}`} crossorigin />
		))
}
<style set:html={data.css}></style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\Image.astro
---
import { type LocalImageProps, type RemoteImageProps, getImage, imageConfig } from 'astro:assets';
import type { UnresolvedImageTransform } from '../dist/assets/types';
import { AstroError, AstroErrorData } from '../dist/core/errors/index.js';
import type { HTMLAttributes } from '../types';

// The TypeScript diagnostic for JSX props uses the last member of the union to suggest props, so it would be better for
// LocalImageProps to be last. Unfortunately, when we do this the error messages that remote images get are complete nonsense
// Not 100% sure how to fix this, seems to be a TypeScript issue. Unfortunate.
type Props = LocalImageProps | RemoteImageProps;

const props = Astro.props;

if (props.alt === undefined || props.alt === null) {
	throw new AstroError(AstroErrorData.ImageMissingAlt);
}

// As a convenience, allow width and height to be string with a number in them, to match HTML's native `img`.
if (typeof props.width === 'string') {
	props.width = parseInt(props.width);
}

if (typeof props.height === 'string') {
	props.height = parseInt(props.height);
}

const layout = props.layout ?? imageConfig.experimentalLayout ?? 'none';
const useResponsive = imageConfig.experimentalResponsiveImages && layout !== 'none';

if (useResponsive) {
	// Apply defaults from imageConfig if not provided
	props.layout ??= imageConfig.experimentalLayout;
	props.fit ??= imageConfig.experimentalObjectFit ?? 'cover';
	props.position ??= imageConfig.experimentalObjectPosition ?? 'center';
}

const image = await getImage(props as UnresolvedImageTransform);

const additionalAttributes: HTMLAttributes<'img'> = {};
if (image.srcSet.values.length > 0) {
	additionalAttributes.srcset = image.srcSet.attribute;
}

if (import.meta.env.DEV) {
	additionalAttributes['data-image-component'] = 'true';
}

const { class: className, ...attributes } = { ...additionalAttributes, ...image.attributes };
---

{/* Applying class outside of the spread prevents it from applying unnecessary astro-* classes */}
<img src={image.src} {...attributes} class={className} />


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\Picture.astro
---
import { type LocalImageProps, type RemoteImageProps, getImage, imageConfig } from 'astro:assets';
import * as mime from 'mrmime';
import { isESMImportedImage, resolveSrc } from '../dist/assets/utils/imageKind.js';
import { AstroError, AstroErrorData } from '../dist/core/errors/index.js';
import type {
	GetImageResult,
	ImageOutputFormat,
	UnresolvedImageTransform,
} from '../dist/types/public/index.js';
import type { HTMLAttributes } from '../types';

export type Props = (LocalImageProps | RemoteImageProps) & {
	formats?: ImageOutputFormat[];
	fallbackFormat?: ImageOutputFormat;
	pictureAttributes?: HTMLAttributes<'picture'>;
};

const defaultFormats = ['webp'] as const;
const defaultFallbackFormat = 'png' as const;

// Certain formats don't want PNG fallbacks:
// - GIF will typically want to stay as a gif, either for animation or for the lower amount of colors
// - SVGs can't be converted to raster formats in most cases
// - JPEGs compress photographs and high-noise images better than PNG in most cases
// For those, we'll use the original format as the fallback instead.
const specialFormatsFallback = ['gif', 'svg', 'jpg', 'jpeg'] as const;

const { formats = defaultFormats, pictureAttributes = {}, fallbackFormat, ...props } = Astro.props;

if (props.alt === undefined || props.alt === null) {
	throw new AstroError(AstroErrorData.ImageMissingAlt);
}

// Picture attribute inherit scoped styles from class and attributes
const scopedStyleClass = props.class?.match(/\bastro-\w{8}\b/)?.[0];
if (scopedStyleClass) {
	if (pictureAttributes.class) {
		pictureAttributes.class = `${pictureAttributes.class} ${scopedStyleClass}`;
	} else {
		pictureAttributes.class = scopedStyleClass;
	}
}

const layout = props.layout ?? imageConfig.experimentalLayout ?? 'none';
const useResponsive = imageConfig.experimentalResponsiveImages && layout !== 'none';

if (useResponsive) {
	// Apply defaults from imageConfig if not provided
	props.layout ??= imageConfig.experimentalLayout;
	props.fit ??= imageConfig.experimentalObjectFit ?? 'cover';
	props.position ??= imageConfig.experimentalObjectPosition ?? 'center';
}

for (const key in props) {
	if (key.startsWith('data-astro-cid')) {
		pictureAttributes[key] = props[key];
	}
}

const originalSrc = await resolveSrc(props.src);
const optimizedImages: GetImageResult[] = await Promise.all(
	formats.map(
		async (format) =>
			await getImage({
				...props,
				src: originalSrc,
				format: format,
				widths: props.widths,
				densities: props.densities,
			} as UnresolvedImageTransform),
	),
);

let resultFallbackFormat = fallbackFormat ?? defaultFallbackFormat;
if (
	!fallbackFormat &&
	isESMImportedImage(originalSrc) &&
	(specialFormatsFallback as ReadonlyArray<string>).includes(originalSrc.format)
) {
	resultFallbackFormat = originalSrc.format;
}

const fallbackImage = await getImage({
	...props,
	format: resultFallbackFormat,
	widths: props.widths,
	densities: props.densities,
} as UnresolvedImageTransform);

const imgAdditionalAttributes: HTMLAttributes<'img'> = {};
const sourceAdditionalAttributes: HTMLAttributes<'source'> = {};

// Propagate the `sizes` attribute to the `source` elements
if (props.sizes) {
	sourceAdditionalAttributes.sizes = props.sizes;
}

if (fallbackImage.srcSet.values.length > 0) {
	imgAdditionalAttributes.srcset = fallbackImage.srcSet.attribute;
}

if (import.meta.env.DEV) {
	imgAdditionalAttributes['data-image-component'] = 'true';
}

const { class: className, ...attributes } = {
	...imgAdditionalAttributes,
	...fallbackImage.attributes,
};
---

<picture {...pictureAttributes}>
	{
		Object.entries(optimizedImages).map(([_, image]) => {
			const srcsetAttribute =
				props.densities || (!props.densities && !props.widths && !useResponsive)
					? `${image.src}${image.srcSet.values.length > 0 ? ', ' + image.srcSet.attribute : ''}`
					: image.srcSet.attribute;
			return (
				<source
					srcset={srcsetAttribute}
					type={mime.lookup(image.options.format ?? image.src) ?? `image/${image.options.format}`}
					{...sourceAdditionalAttributes}
				/>
			);
		})
	}
	{/* Applying class outside of the spread prevents it from applying unnecessary astro-* classes */}
	<img src={fallbackImage.src} {...attributes} class={className} />
</picture>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\ResponsiveImage.astro
---
import type { LocalImageProps, RemoteImageProps } from 'astro:assets';
import Image from './Image.astro';

type Props = LocalImageProps | RemoteImageProps;

const { class: className, ...props } = Astro.props;

import './image.css';
---

{/* Applying class outside of the spread prevents it from applying unnecessary astro-* classes */}
<Image {...props} class={className} />


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\node_modules\astro\components\ResponsivePicture.astro
---
import { default as Picture, type Props as PictureProps } from './Picture.astro';

type Props = PictureProps;

const { class: className, ...props } = Astro.props;
---

{/* Applying class outside of the spread prevents it from applying unnecessary astro-* classes */}

<Picture {...props} class={className} />


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\public\scripts\menu.js
// File: public/scripts/menu.js

/**
 * Manages the state and accessibility attributes of the mobile navigation menu.
 * Handles toggling visibility, animations, closing on link clicks,
 * closing on outside clicks, and closing via the Escape key.
 * Relies on CSS classes defined in Navigation.astro for animations and visibility.
 */
document.addEventListener('DOMContentLoaded', () => {
  // Retrieve essential DOM elements for menu interaction.
  const hamburgerButton = document.getElementById('hamburger-button');
  const navLinks = document.getElementById('nav-links'); // The container for mobile navigation links.

  // Defensive check: Ensure required elements are present before proceeding.
  if (!hamburgerButton || !navLinks) {
    console.error("Error initializing menu.js: Hamburger button (#hamburger-button) or Nav links container (#nav-links) not found in the DOM.");
    return; // Stop execution if elements are missing.
  }

  /**
   * Toggles the mobile menu's visibility and updates ARIA attributes.
   * Manages CSS classes to trigger open/close animations.
   */
  function toggleMenu() {
    // Determine if the menu is currently closed (visually hidden).
    const isCurrentlyHidden = navLinks.classList.contains('hidden');

    if (isCurrentlyHidden) {
      // --- Open Menu ---
      // Remove 'hidden' to make the element part of the layout flow.
      navLinks.classList.remove('hidden');

      // Delay applying animation classes until the next frame.
      // This ensures the browser registers the element as visible *before* starting the transition, preventing animation glitches.
      requestAnimationFrame(() => {
        navLinks.classList.remove('opacity-0', '-translate-y-2'); // Remove initial hidden state classes.
        navLinks.classList.add('opacity-100', 'translate-y-0'); // Apply final visible state classes.
      });

      // Update ARIA attribute to indicate the menu is expanded.
      hamburgerButton.setAttribute('aria-expanded', 'true');

    } else {
      // --- Close Menu ---
      // Apply classes to initiate the closing animation.
      navLinks.classList.remove('opacity-100', 'translate-y-0');
      navLinks.classList.add('opacity-0', '-translate-y-2');

      // Update ARIA attribute to indicate the menu is collapsed.
      hamburgerButton.setAttribute('aria-expanded', 'false');

      // Define a function to add 'hidden' class *after* the CSS transition completes.
      const handleTransitionEnd = () => {
        // Check again if the menu should be hidden (prevents race conditions if toggled rapidly).
        if (hamburgerButton.getAttribute('aria-expanded') === 'false') {
          navLinks.classList.add('hidden'); // Add display: none equivalent.
        }
        // Clean up: Remove this listener after it executes once to prevent memory leaks.
        navLinks.removeEventListener('transitionend', handleTransitionEnd);
      };

      // Attach the event listener to wait for the transition to finish.
      navLinks.addEventListener('transitionend', handleTransitionEnd);
    }
  }

  // --- Initial State Setup ---
  // Set the initial ARIA state for the hamburger button.
  hamburgerButton.setAttribute('aria-expanded', 'false');
  // Ensure the navigation links container is hidden and styled for the start of the opening animation.
  navLinks.classList.add('hidden', 'opacity-0', '-translate-y-2');

  // --- Event Listeners ---

  // Toggle menu when the hamburger button is clicked.
  hamburgerButton.addEventListener('click', toggleMenu);

  // Add listeners to each link within the mobile menu.
  navLinks.querySelectorAll('a').forEach(link => {
    link.addEventListener('click', () => {
      // Check if the menu is currently visible.
      const isMobileMenuVisible = !navLinks.classList.contains('hidden');
      // Define the breakpoint (Tailwind 'md') to determine if in mobile view.
      const isMobileView = window.innerWidth < 768;

      // Close the menu only if it's visible and the screen is mobile-sized.
      // This prevents closing the *desktop* menu if the same link structure were used.
      if (isMobileMenuVisible && isMobileView) {
        toggleMenu(); // Execute the close menu logic.
      }
      // Default link navigation behavior is allowed to proceed.
    });
  });

  // Add listener to the document to detect clicks outside the menu.
  document.addEventListener('click', (event) => {
    // Check if the menu is currently visible.
    const isMobileMenuVisible = !navLinks.classList.contains('hidden');
    // Cache the click target for efficiency.
    const target = event.target;

    // Check if the click target is a valid node and is outside both the button and the nav links container.
    if ( isMobileMenuVisible &&
         target instanceof Node &&
         hamburgerButton && !hamburgerButton.contains(target) && // Click was not on the button or its children.
         navLinks && !navLinks.contains(target) // Click was not on the nav links container or its children.
       ) {
      toggleMenu(); // Close the menu.
    }
  });

  // Add listener for the 'Escape' key to close the menu.
  document.addEventListener('keydown', (event) => {
    // Proceed only if the pressed key is 'Escape'.
    if (event.key === 'Escape') {
      // Check if the menu is currently visible.
      const isMobileMenuVisible = !navLinks.classList.contains('hidden');
      if (isMobileMenuVisible) {
        toggleMenu(); // Close the menu.
        // Improve accessibility by returning focus to the button that opened the menu.
        hamburgerButton?.focus();
      }
    }
  });
});


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\components\Footer.astro
---
// src/components/Footer.astro
// --- Component Setup ---
const currentYear = new Date().getFullYear(); // Dynamically gets the current year for the copyright notice.
const base = import.meta.env.BASE_URL; // Retrieves the base URL configured for the Astro project.

// Defines the SVG markup for an external link icon.
// Used inline to indicate links navigating away from the current site.
const externalLinkIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="inline-block w-3 h-3 ml-0.5 align-baseline text-blue-500/80 dark:text-blue-400/80 group-hover:text-blue-600 dark:group-hover:text-blue-300 transition-colors duration-150 ease-in-out"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 0 0 3 3.5v9A1.5 1.5 0 0 0 4.5 14h9a1.5 1.5 0 0 0 1.5-1.5v-5a.75.75 0 0 0-1.5 0v5a.5.5 0 0 1-.5.5h-9a.5.5 0 0 1-.5-.5v-9a.5.5 0 0 1 .5-.5h5a.75.75 0 0 0 0-1.5h-5ZM10 .75A.75.75 0 0 1 10.75 0h4.5A.75.75 0 0 1 16 .75v4.5a.75.75 0 0 1-1.5 0V1.56l-4.97 4.97a.75.75 0 0 1-1.06-1.06L14.44 1H10.75A.75.75 0 0 1 10 .75Z" clip-rule="evenodd" /></svg>`;
---

<footer class="bg-slate-100 dark:bg-slate-800/50 border-t border-slate-200 dark:border-slate-700/50 mt-16 py-10 sm:py-12">
    <div class="container mx-auto px-4 sm:px-6 lg:px-8 max-w-4xl text-center text-slate-600 dark:text-slate-400 text-sm"> {/* Increased contrast for base footer text */}

        {/* Social Media Links Section */}
        <div class="flex justify-center space-x-6 mb-8">
            {/* Twitter Link - Points to Alzheimer's Association */}
            <a
                href="https://twitter.com/alzassociation"
                target="_blank"
                rel="noopener noreferrer"
                aria-label="Alzheimer's Association on Twitter"
                class="group rounded-full p-2.5 text-slate-500 dark:text-slate-400 transition duration-200 ease-in-out hover:text-blue-600 hover:bg-blue-100/50 dark:hover:text-blue-400 dark:hover:bg-blue-900/30 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 dark:focus-visible:ring-blue-400 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 transform hover:scale-110 active:scale-95"
            >
                <span class="sr-only">Twitter</span>
                {/* SVG Icon for Twitter */}
                <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true"><path d="M8.29 20.251c7.547 0 11.675-6.253 11.675-11.675 0-.178 0-.355-.012-.53A8.348 8.348 0 0022 5.92a8.19 8.19 0 01-2.357.646 4.118 4.118 0 001.804-2.27 8.224 8.224 0 01-2.605.996 4.107 4.107 0 00-6.993 3.743 11.65 11.65 0 01-8.457-4.287 4.106 4.106 0 001.27 5.477A4.072 4.072 0 012.8 9.713v.052a4.105 4.105 0 003.292 4.022 4.095 4.095 0 01-1.853.07 4.108 4.108 0 003.834 2.85A8.233 8.233 0 012 18.407a11.616 11.616 0 006.29 1.84"></path></svg>
            </a>
            {/* GitHub Link - Points to Developer */}
            <a
                href="https://github.com/amirthfultehrani"
                target="_blank"
                rel="noopener noreferrer"
                aria-label="CCH-MIC Project (Amir Tehrani) on GitHub"
                class="group rounded-full p-2.5 text-slate-500 dark:text-slate-400 transition duration-200 ease-in-out hover:text-slate-700 hover:bg-slate-200/50 dark:hover:text-slate-200 dark:hover:bg-slate-700/50 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 dark:focus-visible:ring-blue-400 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 transform hover:scale-110 active:scale-95"
            >
                 <span class="sr-only">GitHub</span>
                 {/* SVG Icon for GitHub */}
                <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true"><path fill-rule="evenodd" d="M12 2C6.477 2 2 6.484 2 12.017c0 4.425 2.865 8.18 6.839 9.504.5.092.682-.217.682-.483 0-.237-.008-.868-.013-1.703-2.782.605-3.369-1.343-3.369-1.343-.454-1.158-1.11-1.466-1.11-1.466-.908-.62.069-.608.069-.608 1.003.07 1.531 1.032 1.531 1.032.892 1.53 2.341 1.088 2.91.832.092-.647.35-1.088.636-1.338-2.22-.253-4.555-1.113-4.555-4.951 0-1.093.39-1.988 1.029-2.688-.103-.253-.446-1.272.098-2.65 0 0 .84-.27 2.75 1.026A9.564 9.564 0 0112 6.844c.85.004 1.705.115 2.504.337 1.909-1.296 2.747-1.026 2.747-1.026.546 1.379.201 2.397.098 2.65.64.7 1.028 1.595 1.028 2.688 0 3.848-2.339 4.695-4.566 4.943.359.309.678.92.678 1.855 0 1.338-.012 2.419-.012 2.747 0 .268.18.58.688.482A10.019 10.019 0 0022 12.017C22 6.484 17.522 2 12 2z" clip-rule="evenodd"></path></svg>
            </a>
             {/* LinkedIn Link - Points to Developer */}
             <a
                href="https://www.linkedin.com/in/amir-tehrani-331185286"
                target="_blank"
                rel="noopener noreferrer"
                aria-label="Amir Tehrani on LinkedIn"
                class="group rounded-full p-2.5 text-slate-500 dark:text-slate-400 transition duration-200 ease-in-out hover:text-blue-700 hover:bg-blue-100/50 dark:hover:text-blue-500 dark:hover:bg-blue-900/30 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 dark:focus-visible:ring-blue-400 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 transform hover:scale-110 active:scale-95"
            >
                 <span class="sr-only">LinkedIn</span>
                 {/* SVG Icon for LinkedIn */}
                <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true"><path fill-rule="evenodd" d="M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z" clip-rule="evenodd"></path></svg>
            </a>
        </div>

        {/* Copyright Notice */}
        <div class="text-sm mb-6">
             Â© {currentYear} Comprehensive Cognitive Health & Memory Information Center (CCH-MIC). {/* Corrected copyright symbol */}
        </div>

        {/* Disclaimer and Build Info Section */}
        <div class="text-xs space-y-2 text-slate-500/90 dark:text-slate-400/90"> {/* Increased contrast slightly */}
            {/* Disclaimer about the nature of the site */}
            <p class="italic max-w-md mx-auto leading-relaxed">
                Disclaimer: This website is an informational resource for GERO 414 (The Neurobiology of Aging course project at USC) and does not provide medical advice.
            </p>
             {/* Attribution for the tools used to build the site */}
            <p class="max-w-md mx-auto leading-relaxed">
                Site built with <a
                    href="https://astro.build/"
                    target="_blank"
                    rel="noopener noreferrer"
                    class="group font-medium text-current hover:text-slate-800 dark:hover:text-slate-100 underline decoration-dotted decoration-current/50 hover:decoration-current/80 dark:hover:decoration-slate-200/80 underline-offset-2 transition-colors focus:outline-none focus-visible:ring-1 focus-visible:ring-current focus-visible:ring-offset-1 dark:focus-visible:ring-offset-slate-800 rounded-sm"
                    >Astro<Fragment set:html={externalLinkIcon} /></a> & <a
                    href="https://tailwindcss.com/"
                    target="_blank"
                    rel="noopener noreferrer"
                    class="group font-medium text-current hover:text-slate-800 dark:hover:text-slate-100 underline decoration-dotted decoration-current/50 hover:decoration-current/80 dark:hover:decoration-slate-200/80 underline-offset-2 transition-colors focus:outline-none focus-visible:ring-1 focus-visible:ring-current focus-visible:ring-offset-1 dark:focus-visible:ring-offset-slate-800 rounded-sm"
                    >Tailwind CSS<Fragment set:html={externalLinkIcon} /></a>.
            </p>
        </div>

    </div>
</footer>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\components\Navigation.astro
---
// src/components/Navigation.astro
// --- Configuration & Data ---
const base = import.meta.env.BASE_URL; // Base URL from Astro config.

// Defines the structure and content for navigation links.
// Includes href, display text, and SVG icon markup for desktop view.
// Ensure these icons meet accessibility and design requirements.
const navLinks = [
  { href: `${base}/`, text: 'Home', icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="w-4 h-4"><path d="M6.75 1.5a.75.75 0 0 0-1.5 0v1.466a3.5 3.5 0 0 0-3.119 2.93l-1.075.179a.75.75 0 0 0-.624.831l.57 3.417a.75.75 0 0 0 .831.624l1.075-.179A3.5 3.5 0 0 0 6 12.533V14.5a.75.75 0 0 0 1.5 0v-1.967a3.5 3.5 0 0 0 3.119-2.93l1.075-.179a.75.75 0 0 0 .624-.831l-.57-3.417a.75.75 0 0 0-.831-.624l-1.075.179A3.5 3.5 0 0 0 10 3.034V1.5a.75.75 0 0 0-1.5 0v1.466a3.503 3.503 0 0 0-1.75 0V1.5Z" /></svg>` },
  { href: `${base}/about/`, text: 'About'},
  { href: `${base}/understanding-ad/`, text: 'Understanding AD'},
  { href: `${base}/diagnosis/`, text: 'Diagnosis'},
  { href: `${base}/treatment/`, text: 'Treatment'},
  { href: `${base}/resources/`, text: 'Resources'},
  { href: `${base}/references/`, text: 'References'},
  { href: `${base}/ai-use/`, text: 'AI Use'},
  { href: `${base}/contact/`, text: 'Contact'},
];

/**
 * Determines if a navigation link should be marked as active based on the current page path.
 * Handles trailing slashes and checks for homepage/nested paths correctly.
 * @param {string} currentPath - The pathname of the current page (e.g., Astro.url.pathname).
 * @param {string} linkHref - The href attribute of the navigation link being checked.
 * @returns {boolean} True if the link corresponds to the current page or its parent section.
 */
function isActive(currentPath: string, linkHref: string): boolean {
  // Ensure paths end with a slash for consistent comparison, avoiding partial matches.
  const normalizedCurrentPath = currentPath.endsWith('/') ? currentPath : `${currentPath}/`;
  const normalizedLinkHref = linkHref.endsWith('/') ? linkHref : `${linkHref}/`;

  // The homepage link requires an exact match with the base URL or the development index page.
  if (linkHref === `${base}/`) {
    return normalizedCurrentPath === `${base}/` || currentPath === `${base}/index.html`;
  }

  // For other pages, check if the current path *starts with* the link's path.
  // This correctly highlights parent sections when viewing child pages (e.g., '/about/' active on '/about/team/').
  return normalizedCurrentPath.startsWith(normalizedLinkHref);
}

// Gets the current page's pathname from the Astro global object.
const currentPath = Astro.url.pathname;
---

{/* Mobile Navigation Flyout Menu */}
{/* Initially hidden, visibility and animations controlled by public/scripts/menu.js */}
<div
  id="nav-links"
  aria-label="Mobile Navigation"
  class="nav-links hidden absolute top-full left-0 z-40 mt-px w-full origin-top transform flex-col space-y-1 border-t border-slate-300 bg-white p-4 shadow-lg opacity-0 transition-all duration-300 ease-in-out dark:border-slate-700 dark:bg-slate-800 md:hidden"
>
  {/* Loop through defined navigation links to generate menu items */}
  {navLinks.map(link => {
    // Determine if the current link should be marked as active.
    const active = isActive(currentPath, link.href);
    return (
      <a
        href={link.href}
        aria-current={active ? 'page' : undefined}
        class:list={[
          // Base styling for all mobile links.
          "block w-full rounded-md px-3 py-2.5 text-left text-base font-medium transition duration-150 ease-in-out",
          // Focus styling for keyboard navigation. Ring is inset for better visibility within the flyout.
          "focus:outline-none focus-visible:ring-2 focus-visible:ring-inset focus-visible:ring-blue-500 dark:focus-visible:ring-blue-400",
          // Conditional styling: Apply distinct background and text colors for the active link.
          active
            ? 'bg-blue-100 font-semibold text-blue-700 dark:bg-blue-900/50 dark:text-blue-300'
            // Default and hover styling for non-active links. Ensures good contrast.
            : 'text-slate-800 hover:bg-slate-100 hover:text-slate-900 dark:text-slate-200 dark:hover:bg-slate-700 dark:hover:text-white'
        ]}
      >
        {link.text} {/* Display the link text */}
      </a>
    );
  })}
</div>

{/* Desktop Navigation Bar */}
{/* Hidden on mobile (md:hidden), displayed as flex row on medium screens and up */}
<nav class="hidden md:flex md:items-center md:space-x-1 lg:space-x-2" aria-label="Main Navigation">
  {/* Loop through defined navigation links */}
  {navLinks.map(link => {
    // Determine if the current link should be marked as active.
    const active = isActive(currentPath, link.href);
    return (
      <a
        href={link.href}
        aria-current={active ? 'page' : undefined}
        class:list={[
          // Base styling: flex container for icon and text, padding, font size, etc.
          "group flex items-center gap-x-1.5 rounded-md px-3 py-2 text-sm font-medium transition duration-150 ease-in-out",
          // Focus styling for desktop, using offset for better visibility against the header background.
          "focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-blue-400 dark:focus-visible:ring-offset-slate-900",
          // Conditional styling for the active link on desktop.
          active
            ? 'bg-slate-200 text-blue-700 dark:bg-slate-700 dark:text-blue-300' // Adjusted active state for better contrast
            // Default and hover styling for non-active desktop links. Ensures high contrast.
            : 'text-slate-700 hover:bg-slate-100 hover:text-slate-900 dark:text-slate-300 dark:hover:bg-slate-700 dark:hover:text-white'
        ]}
      >
        {/* Desktop Icon Container */}
        {/* Icon colors change based on active state and hover, using group-hover */}
        <span class:list={[
            "transition-colors duration-150", // Smooth color transition
            // Conditional text color for the icon based on link state.
            active ? "text-blue-600 dark:text-blue-400" : "text-slate-400 group-hover:text-slate-500 dark:group-hover:text-slate-300"
        ]}>
            {/* Render the SVG icon markup defined in navLinks */}
            {link.icon ? <Fragment set:html={link.icon} /> : null}
        </span>
        {/* Display the link text */}
        <span>{link.text}</span>
      </a>
    );
  })}
</nav>

{/* Hamburger Menu Button (Mobile Only) */}
{/* Hidden on medium screens and up (md:hidden) */}
<button
  id="hamburger-button"
  type="button"
  aria-label="Toggle Menu"
  aria-controls="nav-links"
  aria-expanded="false"
  class="hamburger group relative cursor-pointer rounded-md p-2 text-slate-700 transition-colors duration-200 hover:bg-slate-100 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 dark:text-slate-300 dark:hover:bg-slate-700 dark:focus-visible:ring-blue-400 md:hidden"
>
  {/* Screen reader text provides context for the button's action. */}
  <span class="sr-only">Open main menu</span>
  {/* Container for the three lines of the hamburger icon */}
  <div class="space-y-1.5">
    {/* Top line: Animates into top part of 'X' when menu is open (aria-expanded="true") */}
    <span class="block h-0.5 w-6 transform rounded-full bg-current transition duration-300 ease-in-out group-aria-expanded:translate-y-[7px] group-aria-expanded:rotate-45" aria-hidden="true"></span>
    {/* Middle line: Fades out when menu is open */}
    <span class="block h-0.5 w-6 rounded-full bg-current transition duration-300 ease-in-out group-aria-expanded:opacity-0" aria-hidden="true"></span>
    {/* Bottom line: Animates into bottom part of 'X' when menu is open */}
    <span class="block h-0.5 w-6 transform rounded-full bg-current transition duration-300 ease-in-out group-aria-expanded:-translate-y-[7px] group-aria-expanded:-rotate-45" aria-hidden="true"></span>
  </div>
</button>

{/* CSS for Hamburger Animation controlled by aria-expanded state */}
{/* These styles directly target the spans within the button based on the button's state */}
<style>
  /* Top line animation when button has aria-expanded="true" */
  .group[aria-expanded="true"] .group-aria-expanded\:translate-y-\[7px\] {
    transform: translateY(7px) rotate(45deg); /* Move down and rotate */
  }
  /* Middle line animation when button has aria-expanded="true" */
   .group[aria-expanded="true"] .group-aria-expanded\:opacity-0 {
    opacity: 0; /* Fade out */
  }
  /* Bottom line animation when button has aria-expanded="true" */
   .group[aria-expanded="true"] .group-aria-expanded\:-translate-y-\[7px\] {
     transform: translateY(-7px) rotate(-45deg); /* Move up and rotate opposite */
  }

  /* Define the transition properties for the mobile navigation container */
  .nav-links {
      transition: opacity 0.3s ease-in-out, transform 0.3s ease-in-out;
  }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\components\ThemeIcon.astro
---
// src/components/ThemeIcon.astro
// --- Component Definition ---
// This component renders a button to toggle between light and dark color themes.
// It uses localStorage to persist the user's preference and applies a 'dark' class to the <html> element.
// Icons are conditionally displayed using CSS based on the presence of the 'dark' class.
---

{/* Theme Toggle Button */}
<button
  id="themeToggle"
  type="button"
  aria-label="Toggle light and dark theme"
  class="group rounded-full p-2 text-slate-600 transition-all duration-200 ease-in-out hover:bg-slate-100/80 hover:text-blue-600 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:text-slate-400 dark:hover:bg-slate-700/50 dark:hover:text-blue-400 dark:focus-visible:ring-blue-400 dark:focus-visible:ring-offset-slate-900 transform hover:scale-110 hover:rotate-12 active:scale-95 active:rotate-0"
>
  {/* Provides accessible text for screen readers */}
  <span class="sr-only">Toggle theme</span>

  {/* Container for the Sun/Moon icons */}
  {/* SVG uses currentColor, allowing color changes via parent text color classes */}
  <svg width="20" height="20" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor" aria-hidden="true" class="transition-transform duration-300 ease-out group-hover:rotate-[30deg]">

    {/* Sun Icon: Displayed by default (light mode) */}
    {/* Hidden when the 'dark' class is present on a parent element */}
    <path
      class="inline dark:hidden"
      d="M12 17.5a5.5 5.5 0 1 0 0-11 5.5 5.5 0 0 0 0 11zm0 1.5a7 7 0 1 0 0-14 7 7 0 0 0 0 14zm12-7a.8.8 0 0 1-.8.8h-2.4a.8.8 0 0 1 0-1.6h2.4a.8.8 0 0 1 .8.8zM4 12a.8.8 0 0 1-.8.8H.8a.8.8 0 0 1 0-1.6h2.5a.8.8 0 0 1 .8.8zm16.5-8.5a.8.8 0 0 1 0 1l-1.8 1.8a.8.8 0 0 1-1-1l1.7-1.8a.8.8 0 0 1 1 0zM6.3 17.7a.8.8 0 0 1 0 1l-1.7 1.8a.8.8 0 1 1-1-1l1.7-1.8a.8.8 0 0 1 1 0zM12 0a.8.8 0 0 1 .8.8v2.5a.8.8 0 0 1-1.6 0V.8A.8.8 0 0 1 12 0zm0 20a.8.8 0 0 1 .8.8v2.4a.8.8 0 0 1-1.6 0v-2.4a.8.8 0 0 1 .8-.8zM3.5 3.5a.8.8 0 0 1 1 0l1.8 1.8a.8.8 0 1 1-1 1L3.5 4.6a.8.8 0 0 1 0-1zm14.2 14.2a.8.8 0 0 1 1 0l1.8 1.7a.8.8 0 0 1-1 1l-1.8-1.7a.8.8 0 0 1 0-1z"
    />
    {/* Moon Icon: Hidden by default, displayed when 'dark' class is present */}
    <path
      class="hidden dark:inline"
      d="M16.5 6A10.5 10.5 0 0 1 4.7 16.4 8.5 8.5 0 1 0 16.4 4.7l.1 1.3zm-1.7-2a9 9 0 0 1 .2 2 9 9 0 0 1-11 8.8 9.4 9.4 0 0 1-.8-.3c-.4 0-.8.3-.7.7a10 10 0 0 0 .3.8 10 10 0 0 0 9.2 6 10 10 0 0 0 4-19.2 9.7 9.7 0 0 0-.9-.3c-.3-.1-.7.3-.6.7a9 9 0 0 1 .3.8z"
    />
  </svg>
</button>

{/* Inline Script for Theme Logic */}
{/* `is:inline` prevents Astro from processing/bundling; runs early in the browser. */}
{/* Script is minified for slightly better performance. */}
<script is:inline>
  // Wrapped in strict mode for potential optimizations and stricter error handling.
  "use strict";
  // Define constants for keys and class names for clarity and easier maintenance.
  const themeStorageKey="theme", darkClassName="dark", lightValue="light", darkValue="dark", htmlElement=document.documentElement;

  // Function to apply the stored or preferred theme on page load.
  function applyTheme(){
    let themeToApply = lightValue; // Default to light theme.
    try {
      // Get theme preference from localStorage.
      const storedTheme = localStorage.getItem(themeStorageKey);
      // Check system preference for dark mode.
      const prefersDark = window.matchMedia("(prefers-color-scheme: dark)").matches;

      // Determine the theme: Use stored value if set, otherwise use system preference.
      if (storedTheme === darkValue || (storedTheme === null && prefersDark)) {
        themeToApply = darkValue;
      } else {
        themeToApply = lightValue;
      }

      // Apply the determined theme class to the <html> element.
      if (themeToApply === darkValue) {
        htmlElement.classList.add(darkClassName);
      } else {
        htmlElement.classList.remove(darkClassName);
      }

      // If no theme was explicitly stored, save the detected preference.
      if (storedTheme === null) {
        localStorage.setItem(themeStorageKey, themeToApply);
      }
    } catch (error) {
      // Log errors during theme application (e.g., localStorage access denied).
      console.error("ThemeIcon script: Error in applyTheme():", error);
    }
  }

  // Apply the theme immediately on script execution.
  applyTheme();

  // Add event listener after the DOM is fully loaded to handle button clicks.
  document.addEventListener("DOMContentLoaded", () => {
    try {
      // Get the theme toggle button element.
      const toggleButton = document.getElementById("themeToggle");
      if (toggleButton) {
        // Attach click event listener to the button.
        toggleButton.addEventListener("click", () => {
          try {
            // Toggle the 'dark' class on the <html> element.
            htmlElement.classList.toggle(darkClassName);
            // Check if the 'dark' class is now present.
            const isDarkMode = htmlElement.classList.contains(darkClassName);
            // Update localStorage with the new theme preference.
            localStorage.setItem(themeStorageKey, isDarkMode ? darkValue : lightValue);
          } catch (error) {
             // Log errors during theme toggling (e.g., localStorage access denied).
            console.error("ThemeIcon script: Error in click handler:", error);
          }
        });
      } else {
        // Log an error if the button isn't found after DOM load.
        console.error("ThemeIcon script: Theme toggle button (#themeToggle) not found after DOMContentLoaded.");
      }
    } catch (error) {
      // Log errors related to the DOMContentLoaded listener setup.
      console.error("ThemeIcon script: Error in DOMContentLoaded handler:", error);
    }
  });
</script>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\layouts\BaseLayout.astro
---
import Navigation from '../components/Navigation.astro';
import Footer from '../components/Footer.astro';
import ThemeIcon from '../components/ThemeIcon.astro';
import '../styles/global.css'; // Crucial import for Tailwind styles

interface Breadcrumb {
  label: string;
  href: string;
}

interface Props {
  title: string;
  description?: string;
  breadcrumbs?: Breadcrumb[];
  schema?: {
    "@context": string;
    "@type": string;
    headline: string;
    description: string;
    author: { "@type": string; name: string };
    publisher: { "@type": string; name: string; logo: { "@type": string; url: string } };
    image: string;
  };
}

const {
  title,
  description = "Understanding the Science of Brain Aging, Alzheimer's, and Dementia. Your evidence-based resource for clarity and knowledge.",
  breadcrumbs = []
} = Astro.props;

const base = import.meta.env.BASE_URL;
const canonicalURL = new URL(Astro.url.pathname, Astro.site);
const structuredBreadcrumbs = {
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": breadcrumbs.map((crumb, index) => ({
    "@type": "ListItem",
    "position": index + 1,
    "name": crumb.label,
    "item": new URL(crumb.href, Astro.site).toString() // Use absolute URL
  }))
};
---
<!doctype html>
<html lang="en" class="scroll-smooth antialiased">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <link rel="icon" type="image/svg+xml" href={`${base}/favicon.svg`} />
  <link rel="canonical" href={canonicalURL.toString()} />
  <meta name="generator" content={Astro.generator} />
  <title>{title} | CCH-MIC</title>
  <meta name="description" content={description} />

  {/* Preconnect for potential fonts or external resources */}
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  {/* Example: Add font links here if needed */}
  {/* <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400..700&display=swap" rel="stylesheet"> */}

  {/* Open Graph */}
  <meta property="og:title" content={`${title} | CCH-MIC`} />
  <meta property="og:description" content={description} />
  <meta property="og:url" content={canonicalURL.toString()} />
  <meta property="og:type" content="website" />
  {/* Add a real OG image URL */}
  {/* <meta property="og:image" content={new URL('/assets/og-image.png', Astro.site).toString()} /> */}
  <meta property="og:site_name" content="CCH-MIC" />
  <meta property="og:locale" content="en_US" />

  {/* Twitter Card */}
  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:title" content={`${title} | CCH-MIC`} />
  <meta name="twitter:description" content={description} />
  {/* Add a real Twitter image URL */}
  {/* <meta name="twitter:image" content={new URL('/assets/twitter-image.png', Astro.site).toString()} /> */}

  {/* Structured Data for Breadcrumbs */}
  {breadcrumbs.length > 0 && (
    <script type="application/ld+json" set:html={JSON.stringify(structuredBreadcrumbs)} />
  )}

  <slot name="head" />
</head>
<body class="flex min-h-screen flex-col bg-slate-50 text-slate-800 dark:bg-slate-900 dark:text-slate-200 selection:bg-blue-200 selection:text-blue-900 dark:selection:bg-blue-800 dark:selection:text-blue-100">

  <a href="#main-content" class="skip-link absolute left-[-9999px] top-auto z-[9999] block w-px h-px overflow-hidden text-current focus:static focus:w-auto focus:h-auto focus:px-4 focus:py-2 focus:bg-white dark:focus:bg-slate-800 focus:shadow-md focus:outline-none focus:ring-2 focus:ring-blue-500 focus:ring-offset-2 dark:focus:ring-offset-slate-900 rounded-md">
    Skip to main content
  </a>

  <header class="sticky top-0 z-50 w-full border-b border-slate-200/80 bg-white/90 backdrop-blur-lg dark:border-slate-700/80 dark:bg-slate-900/90 transition-shadow duration-200 hover:shadow-sm">
    {/* Container for Nav */}
    <div class="container mx-auto flex max-w-6xl items-center justify-between px-4 py-3 sm:px-6 lg:px-8">
      {/* Site Title/Logo Link - Enhanced Focus State */}
      <a href={base} class="rounded-sm text-xl font-serif font-bold text-slate-900 transition hover:text-blue-600 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:text-white dark:hover:text-blue-400 dark:focus-visible:ring-blue-400 dark:focus-visible:ring-offset-slate-900">
        CCH-MIC
      </a>
      {/* Right side controls */}
      <div class="flex items-center gap-x-2 sm:gap-x-3">
        <ThemeIcon />
        <Navigation /> {/* Contains Hamburger + Desktop Nav */}
      </div>
    </div>
  </header>

  <main id="main-content" class="container mx-auto flex-grow px-4 py-8 sm:px-6 md:py-12 lg:px-8 max-w-4xl">
    {/* Breadcrumb Navigation - Enhanced Styling */}
    {breadcrumbs.length > 1 && ( // Only show breadcrumbs if there's more than just 'Home'
      <nav aria-label="Breadcrumb" class="mb-8 text-sm text-slate-500 dark:text-slate-400">
        <ol class="flex flex-wrap items-center gap-x-2 gap-y-1">
          {breadcrumbs.map((crumb, index) => (
            <li class="flex items-center">
              {index > 0 && (
                <svg class="mx-1 h-4 w-4 flex-shrink-0 text-slate-400 dark:text-slate-500" fill="currentColor" viewBox="0 0 20 20" aria-hidden="true">
                  <path fill-rule="evenodd" d="M7.21 14.77a.75.75 0 01.02-1.06L11.168 10 7.23 6.29a.75.75 0 111.04-1.08l4.5 4.25a.75.75 0 010 1.08l-4.5 4.25a.75.75 0 01-1.06-.02z" clip-rule="evenodd" />
                </svg>
              )}
              {index === breadcrumbs.length - 1 ? (
                <span class="font-medium text-slate-700 dark:text-slate-300" aria-current="page">{crumb.label}</span>
              ) : (
                <a
                  href={crumb.href}
                  class="rounded-sm hover:text-slate-700 hover:underline focus:text-slate-700 focus:underline focus:outline-none dark:hover:text-slate-200 dark:focus:text-slate-200 transition-colors"
                >
                  {crumb.label}
                </a>
              )}
            </li>
          ))}
        </ol>
      </nav>
    )}
    {/* Wrap slotted content in prose for default styling - adjust prose modifiers as needed */}
    <article class="prose prose-slate dark:prose-invert max-w-none
                    prose-headings:tracking-tight prose-headings:font-semibold
                    prose-a:text-blue-600 prose-a:no-underline hover:prose-a:underline dark:prose-a:text-blue-400
                    prose-strong:font-semibold
                    prose-code:before:content-none prose-code:after:content-none prose-code:rounded prose-code:font-normal prose-code:bg-slate-100 prose-code:px-1 prose-code:py-0.5 dark:prose-code:bg-slate-700/50 dark:prose-code:text-slate-300
                    lg:prose-lg xl:prose-xl
                    prose-img:rounded-lg prose-img:shadow-md prose-img:border prose-img:border-slate-200 dark:prose-img:border-slate-700
                    prose-figure:text-center prose-figcaption:text-xs prose-figcaption:italic prose-figcaption:text-slate-500 dark:prose-figcaption:text-slate-400 prose-figcaption:mt-2
                    prose-blockquote:border-l-blue-500 dark:prose-blockquote:border-blue-400 prose-blockquote:bg-blue-50/50 dark:prose-blockquote:bg-slate-800/50 prose-blockquote:py-2 prose-blockquote:px-4 prose-blockquote:rounded-r-lg prose-blockquote:not-italic prose-blockquote:shadow-sm">
        <slot />
    </article>
  </main>

  <Footer />

  <script is:inline src={`${base}/scripts/menu.js`}></script>

</body>
</html>

<style is:global>
  /* Add global styles for better readability and typography */
  body {
    font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;
    -webkit-font-smoothing: antialiased; /* Smoother fonts on WebKit */
    -moz-osx-font-smoothing: grayscale; /* Smoother fonts on Firefox */
  }
  /* Ensure sufficient contrast in dark mode for prose links */
  .dark .prose-a {
      color: var(--color-blue-400); /* Use CSS variable */
  }
  .dark .prose-a:hover {
      color: var(--color-blue-300); /* Use CSS variable */
  }
  /* Style for the skip link */
  .skip-link {
    position: absolute;
    left: -9999px;
    top: auto;
    width: 1px;
    height: 1px;
    overflow: hidden;
  }
  .skip-link:focus {
    position: static;
    width: auto;
    height: auto;
    padding: 0.5rem 1rem; /* Tailwind: px-4 py-2 */
    margin: 0.5rem; /* Add some margin */
    background-color: white;
    color: var(--color-slate-900); /* Use CSS variable */
    box-shadow: var(--shadow-md); /* Use CSS variable */
    border-radius: var(--radius-md); /* Use CSS variable */
    z-index: 50; /* Ensure it's on top */
    outline: 2px solid transparent;
    outline-offset: 2px;
    ring: 2px;
    ring-offset: 2px;
    ring-color: var(--color-blue-500); /* Use CSS variable */
  }
  .dark .skip-link:focus {
    background-color: var(--color-slate-800); /* Use CSS variable */
    color: var(--color-slate-200); /* Use CSS variable */
    ring-color: var(--color-blue-400); /* Use CSS variable */
    ring-offset-color: var(--color-slate-900); /* Use CSS variable */
  }

   /* Custom scrollbar styling (optional, subtle) - Using CSS variables */
    ::-webkit-scrollbar {
        width: 8px;
        height: 8px;
    }
    ::-webkit-scrollbar-track {
        background: var(--color-slate-100);
        border-radius: 10px;
    }
    ::-webkit-scrollbar-thumb {
        background: var(--color-slate-300);
        border-radius: 10px;
    }
    ::-webkit-scrollbar-thumb:hover {
        background: var(--color-slate-400);
    }
    .dark ::-webkit-scrollbar-track {
        background: var(--color-slate-700);
    }
    .dark ::-webkit-scrollbar-thumb {
        background: var(--color-slate-500);
    }
    .dark ::-webkit-scrollbar-thumb:hover {
        background: var(--color-slate-400);
    }
     /* Firefox scrollbar styling - Using CSS variables */
    * {
        scrollbar-width: thin;
        scrollbar-color: var(--color-slate-300) var(--color-slate-100);
    }
    .dark * {
         scrollbar-color: var(--color-slate-500) var(--color-slate-700);
    }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\about.astro
---
// src/pages/about.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "About Us & Our Approach";
const pageDescription = "Learn about the mission of CCH-MIC, the evidence-based foundation of our content, and why understanding Alzheimer's and dementia is crucial.";

// --- Data ---
// Defines breadcrumb navigation structure for this page.
const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "About", href: `${base}/about/` } // Current page.
];

// Defines SVG icons used in this page's sections.
// Includes accessibility attributes (role, aria-hidden).
const goalIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M15.312 11.424a5.5 5.5 0 0 1-9.124 0 5.5 5.5 0 0 1 9.124 0ZM10 2.5a7.5 7.5 0 1 1 0 15 7.5 7.5 0 0 1 0-15Z" clip-rule="evenodd" /></svg>`;
const sourceIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6" role="img" aria-hidden="true"><path d="M10.75 4.75a.75.75 0 0 0-1.5 0v4.5h-4.5a.75.75 0 0 0 0 1.5h4.5v4.5a.75.75 0 0 0 1.5 0v-4.5h4.5a.75.75 0 0 0 0-1.5h-4.5v-4.5Z" /></svg>`;
const whyIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M18 10a8 8 0 1 1-16 0 8 8 0 0 1 16 0ZM9 8a1 1 0 0 1 1-1h.01a1 1 0 1 1 0 2H10a1 1 0 0 1-1-1Zm.01 3a1 1 0 1 0 0 2h.002a1 1 0 1 0 0-2h-.002Z" clip-rule="evenodd" /></svg>`;

/**
 * Renders text as an inline citation using styled `<code>` tags.
 * Removes surrounding brackets/parentheses for cleaner presentation.
 * Ensures citations are visually distinct but readable.
 * @param {string} text - The citation text (e.g., "Author, Year").
 * @returns {string} HTML string for the styled citation.
 */
function renderCitation(text: string): string {
  const textString = String(text); // Ensure input is treated as a string.
  // Styling provides a subtle background, border, and padding for visual distinction.
  // Uses high-contrast text colors for light/dark modes.
  return `<code class="inline-block align-baseline text-[0.7rem] font-normal not-italic bg-slate-200/70 dark:bg-slate-700/80 text-slate-800 dark:text-slate-200 px-1.5 py-0.5 rounded-sm mx-0.5 border border-slate-300/50 dark:border-slate-600/50">${textString.replace(/[\[\]()]/g, '')}</code>`;
}
---

{/* Use BaseLayout, passing title, description, and breadcrumbs */}
<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs}>

    {/* Page Header Section */}
    <header class="mb-12 md:mb-16 text-center opacity-0 animate-fade-in [--animation-delay:100ms]">
      {/* Main page heading */}
      <h1 class="mt-0 mb-4">{pageTitle}</h1> {/* Updated: Uses BaseLayout h1 styling */}
      {/* Subtitle providing context */}
      <p class="text-lg lg:text-xl text-slate-600 dark:text-slate-400 max-w-3xl mx-auto">
        Clarifying our mission and the foundation of the information provided on this site.
      </p>
    </header>

    {/* Main Content Sections Container */}
    <div class="space-y-10 md:space-y-12">

      {/* Section 1: Our Goal */}
      <section class="group rounded-xl border border-slate-200 bg-gradient-to-br from-blue-50/90 to-indigo-50/90 p-6 md:p-8 shadow-sm transition-all duration-300 ease-in-out hover:shadow-lg dark:border-slate-700/50 dark:from-slate-800/70 dark:to-slate-800/90 hover:border-blue-300 dark:hover:border-blue-600/70 transform hover:-translate-y-1 hover:scale-[1.01] opacity-0 animate-fade-in-up [--animation-delay:200ms]">
        {/* Section Header with Icon */}
        <div class="flex items-start gap-x-4 mb-4">
            <span class="mt-1 flex-shrink-0 rounded-full bg-blue-100 dark:bg-blue-900/50 p-2.5 text-blue-600 dark:text-blue-400 transition-transform duration-300 ease-out group-hover:scale-110 group-hover:rotate-[-5deg]">
                <Fragment set:html={goalIcon} />
            </span>
            <h2 class="text-2xl font-semibold text-slate-900 dark:text-slate-100 mt-0 mb-0 transition-colors duration-300 group-hover:text-blue-800 dark:group-hover:text-blue-300">Our Goal</h2>
        </div>
        {/* Section Content */}
        <div class="pl-10 md:pl-12"> {/* Indents content relative to the icon/heading */}
            <p class="text-base leading-relaxed text-slate-700 dark:text-slate-300 max-w-prose prose-strong:font-medium prose-strong:text-slate-800 dark:prose-strong:text-slate-100"> {/* Ensure strong text contrast */}
              Functioning as an educational resource, we integrate rigorously validated scientific knowledge concerning brain aging's multifaceted natureâ€”examining specific cellular senescence pathways and detailing synaptic plasticity mechanism alterationsâ€”and active preservation of high-level cognitive faculties. Central to our objective is explaining complex biological sequencesâ€”for instance, the molecular steps of amyloidogenesis, cell-to-cell propagation characteristic of tauopathy, and sustained microglial reactivity patternsâ€”constituting the foundation of neurodegenerative disorders such as Alzheimer's disease, incorporating granular evidence derived from neurobiology (pinpointing protein-protein interactions), gerontology (charting age-related systemic physiological changes), and public health epidemiology (quantifying population-level risk factor contributions).
            </p>
        </div>
      </section>

      {/* Section 2: Information Source */}
      <section class="group rounded-xl border border-slate-200 bg-gradient-to-br from-teal-50/90 to-cyan-50/90 p-6 md:p-8 shadow-sm transition-all duration-300 ease-in-out hover:shadow-lg dark:border-slate-700/50 dark:from-slate-800/70 dark:to-slate-800/90 hover:border-teal-300 dark:hover:border-teal-600/70 transform hover:-translate-y-1 hover:scale-[1.01] opacity-0 animate-fade-in-up [--animation-delay:350ms]">
         {/* Section Header with Icon */}
         <div class="flex items-start gap-x-4 mb-4">
            <span class="mt-1 flex-shrink-0 rounded-full bg-teal-100 dark:bg-teal-900/50 p-2.5 text-teal-600 dark:text-teal-400 transition-transform duration-300 ease-out group-hover:scale-110 group-hover:rotate-[5deg]">
                <Fragment set:html={sourceIcon} />
            </span>
            <h2 class="text-2xl font-semibold text-slate-900 dark:text-slate-100 mt-0 mb-0 transition-colors duration-300 group-hover:text-teal-800 dark:group-hover:text-teal-300">Information Source</h2>
        </div>
        {/* Section Content */}
        <div class="pl-10 md:pl-12">
          <p class="text-base leading-relaxed text-slate-700 dark:text-slate-300 max-w-prose prose-strong:font-medium prose-strong:text-slate-800 dark:prose-strong:text-slate-100">
            Grounded in established scientific evidence, all content directly reflects the best of modern research and medical understanding, drawing from key review articles that synthesize wide-ranging empirical landscapes, individual research studies, and official reports from leading health organizations (like the NIA and Alzheimer's Association). The goal is to maintain a clear line between this information and direct advice. Sources are cited using <Fragment set:html={renderCitation("(Author, Year)")} /> to ensure credibility and adhere to academic attribution standards. A full list of all sources is available on the
            <a href={`${base}/references/`} target="_blank" rel="noopener noreferrer" class="font-medium text-teal-600 dark:text-teal-400 hover:text-teal-700 dark:hover:text-teal-300 underline decoration-teal-500/50 hover:decoration-teal-500 underline-offset-2 transition-all duration-200 focus:outline-none focus-visible:ring-1 focus-visible:ring-teal-500 rounded-sm">References page</a>.
          </p>
        </div>
      </section>

      {/* Section 3: Why This Matters */}
      <section class="group rounded-xl border border-slate-200 bg-gradient-to-br from-amber-50/90 to-yellow-50/90 p-6 md:p-8 shadow-sm transition-all duration-300 ease-in-out hover:shadow-lg dark:border-slate-700/50 dark:from-slate-800/70 dark:to-slate-800/90 hover:border-amber-300 dark:hover:border-amber-600/70 transform hover:-translate-y-1 hover:scale-[1.01] opacity-0 animate-fade-in-up [--animation-delay:500ms]">
         {/* Section Header with Icon */}
         <div class="flex items-start gap-x-4 mb-4">
            <span class="mt-1 flex-shrink-0 rounded-full bg-amber-100 dark:bg-amber-900/50 p-2.5 text-amber-600 dark:text-amber-400 transition-transform duration-300 ease-out group-hover:scale-110 group-hover:rotate-[-5deg]">
                <Fragment set:html={whyIcon} />
            </span>
            <h2 class="text-2xl font-semibold text-slate-900 dark:text-slate-100 mt-0 mb-0 transition-colors duration-300 group-hover:text-amber-800 dark:group-hover:text-amber-300">Why This Information Matters</h2>
        </div>
         {/* Section Content */}
         <div class="pl-10 md:pl-12">
            <p class="text-base leading-relaxed text-slate-700 dark:text-slate-300 max-w-prose prose-strong:font-medium prose-strong:text-slate-800 dark:prose-strong:text-slate-100">
              To enable a more complete understanding of the fundamental neurobiology underlying Alzheimer's Disease and Related Dementias (ADRD), one must know the specific molecular and cellular processes that drive the development and progression of these diseasesâ€”specifically, the neuropathological mechanisms involved â€” which is essential for evaluating advancements in diagnostics, potential treatments, and strategies to promote brain health effectively.
            </p>
        </div>
      </section>

    </div> {/* End Main Content Sections Container */}
</BaseLayout>

{/* Global keyframes for animations (can be in global.css or BaseLayout <style is:global>) */}
{/* Included here for component self-containment, but global definition is often cleaner */}
<style is:global>
  @keyframes fade-in {
    from { opacity: 0; }
    to { opacity: 1; }
  }
  @keyframes fade-in-up {
    from { opacity: 0; transform: translateY(20px); }
    to { opacity: 1; transform: translateY(0); }
  }
  /* Utility classes to apply the animations with optional delays */
  .animate-fade-in {
    animation: fade-in 0.6s ease-out forwards;
    /* Allows delay control via inline style or CSS custom property */
    animation-delay: var(--animation-delay, 0ms);
  }
  .animate-fade-in-up {
    animation: fade-in-up 0.6s ease-out forwards;
    /* Allows delay control via inline style or CSS custom property */
    animation-delay: var(--animation-delay, 0ms);
  }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\ai-use.astro
---
// src/pages/ai-use.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "AI Use Statement";
// SEO Description specific to this page.
const pageDescription = "Clarification on the use of Artificial Intelligence (AI) in the development of the written content for the CCH-MIC website, a GERO 414 project.";

// --- Data ---
// Defines breadcrumb navigation for this page.
const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "AI Use", href: `${base}/ai-use/` } // Current page.
];

// SVG Icon used for emphasis in the statement block.
const checkIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor" class="w-8 h-8 md:w-10 md:h-10 shrink-0 text-emerald-500 dark:text-emerald-400 transition-transform duration-300 ease-out group-hover:scale-110"><path fill-rule="evenodd" d="M2.25 12c0-5.385 4.365-9.75 9.75-9.75s9.75 4.365 9.75 9.75-4.365 9.75-9.75 9.75S2.25 17.385 2.25 12Zm13.36-1.814a.75.75 0 1 0-1.22-.872l-3.236 4.53L9.53 12.22a.75.75 0 0 0-1.06 1.06l2.25 2.25a.75.75 0 0 0 1.14-.094l3.75-5.25Z" clip-rule="evenodd" /></svg>`;
---

{/* Apply BaseLayout with page-specific title, description, and breadcrumbs */}
<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs}>

    {/* Page Header */}
    <header class="mb-10 md:mb-16 text-center">
        {/* Main page heading */}
        <h1 class="text-3xl md:text-4xl lg:text-5xl font-extrabold tracking-tight text-slate-900 dark:text-slate-100 mt-0 mb-4 transition duration-300 ease-in-out hover:text-blue-600 dark:hover:text-blue-400">
            {pageTitle}
        </h1>
        {/* Subtitle explaining the page's purpose */}
        <p class="text-lg lg:text-xl text-slate-600 dark:text-slate-400 max-w-3xl mx-auto leading-relaxed">
            Transparency regarding the role of Artificial Intelligence in the creation of this website's content.
        </p>
    </header>

    {/* Primary Statement Block */}
    <div
        class="group relative mb-12 md:mb-16 rounded-xl border border-emerald-300/50 dark:border-emerald-700/50 bg-gradient-to-br from-emerald-50/90 via-white to-emerald-50/90 p-8 md:p-12 shadow-lg dark:from-slate-800/80 dark:via-slate-800/70 dark:to-slate-900/80 overflow-hidden transition-all duration-300 ease-in-out hover:shadow-xl hover:border-emerald-400 dark:hover:border-emerald-600 hover:-translate-y-1 hover:scale-[1.01]"
    >
        {/* Optional decorative background element */}
        <div class="absolute inset-0 -z-10 opacity-[0.04] dark:opacity-[0.03]" aria-hidden="true">
             {/* Animated radial gradient for subtle background texture */}
             <div class="absolute inset-0 bg-[radial-gradient(circle_at_top_left,_theme(colors.emerald.100)_0%,_transparent_50%),radial-gradient(circle_at_bottom_right,_theme(colors.emerald.200)_0%,_transparent_50%)] dark:bg-[radial-gradient(circle_at_top_left,_theme(colors.emerald.900/40)_0%,_transparent_50%),radial-gradient(circle_at_bottom_right,_theme(colors.emerald.800/30)_0%,_transparent_50%)] opacity-60 animate-pulse duration-[5000ms]"></div>
        </div>

        {/* Blockquote containing the core statement */}
        <blockquote class="text-center relative z-10 flex flex-col items-center gap-y-5 md:gap-y-6">
            {/* Checkmark Icon */}
            <div class="transition-transform duration-300 ease-out group-hover:rotate-[-5deg]">
              <Fragment set:html={checkIcon} />
            </div>
            {/* The statement itself, styled for emphasis */}
            <p class="text-xl md:text-2xl lg:text-3xl font-semibold leading-snug text-emerald-800 dark:text-emerald-200 transition-colors duration-200 group-hover:text-emerald-600 dark:group-hover:text-emerald-100">
                "No artificial intelligence (AI) tools were used in the generation of this written content."
            </p>
        </blockquote>
    </div>

    {/* Explanatory Paragraph */}
    <div class="text-center text-base text-slate-700 dark:text-slate-300 max-w-xl mx-auto mt-8 md:mt-10 leading-relaxed">
        <p>
            This statement confirms that the text, analysis, and synthesis presented on this website were authored solely by <strong class="font-medium text-slate-800 dark:text-slate-100">human effort</strong> as part of the GERO 414 course project requirements.
        </p>
    </div>

</BaseLayout>

{/* Keyframes for optional background pulse animation */}
{/* Define globally (e.g., in global.css) if used elsewhere, or keep scoped here */}
<style is:global>
  @keyframes pulse {
    0%, 100% { opacity: 0.6; } /* Adjusted opacity for visibility */
    50% { opacity: 0.3; }
  }
  .animate-pulse {
    /* Applies the pulse animation infinitely */
    animation: pulse 5s cubic-bezier(0.4, 0, 0.6, 1) infinite;
  }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\contact.astro
---
// src/pages/contact.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "Contact Us";
// SEO Description specific to this page.
const pageDescription = "Get in touch with feedback or questions about the CCH-MIC educational project (GERO 414 at USC).";

// --- Data ---
// Defines breadcrumb navigation for this page.
const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "Contact", href: `${base}/contact/` } // Current page.
];

// Defines SVG icon markup for the email button.
const emailIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-5 h-5 transition-transform duration-200 ease-out group-hover:translate-x-0.5"><path d="M3 4a2 2 0 0 0-2 2v1.161l8.441 4.221a1.25 1.25 0 0 0 1.118 0L19 7.162V6a2 2 0 0 0-2-2H3Z" /><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 0 1-2.46 0L1 8.839V14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V8.839Z" /></svg>`;
// Defines SVG icon markup for the disclaimer blockquote.
const infoIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-5 h-5 shrink-0 text-amber-600 dark:text-amber-400 mt-0.5"><path fill-rule="evenodd" d="M18 10a8 8 0 1 1-16 0 8 8 0 0 1 16 0ZM8.94 6.94a.75.75 0 1 1-1.061-1.061 3 3 0 1 1 2.871 5.026v.345a.75.75 0 0 1-1.5 0v-.5c0-.72.57-1.172 1.081-1.287A1.5 1.5 0 1 0 8.94 6.94ZM10 15a1 1 0 1 0 0-2 1 1 0 0 0 0 2Z" clip-rule="evenodd" /></svg>`;
---

{/* Apply BaseLayout with page-specific title, description, and breadcrumbs */}
<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs}>

  {/* Page Header with animation */}
  <header class="mb-10 md:mb-12 text-center group">
    <h1 class="mt-0 mb-4 text-4xl md:text-5xl font-extrabold tracking-tight text-slate-900 dark:text-white animate-fade-in-down duration-500">Contact Us</h1>
    <p class="text-lg lg:text-xl text-slate-600 dark:text-slate-400 max-w-2xl mx-auto leading-relaxed animate-fade-in-down duration-500 delay-100">
      We welcome feedback and questions about this educational project.
    </p>
  </header>

  {/* Contact Information Section */}
  {/* Styled container with gradient, border, shadow, and hover effects */}
  <div class="mb-12 md:mb-16 rounded-2xl border border-blue-200/70 bg-gradient-to-br from-blue-50/80 via-indigo-50/50 to-white dark:from-slate-800/70 dark:via-slate-800/50 dark:to-slate-900/70 p-6 py-10 md:p-10 md:py-14 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:border-blue-300 dark:border-blue-900/50 dark:hover:border-blue-700/60 transform hover:-translate-y-1 hover:scale-[1.01] flex flex-col items-center">
    {/* Section Heading with gradient text */}
    <h2 class="text-3xl md:text-4xl font-bold mb-6 text-center mt-0 bg-clip-text text-transparent bg-gradient-to-r from-blue-600 to-indigo-600 dark:from-blue-400 dark:to-indigo-400 pb-1 animate-fade-in duration-500 delay-200">
      Get in Touch
    </h2>
    {/* Explanatory text */}
    <p class="leading-relaxed text-slate-700 dark:text-slate-300 max-w-prose mx-auto mb-8 text-center animate-fade-in duration-500 delay-300">
      For questions or feedback regarding the information presented on this website (a GERO 414 course project at USC), please reach out via email:
    </p>
    {/* Email Button Container (using <p> for centering) */}
    <p class="flex justify-center animate-fade-in duration-500 delay-400">
      {/* Email Link styled as a prominent button */}
      <a
        href="mailto:amirreza@usc.edu"
        class="group inline-flex items-center justify-center gap-x-3 rounded-full bg-gradient-to-r from-blue-600 to-indigo-600 px-8 py-4 text-lg font-semibold text-white shadow-lg ring-2 ring-blue-500/30 ring-offset-2 ring-offset-blue-50 dark:ring-offset-slate-800 transition-all duration-300 ease-out hover:from-blue-700 hover:to-indigo-700 hover:shadow-xl hover:ring-4 hover:ring-blue-400/40 hover:-translate-y-0.5 hover:scale-[1.03] focus:outline-none focus-visible:ring-4 focus-visible:ring-blue-400 dark:focus-visible:ring-blue-600 active:scale-95 active:shadow-md active:translate-y-0 transform-gpu"
      >
        {/* Email Icon container with hover animation */}
        <span class="transition-transform duration-200 ease-out group-hover:rotate-[-5deg]">
          <Fragment set:html={emailIcon} />
        </span>
        {/* Email Address */}
        <span>amirreza@usc.edu</span>
      </a>
    </p>
  </div>

    {/* Disclaimer Reminder Section */}
    {/* Styled blockquote for emphasis */}
    <blockquote class="mt-12 md:mt-16 rounded-lg border-l-4 border-amber-500 bg-amber-50 p-5 shadow-md dark:border-amber-400 dark:bg-slate-800/70 backdrop-blur-sm transition-shadow duration-300 hover:shadow-lg">
        <div class="flex items-start gap-x-4">
            {/* Info Icon */}
            <span class="mt-0.5 shrink-0">
                <Fragment set:html={infoIcon} />
            </span>
            {/* Disclaimer Content */}
            <div>
                <p class="font-semibold text-amber-900 dark:text-amber-300 mb-2">
                    Disclaimer Reminder
                </p>
                {/* Disclaimer Text - High contrast and readable */}
                <p class="text-sm italic text-amber-800/90 dark:text-slate-300/90 leading-relaxed"> {/* Increased contrast */}
                   Please remember, this website is an informational resource created by me (Amir Tehrani) as part of a university course project (specifically, a Spring 2025 course at USC titled GERO 414: The Neurobiology of Aging - taught by Dr. John Walsh and Dr. Tara Mastro). Given its student nature, it does not aim to provide medical advice or clinical services. Please always talk with qualified healthcare professionals for personal health concerns. May you be blessed!
                </p>
            </div>
        </div>
    </blockquote>
</BaseLayout>

{/* Animation Keyframes (Define globally or keep scoped) */}
<style>
  @keyframes fade-in {
    from { opacity: 0; }
    to { opacity: 1; }
  }
  @keyframes fade-in-down {
    from { opacity: 0; transform: translateY(-10px); }
    to { opacity: 1; transform: translateY(0); }
  }
  /* Animation Utility Classes */
  .animate-fade-in {
    animation: fade-in 0.5s ease-out forwards;
  }
  .animate-fade-in-down {
      animation: fade-in-down 0.5s ease-out forwards;
  }
  /* Delay Utility Classes */
  .delay-100 { animation-delay: 100ms; }
  .delay-200 { animation-delay: 200ms; }
  .delay-300 { animation-delay: 300ms; }
  .delay-400 { animation-delay: 400ms; }
  .duration-500 { animation-duration: 500ms; }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\diagnosis.astro
---
// src/pages/diagnosis.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "How Alzheimer's & Dementia Are Diagnosed";
// SEO Description specific to this page.
const pageDescription = "Explore the comprehensive, multi-step process for diagnosing Alzheimer's disease (AD) and dementia, including clinical evaluations, neuropsychological testing, biomarker analysis (CSF, PET), and neuroimaging (MRI, FDG-PET).";

// --- Data ---
// Defines breadcrumb navigation structure for this page.
const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "Diagnosis", href: `${base}/diagnosis/` } // Current page.
];

// --- Schema.org Data ---
// Basic Article schema for SEO.
const articleSchema = {
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": pageTitle,
  "description": pageDescription,
  "author": {
    "@type": "Person",
    "name": "Amir Tehrani" // TODO: Confirm author name
  },
  "publisher": {
    "@type": "Organization",
    "name": "CCH-MIC",
    "logo": {
      "@type": "ImageObject",
      "url": new URL(`${base}/favicon.svg`, Astro.site).toString()
    }
  },
  // "datePublished": "YYYY-MM-DD", // Optional: Add publication date
  // "dateModified": "YYYY-MM-DD", // Optional: Add last modified date
   "image": new URL(`${base}/assets/ad-diagnosis-flowchart.png`, Astro.site).toString() // Represents the main topic.
};

/**
 * Renders text as an inline citation using styled `<code>` tags.
 * Removes surrounding brackets/parentheses for cleaner presentation.
 * Ensures citations are visually distinct but readable with high contrast.
 * @param {string} text - The citation text (e.g., "Author, Year").
 * @returns {string} HTML string for the styled citation.
 */
function renderCitation(text: string): string {
  const textString = String(text);
  // Styling uses high contrast colors and a subtle border for distinction.
  return `<code class="inline-block align-baseline text-[0.7rem] font-normal not-italic bg-slate-200/80 dark:bg-slate-700/80 text-slate-800 dark:text-slate-200 px-1.5 py-0.5 rounded-sm mx-0.5 border border-slate-300/50 dark:border-slate-600/50">${textString.replace(/[\[\]()]/g, '')}</code>`;
}

// Defines SVG icons used as visual cues for section headings.
// Accessibility attributes ensure they are ignored by screen readers.
const clinicalIcon = `<svg class="size-6 text-blue-500 shrink-0 group-hover:scale-110 transition-transform duration-200 ease-in-out" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" role="img" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" d="M12 7.5h1.5m-1.5 3h1.5m-7.5 3h7.5m-7.5 3h7.5m3-9h3.375c.621 0 1.125.504 1.125 1.125V18a2.25 2.25 0 01-2.25 2.25M16.5 7.5V18a2.25 2.25 0 002.25 2.25M16.5 7.5V4.875c0-.621-.504-1.125-1.125-1.125H4.125C3.504 3.75 3 4.254 3 4.875V18a2.25 2.25 0 002.25 2.25h13.5M6 7.5h3v3H6v-3z" /></svg>`;
const neuropsychIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 text-green-500 shrink-0 group-hover:scale-110 transition-transform duration-200 ease-in-out" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M8.5 4.75a.75.75 0 0 0-1.5 0v2.5h-2.5a.75.75 0 0 0 0 1.5h2.5v2.5a.75.75 0 0 0 1.5 0v-2.5h2.5a.75.75 0 0 0 0-1.5h-2.5v-2.5Z" clip-rule="evenodd" /><path fill-rule="evenodd" d="M10 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16ZM3 10a7 7 0 1 1 14 0 7 7 0 0 1-14 0Z" clip-rule="evenodd" /></svg>`;
const biomarkerIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 text-violet-500 shrink-0 group-hover:scale-110 transition-transform duration-200 ease-in-out" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M2.5 4A1.5 1.5 0 0 0 1 5.5V6h18v-.5A1.5 1.5 0 0 0 17.5 4h-15ZM1 7.5v7A1.5 1.5 0 0 0 2.5 16h15a1.5 1.5 0 0 0 1.5-1.5v-7H1ZM8.75 9.75a.75.75 0 0 0-1.5 0v2a.75.75 0 0 0 1.5 0v-2Zm3 0a.75.75 0 0 0-1.5 0v2a.75.75 0 0 0 1.5 0v-2Z" clip-rule="evenodd" /></svg>`;
const imagingIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 text-teal-500 shrink-0 group-hover:scale-110 transition-transform duration-200 ease-in-out" role="img" aria-hidden="true"><path d="M11.09 6.994a7.5 7.5 0 0 1 6.913 7.006l.046.016a.75.75 0 0 1 .088 1.492l-.088.006h-.046a7.5 7.5 0 0 1-6.913-7.006l-.046-.016a.75.75 0 0 1-.088-1.492l.088-.006ZM12.91 8.8a5.5 5.5 0 0 0-4.697 4.697l.035-.01a.75.75 0 0 1 .966.412l-.01.035a5.5 5.5 0 0 0 4.697-4.697l-.035.01a.75.75 0 0 1-.966-.412l.01-.035Z" /><path fill-rule="evenodd" d="M8 4a4 4 0 1 0 0 8 4 4 0 0 0 0-8Zm-6 4a6 6 0 1 1 12 0A6 6 0 0 1 2 8Z" clip-rule="evenodd" /></svg>`;
---

{/* Apply BaseLayout with page-specific title, description, breadcrumbs, and schema */}
<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs} schema={articleSchema}>
    {/* Page Header */}
    <header class="mb-10 md:mb-12">
      <h1 class="text-3xl md:text-4xl lg:text-5xl font-bold tracking-tight text-slate-900 dark:text-white mt-0 mb-4 text-center">{pageTitle}</h1>
      <p class="text-lg lg:text-xl text-center text-slate-700 dark:text-slate-300 leading-relaxed max-w-3xl mx-auto"> {/* Increased contrast */}
          Diagnosing <strong class="font-semibold text-slate-800 dark:text-slate-100">Alzheimer's Disease (AD)</strong>â€”a specific, progressive neurodegenerative disorder primarily compromising memory, thinking, and behaviorâ€”constitutes a complex, iterative process; indeed, it cannot be definitively ascertained through any single, isolated test. Instead, diagnosis relies upon a comprehensive, multi-step evaluation meticulously conducted by qualified medical professionals. Typically commencing when an individual, or often their concerned family members, first notices potentially worrisome cognitive or behavioral alterations, the diagnostic journey unfolds. Core purpose of evaluation is twofold: first, systematically gathering converging lines of evidence that either support or refute AD as the specific underlying etiology; second, meticulously excluding other potential medical, neurological, or psychiatric conditions capable of mimicking the clinical symptoms of AD. Adhering to established diagnostic frameworks, themselves developed through extensive clinical research and expert consensus, a structured approach guides evaluation <Fragment set:html={renderCitation("McKhann et al., 2011; Jack et al., 2018")} />. Critically important remains distinguishing AD, the specific disease process, from <strong class="font-semibold text-slate-800 dark:text-slate-100">dementia</strong>â€”the broader, syndromic term describing a decline in cognitive function sufficiently severe to interfere demonstrably with independent daily living. AD represents the most common single cause of dementia, yet numerous other distinct diseases can also precipitate the clinical syndrome.
      </p>
    </header>

    {/* Image: AD Diagnosis Flowchart */}
    <figure class="my-12 md:my-16 group text-center transition-all duration-300 ease-in-out hover:scale-[1.01]">
      <img
        src={`${base}/assets/ad-diagnosis-flowchart.png`}
        alt="Flowchart detailing the 4-step clinical pathway for Alzheimer's Disease assessment and diagnosis, progressing from Detection, Assess/Differentiate, Diagnose (Etiology), to Treat/Manage."
        class="mx-auto block max-w-full rounded-lg border border-slate-200 shadow-lg transition duration-300 ease-in-out group-hover:shadow-xl dark:border-slate-700 md:max-w-xl lg:max-w-2xl group-hover:border-slate-300 dark:group-hover:border-slate-600"
        loading="lazy" width="800" height="600"
      />
      <figcaption class="mt-4 text-xs italic text-slate-500 dark:text-slate-400 transition group-hover:text-slate-600 dark:group-hover:text-slate-300 px-4 max-w-xl mx-auto">
        <strong class="font-semibold not-italic">Fig. 1:</strong> A visual representation of the structured, multi-step clinical pathway used for the assessment and diagnosis of Alzheimer's Disease, highlighting the progression from initial detection to specialized testing and management.
      </figcaption>
    </figure>

    {/* Section: Explaining the Diagnostic Pathway (using details/summary for accordion) */}
    <section class="p-6 md:p-8 rounded-xl bg-white dark:bg-slate-800/50 border border-slate-200 dark:border-slate-700/50 shadow-md hover:shadow-lg transition-shadow duration-300 ease-in-out mb-12 md:mb-16">
        <h2 class="mb-6 text-2xl md:text-3xl font-semibold text-slate-900 dark:text-slate-100 mt-0">Deconstructing the Diagnostic Pathway (Figure 1)</h2>
        <p class="mb-6 text-slate-700 dark:text-slate-300 max-w-prose text-base leading-relaxed"> {/* Increased contrast */}
            Figure 1 visually delineates the typical, systematic progression employed for evaluating an individual presenting with suspected cognitive impairment. Representing a structured process conventionally divided into four core, sequential steps, it often involves escalating levels of medical specialization:
        </p>
        {/* Container for accordion items */}
        <div class="space-y-4"> {/* Reduced spacing between details elements */}
            {/* Step 1 Details */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out"> {/* Subtle open state ring */}
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    {/* Chevron icon rotates when details element is open */}
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Step 1: Detect
                </summary>
                {/* Content revealed when details element is open */}
                <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3"> {/* Increased contrast */}
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Purpose:</strong> Focusing on identifying potential cognitive issues and gathering crucial baseline information, the initial phase often occurs within primary care settings. Frequently occurring within primary care settings, this step is foundational.
                    </p>
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Who:</strong> Typically initiated by non-specialist clinicians, such as Primary Care Physicians (PCPs) or general practitionersâ€”often prompted by expressed concerns from the patient themselves or, more commonly, from observant family members.
                    </p>
                    <p class="max-w-prose leading-relaxed"><strong class="font-medium text-slate-800 dark:text-slate-100">Components (as depicted in Fig. 1):</strong></p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed mt-2"> {/* Slightly more space */}
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Patient History:</strong> Involving compilation of a detailed medical history, documentation of any family history pertinent to dementia, obtaining a precise description of presenting symptoms (including onset characteristics, specific nature, and observed progression), conducting a thorough medication review (prescription, over-the-counter, supplements), and assessing relevant lifestyle factors (dietary habits, physical activity levels, smoking history, alcohol consumption)â€”all crucial for establishing clinical context.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Caregiver Perspective:</strong> Incorporating input from a close family member or trusted friend possessing intimate knowledge of the patient's baseline functioning is vital, as individuals experiencing cognitive impairment may exhibit limited insight into their own deficits (a phenomenon termed anosognosia).</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Basic Examinations:</strong> Performing standard physical and neurological examinations serves to identify potential signs of other underlying medical conditions (e.g., evidence suggesting prior stroke, Parkinsonian features, thyroid abnormalities).</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Blood Tests:</strong> Utilizing laboratory screening tests helps rule out potentially reversible causes contributing to cognitive symptoms (e.g., Vitamin B12 deficiency, thyroid dysfunction assessed via TSH levels, significant electrolyte imbalances, systemic infections indicated by a full blood count).</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Genotyping (Optional):</strong> Testing for specific genetic markers like the APOE ÃŽÂµ4 allele, significantly increasing AD risk but not definitively confirming the disease, may be considered; however, its routine application in clinical diagnosis remains debated and highly context-dependent.</li>
                    </ul>
                </div>
            </details>
            {/* Step 2 Details */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Step 2: Assess/Differentiate
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Purpose:</strong> Aiming to objectively quantify cognitive function across various domains, rigorously assess the functional impact of any deficits on daily life, evaluate behavioral and psychological symptoms, and begin excluding structural brain abnormalities or other specific types of dementia, this step is crucial. Referral to specialists often occurs if initial screening raises significant concernsâ€”the "Optimal referral window" highlights the timeframe when specialist input yields maximum diagnostic benefit.
                    </p>
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Who:</strong> Involving contributions from both non-specialists and, increasingly, referrals to specialists such as neurologists, geriatricians, neuropsychologists, or dedicated memory clinics, this phase requires collaboration.
                    </p>
                    <p class="max-w-prose leading-relaxed"><strong class="font-medium text-slate-800 dark:text-slate-100">Components (as depicted in Fig. 1):</strong></p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed mt-2">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Cognitive Assessments:</strong> Employing standardized cognitive screening instruments (e.g., the Mini-Mental State Examination [MMSE], Montreal Cognitive Assessment [MoCA], Mini-Cog) provides objective performance scores but necessitates more in-depth testing for definitive diagnosis; alternative tools like the AD8 or Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) rely specifically on reports from knowledgeable informants.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Functional Assessments:</strong> Utilizing structured questionnaires (e.g., Amsterdam Instrumental Activities of Daily Living Questionnaire [A-IADL-Q], Functional Assessment Staging Tool [FAST], Functional Activities Questionnaire [FAQ]) systematically assesses the individual's ability to perform essential daily tasks (such as managing finances accurately, taking medications correctly, driving safely, bathing independently, dressing appropriately). Helping determine the overall severity of impairment (distinguishing Mild Cognitive Impairment [MCI] from dementia), critical assessment is key.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Behavioral Assessments:</strong> Employing screening tools like the Geriatric Depression Scale (GDS) or the Neuropsychiatric Inventory Questionnaire (NPI-Q) serves to identify the presence and severity of depression, anxiety, apathy, agitation, or psychotic symptomsâ€”conditions which can frequently accompany dementia or, in some cases, mimic its presentation.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Structural Imaging:</strong> Typically, Magnetic Resonance Imaging (MRI) is the preferred modality owing to its superior detailed visualization of brain structure. Clinicians examine MRI scans for specific patterns of regional atrophy (such as characteristic hippocampal shrinkage often seen in AD) or for evidence of other relevant pathologies (e.g., infarcts indicative of stroke, space-occupying tumors). Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)â€”an imaging technique measuring regional brain metabolismâ€”may be utilized if MRI is inconclusive or contraindicated, searching for characteristic patterns of reduced metabolic activity suggestive of specific dementia types.</li>
                    </ul>
                </div>
            </details>
            {/* Step 3 Details */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                         <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Step 3: Diagnose (Etiology)
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Purpose:</strong> Focusing specifically on confirming the underlying biological cause (the specific etiology) responsible for the observed cognitive impairment, this advanced step primarily seeks direct in vivo evidence of core AD pathology (namely, the presence of amyloid plaques and tau tangles).
                    </p>
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Who:</strong> Primarily undertaken by specialists operating within dedicated memory clinics or specialized academic centers possessing access to advanced biomarker testing capabilities.
                    </p>
                    <p class="max-w-prose leading-relaxed"><strong class="font-medium text-slate-800 dark:text-slate-100">Components (as depicted in Fig. 1):</strong></p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed mt-2">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Access to Biomarkers:</strong> Relying upon specific diagnostic tests capable of directly measuring the key proteins implicated in AD pathophysiology, this crucial step is vital.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Amyloid PET:</strong> Involving a specialized brain scan utilizing a radioactive tracer meticulously designed to bind specifically to amyloid plaques, Amyloid PET thereby visualizes their presence, density, and distribution within the living brain.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Cerebrospinal Fluid (CSF) Analysis:</strong> CSF, obtained via a lumbar puncture (spinal tap) procedure, allows for the direct measurement of specific protein concentrations: Amyloid-beta 42 (AÃŽÂ²42 â€“ levels are typically *low* in the CSF of AD patients, reflecting its sequestration within brain plaques), phospho-Tau (p-tau â€“ levels are typically *high*, indicating active tangle formation within neurons), and total-Tau (t-tau â€“ levels are typically *high*, reflecting the overall degree of neuronal injury or death). Increasingly, the calculated ratio of AÃŽÂ²42 to AÃŽÂ²40 provides enhanced diagnostic accuracy.</li>
                    </ul>
                </div>
            </details>
            {/* Step 4 Details */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                         <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Step 4: Treat / Patient Management
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Purpose:</strong> Once a definitive diagnosis (or a highly probable diagnosis) is established, clinical focus necessarily shifts towards comprehensively managing symptoms, providing essential support to both the patient and their caregivers, and proactively planning for future care needs.
                    </p>
                    <p class="max-w-prose leading-relaxed">
                        <strong class="font-medium text-slate-800 dark:text-slate-100">Who:</strong> Typically coordinated collaboratively by specialists and the primary care team, this ongoing process always involves active participation from the patient (to the extent possible) and their family.
                    </p>
                    <p class="max-w-prose leading-relaxed"><strong class="font-medium text-slate-800 dark:text-slate-100">Components (as depicted in Fig. 1):</strong></p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed mt-2">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Symptomatic Treatments:</strong> Prescribing medications such as Acetylcholinesterase (ACh) inhibitors (e.g., donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine) can offer temporary assistance in managing cognitive and behavioral symptoms for some individuals, although these agents do not fundamentally alter the underlying disease progression. Newer disease-modifying therapies specifically targeting amyloid pathology may also be considered for eligible patients in specific, early stages of the disease.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Lifestyle Changes:</strong> Providing tailored recommendations often includes promoting regular physical exercise, encouraging cognitive engagement activities, fostering continued social activity, and advocating for adherence to a healthy dietary pattern (such as the Mediterranean diet) to support overall brain health resilience.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Social Work Support:</strong> Actively connecting patients and their families with vital community resources constitutes a key component: facilitating access to support groups, providing counseling services, and assisting with complex long-term care planning.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Clinical Trial Registries:</strong> Discussing potential opportunities for patients to participate in ongoing research studies investigating novel potential treatments offers hope and contributes to future advancements.</li>
                    </ul>
                </div>
            </details>
        </div>
    </section>
    {/* == End Fig 1 Explanation == */}

    {/* Container for remaining content sections */}
    <div class="space-y-12 md:space-y-16 lg:space-y-20 mt-12 md:mt-16">

      {/* == Section: Clinical Evaluation == */}
      {/* This section details the initial assessment steps. */}
      <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-white to-slate-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-slate-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-0.5">
          {/* Section Heading with Icon */}
          <h2 class="text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white mb-6 mt-0 flex items-start gap-x-3">
            <span class="mt-1 shrink-0 text-blue-500 group-hover:scale-110 transition-transform duration-200 ease-in-out"><Fragment set:html={clinicalIcon} /></span>
             Clinical Evaluation (The Initial Assessment)
          </h2>
          {/* Introduction to Clinical Evaluation */}
          <p class="mb-6 text-slate-700 dark:text-slate-300 max-w-prose text-base leading-relaxed">
             Performed first by a medical doctor (often initially a PCP, potentially followed by consultation with a neurologist or geriatrician) within a standard clinical setting like an office or hospital, this foundational step entails a thorough, systematic investigation. Its purpose is twofold: first, comprehensively understanding the precise nature of the patient's presenting problem, and second, systematically eliminating other potential non-AD causes that could account for the observed symptoms. Effectively establishing the essential groundwork for any subsequent, more specialized testing that may prove necessary, initial evaluation is key.
          </p>
           {/* Accordion for subsections within Clinical Evaluation */}
          <div class="space-y-4"> {/* Reduced spacing */}
              {/* Medical & Cognitive History */}
              <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Medical & Cognitive History
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Physician conducts meticulous, detailed interviews involving both the patient experiencing symptoms andâ€”criticallyâ€”a reliable informant. An informant is typically a spouse, an adult child, a close relative, or a long-standing friend who knows the patient intimately and can provide an objective, longitudinal perspective on observed changes over time. Proving vital because individuals with AD frequently develop anosognosia (a neurological condition characterized by a lack of awareness or insight into their own cognitive deficits), dual-source input is crucial.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Mechanism:</strong> Primary goal is to construct a comprehensive timeline and detailed characterization of the presenting symptoms. Clinician systematically probes for specific information:</p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Symptom Onset and Progression:</strong> Precisely when did the changes first become noticeable (was the onset sudden or gradual)? How have the symptoms evolved over time (slowly worsening, fluctuating significantly, or exhibiting a stepwise decline)? AD typically manifests with an insidious onset and a gradual, progressive worsening; conversely, sudden changes might suggest a vascular event (stroke) or delirium.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Specific Cognitive Difficulties:</strong> What exact cognitive problems are being observed? Is there prominent difficulty remembering recent conversations or events (indicative of episodic memory impairmentâ€”often the earliest and most salient sign in typical AD)? Is there noticeable trouble finding the right words during conversation (anomia)? Are there challenges with planning complex activities or solving novel problems (executive dysfunction)? Is the individual getting lost in previously familiar places (suggesting visuospatial difficulties)?</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Behavioral/Personality Changes:</strong> Have any new behavioral patterns emerged, such as apathy (a significant loss of interest or motivation), symptoms of depression or anxiety, increased irritability or agitation, presence of delusions (fixed, false beliefs), or noticeable alterations in social conduct or etiquette?</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Functional Impact:</strong> How are these observed cognitive and behavioral changes concretely affecting the individual's ability to manage their daily life independently (explored further under Functional Assessment)?</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Medical History:</strong> A thorough review includes past significant illnesses, prior surgeries, history of head injuries, documented strokes, presence of chronic conditions like diabetes, hypertension, heart disease, obstructive sleep apnea, or pre-existing psychiatric conditions.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Medications:</strong> A comprehensive review encompasses all current prescription medications, regularly used over-the-counter drugs, and any dietary supplementsâ€”as certain pharmacological agents can induce cognitive side effects that mimic dementia symptoms.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Family History:</strong> Inquiring about the presence of dementia or other neurodegenerative diseases among first-degree relatives (parents, siblings).</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Lifestyle:</strong> Gathering information on the individual's highest level of educational attainment, occupational history, current and past alcohol or substance use patterns, typical dietary habits, and baseline level of physical activity.</li>
                    </ul>
                    <p class="max-w-prose leading-relaxed">Yielding critical diagnostic clues, the detailed narrative helps: for instance, a primary complaint centered on memory loss gradually worsening over several years strongly suggests underlying AD pathology. In contrast, prominent personality changes emerging early in the clinical course might point towards frontotemporal dementia (FTD), while the early appearance of well-formed visual hallucinations could suggest Dementia with Lewy Bodies (DLB) <Fragment set:html={renderCitation("Arvanitakis et al., 2019")} />.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1"> {/* Adjusted contrast */}
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Suggestive of AD):</strong> A 72-year-old patient self-reports only "minor forgetfulness"â€”yet their spouse provides detailed accounts of increasingly frequent repetitive questioning, consistent forgetting of scheduled appointments, and recent difficulties managing household finances, all emerging gradually over the preceding two years. Family history is positive for late-onset AD in a parent.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Suggestive of Vascular Issues):</strong> A 68-year-old individual with a known history of chronic hypertension and type 2 diabetes reports experiencing a distinct stepwise decline in cognitive function; noticeable deteriorations occurred immediately following two minor strokes previously confirmed by brain imaging.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Suggestive of FTD):</strong> Family of a 55-year-old patient reports observing significant alterations in personality (manifesting as increased impulsivity and socially inappropriate behavior) coupled with profound apathy, beginning approximately 18 months priorâ€”with memory function noted as relatively preserved during the initial stages.</li>
                    </ul>
                </div>
              </details>

              {/* Neurological & Physical Examination */}
               <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                     Neurological & Physical Examination
                 </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Constituting a standard, hands-on medical assessment performed directly by the examining physician, this evaluation is routine. <strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose:</strong> To identify any objective physical signs indicative of other neurological conditions or systemic illnesses potentially causing or significantly contributing to presenting cognitive symptoms. Notably, ADâ€”particularly in its early and middle stagesâ€”often presents with a remarkably normal neurological examination; consequently, *absence* of specific abnormal findings can itself be diagnostically significant, increasing suspicion for AD.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism & What's Checked:</strong></p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Cranial Nerves:</strong> Systematically testing functions mediated by the twelve cranial nerves, including vision (visual acuity, visual fields), eye movements, facial sensation, and facial muscle strength; abnormalities detected here could indicate stroke or other focal neurological lesions.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Motor System:</strong> Carefully assessing muscle strength throughout the limbs, evaluating muscle tone (for spasticity or rigidity), and checking for the presence of involuntary movements such as tremor (especially resting tremor), rigidity (increased resistance to passive movement), or bradykinesia (slowness of movement)â€”features characteristic of Parkinson's disease or related Parkinsonian syndromes.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Reflexes:</strong> Testing deep tendon reflexes (e.g., eliciting the knee-jerk reflex); significant asymmetry in reflexes might suggest a prior stroke affecting one side of the body.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Sensation:</strong> Evaluating the patient's response to various sensory stimuli, including light touch, pinprick (pain sensation), and vibration sense; deficits identified could indicate peripheral neuropathy (a common complication of diabetes or Vitamin B12 deficiency) or potentially spinal cord pathology.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Coordination & Cerebellar Function:</strong> Assessing performance on specific tasks like the finger-to-nose test or rapid alternating hand movements; impaired coordination (ataxia) might suggest underlying cerebellar disorders or stroke affecting cerebellar pathways.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Gait & Balance:</strong> Observing carefully how the patient walks (gait pattern) and maintains their balance while standing. A shuffling gait is often seen in Parkinsonism; an unsteady or wide-based gait could result from various causes, including normal pressure hydrocephalus (NPH) or significant cerebrovascular disease.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">General Physical Exam:</strong> Auscultating the heart and lungs, measuring blood pressure, visually inspecting for signs suggestive of thyroid disease (e.g., goiter, eye changes), liver disease (e.g., jaundice), or other relevant systemic problems.</li>
                    </ul>
                    <p class="max-w-prose leading-relaxed">Detecting specific abnormalities helps differentiate potential causes; for example, identifying unilateral weakness strongly points towards a stroke etiology, whereas observing resting tremor and muscle rigidity suggests Parkinson's disease (which can itself be associated with dementia) <Fragment set:html={renderCitation("Arvanitakis et al., 2019")} />. Conversely, finding entirely normal results on both neurological and physical exams increases clinical suspicion for a primary degenerative dementia process, such as AD.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Normal Exam):</strong> A patient presenting primarily with memory complaints undergoes examination and exhibits a completely normal neurological and physical assessmentâ€”making AD a more probable underlying cause relative to other conditions.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Suggests Parkinsonism):</strong> Examination reveals a mild resting tremor predominantly in the right hand, slight cogwheel rigidity detected in the limbs, and observable slowness in initiating movementsâ€”raising suspicion for Parkinson's disease dementia or potentially Dementia with Lewy Bodies.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Suggests Vascular Component):</strong> Patient demonstrates a slightly slowed gait pattern, exhibits brisk deep tendon reflexes on the left side compared to the right, and has documented poorly controlled hypertensionâ€”suggesting a possible contribution from underlying vascular brain injury to their cognitive symptoms.</li>
                    </ul>
                </div>
               </details>

              {/* Cognitive Screening */}
              <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Cognitive Screening
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Brief, standardized assessment tools, cognitive screenings are administered typically by the physician or other trained clinical staff (such as a nurse or medical assistant). Widely used examples include the <strong class="font-medium text-slate-800 dark:text-slate-100">Mini-Mental State Examination (MMSE)</strong> and the <strong class="font-medium text-slate-800 dark:text-slate-100">Montreal Cognitive Assessment (MoCA)</strong>; administration generally requires only 10â€“15 minutes.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose:</strong> To provide a rapid, objective snapshot of cognitive performance across several key domains (e.g., orientation to time and place, immediate and delayed memory recall, attention span, language functions like naming and repetition, visuospatial construction skills). Primarily serving to help identify the likely presence of cognitive impairment, tools establish a quantitative baseline score useful for tracking subsequent changes over time.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> Patients are asked to perform a series of simple cognitive tasks: recalling a short list of unrelated words after a brief delay; drawing the face of a clock and setting the hands to a specific time; naming as many animals as possible within one minute; accurately copying a complex geometric figure; and correctly answering basic orientation questions (e.g., current date, day of the week, location). Performance on each item is scored, and scores are summed to yield a total score (e.g., out of a possible 30 points for both MMSE and MoCA).</p>
                    <p class="max-w-prose leading-relaxed">Crucially, emphasizing that cognitive screenings are *screening* instrumentsâ€”not definitive diagnostic tests in isolationâ€”is vital. A low score strongly indicates the presence of cognitive impairment and clearly warrants further, more detailed investigation, but it does not specify the underlying cause. Conversely, achieving a score within the normal range does not definitively rule out early or subtle cognitive decline, particularly in individuals with high baseline educational or occupational attainment (sometimes referred to as high cognitive reserve) <Fragment set:html={renderCitation("Arevalo-Rodriguez et al., 2015; Arvanitakis et al., 2019")} />. However, specific patterns of performance on screening tests can sometimes offer diagnostic clues (e.g., disproportionately severe deficits in delayed recall are highly characteristic of early-stage AD).</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Impairment Detected):</strong> A patient achieves a score of 21 out of 30 on the MoCA, losing points primarily on the delayed word recall task and sentence repetitionâ€”a pattern consistent with potential AD-related cognitive deficits.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Normal Screen, Still Concerned):</strong> A retired engineer scores 27 out of 30 on the MMSE (a score typically considered within the normal range), yet their family adamantly insists on observing significant recent decline in their complex planning and organizational abilities. Discrepancy warrants more sensitive, comprehensive testing (i.e., formal neuropsychological evaluation).</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Specific Deficit Pattern):</strong> A patient scores 24 out of 30 on the MoCA but demonstrates considerable difficulty with the clock drawing task and accurately copying the cube (visuospatial tasks)â€”suggesting a greater contribution from underlying vascular disease or potentially Lewy Body Dementia rather than typical amnestic AD.</li>
                    </ul>
                </div>
              </details>

              {/* Functional Assessment */}
              <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-blue-300 open:dark:ring-blue-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                    <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                         <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Functional Assessment
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Systematically evaluating how identified cognitive changes concretely impact the individual's ability to function independently and effectively in their everyday life activities, this component is essential. Relying heavily on information gathered from both the patient themselves andâ€”often more reliably, especially as the disease progressesâ€”from a knowledgeable informant, assessment is comprehensive.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose:</strong> To determine whether observed cognitive impairment has reached a level of severity sufficient to interfere significantly with the performance of daily activities. Representing the defining characteristic that distinguishes dementia from milder forms of cognitive impairment, functional impairment is key. If objective cognitive impairment is detected but does not yet substantially impact independent daily functioning, the appropriate diagnosis might be Mild Cognitive Impairment (MCI): a recognized transitional stage often preceding dementia development.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> Clinician poses specific, detailed questions regarding the patient's current ability to perform two categories of daily tasks:</p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Activities of Daily Living (ADLs):</strong> Encompassing basic self-care tasks essential for personal maintenance, ADLs include bathing or showering independently, dressing oneself appropriately for the weather, grooming (e.g., brushing teeth, combing hair), feeding oneself, managing toileting needs, and transferring safely (e.g., moving from a bed to a chair). Difficulty performing ADLs typically emerges during moderate to severe stages of AD progression.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Instrumental Activities of Daily Living (IADLs):</strong> Representing more complex tasks that necessitate higher-level cognitive functions for successful execution, IADLs are critical indicators. Examples include managing personal finances accurately (e.g., paying bills on time, balancing a checkbook), managing medications correctly (e.g., remembering doses and times), shopping independently for groceries or necessities, preparing complete meals safely, using the telephone or other communication technologies effectively, performing basic housekeeping tasks, arranging transportation (either driving oneself or utilizing public transit), and independently managing scheduled appointments. Difficulty with IADLs often becomes apparent earlier in the course of ADâ€”frequently serving as one of the first functional declines noticed by concerned family members <Fragment set:html={renderCitation("Galvin et al., 2006")} />. Standardized questionnaires, such as the Functional Activities Questionnaire (FAQ) or specific IADL rating scales, may be employed to structure the assessment.</li>
                    </ul>
                    <p class="max-w-prose leading-relaxed">Documented presence and quantifiable severity of functional impairment are critical factors for accurately staging the disease process and developing an appropriate, individualized care plan.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (MCI):</strong> A patient demonstrates objective deficits on cognitive screening (e.g., MoCA score of 24/30), but their informant confirms continued management of all personal finances, driving without incident, and handling all household tasks independentlyâ€”suggesting a diagnosis of Mild Cognitive Impairment (MCI).</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Mild Dementia):</strong> A patient performs reasonably well on most basic ADLs, but their informant reports recent concerning incidents, such as bouncing checks, forgetting to pay important bills (necessitating spouse taking over financial management), and recently getting lost while driving in a previously familiar neighborhoodâ€”indicating significant IADL impairment consistent with a diagnosis of mild dementia.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Moderate/Severe Dementia):</strong> Informant reports patient now requires direct assistance with selecting appropriate clothing for the weather (indicating ADL impairment) and can no longer safely prepare even simple meals (indicating significant IADL impairment)â€”suggesting a more advanced stage of dementia due to this level of functional dependence.</li>
                    </ul>
                 </div>
              </details>
          </div>
      </section>

      {/* == Section: Neuropsychological Testing == */}
       <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-white to-slate-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-slate-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-0.5">
          {/* Section Heading with Icon */}
          <h2 class="mb-6 text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white mt-0 flex items-start gap-x-3">
            <span class="mt-1 shrink-0 text-green-500 group-hover:scale-110 transition-transform duration-200 ease-in-out"><Fragment set:html={neuropsychIcon} /></span>
             Neuropsychological Testing (In-Depth Cognitive Assessment)
          </h2>
          {/* Main content styled using Tailwind Typography prose classes */}
          <div class="prose prose-slate dark:prose-invert max-w-none text-sm sm:text-base space-y-4 prose-strong:text-slate-800 dark:prose-strong:text-slate-100 prose-ul:space-y-1.5 prose-li:marker:text-green-500 dark:prose-li:marker:text-green-400">
              <p>
                  Representing a significantly more detailed, comprehensive, and nuanced evaluation of cognitive abilities compared to brief screening instruments administered during initial clinical evaluation, neuropsychological testing is specialized. Conducted by a <strong>neuropsychologist</strong>â€”a licensed psychologist possessing specialized doctoral-level training and expertise in brain-behavior relationshipsâ€”specialized testing typically occurs within a quiet, controlled office or clinic setting conducive to optimal performance. Neuropsychological testing is often recommended in several specific clinical scenarios: when initial clinical evaluation and cognitive screening results are inconclusive or ambiguous; when accurately differentiating between conditions presenting with similar symptoms is critically needed (e.g., distinguishing early AD from major depression, or differentiating AD from Frontotemporal Dementia [FTD]); or when establishing a highly detailed, quantitative baseline cognitive profile is desired for meticulously tracking future changes over time. Complete assessment usually requires several hours to administer (often spanning 2â€“4 hours or potentially longer) and involves administering a carefully selected battery of standardized tests.
              </p>
              <p>
                  <strong class="block mb-1">Purpose:</strong> To provide a precise, quantitative profile delineating an individual's specific cognitive strengths and weaknesses across multiple distinct cognitive domains. Domains typically include:
              </p>
              <ul>
                  <li><strong>Episodic Memory:</strong> Assessing the ability to learn and subsequently recall new verbal information (e.g., word lists, short stories) and visual information (e.g., complex geometric designs) after a specified delay periodâ€”a domain often significantly and disproportionately impaired early in the course of typical AD.</li>
                  <li><strong>Executive Functions:</strong> Evaluating higher-level cognitive control processes such as planning multi-step tasks, strategic problem-solving, working memory capacity (ability to hold and mentally manipulate information), cognitive flexibility (ability to shift efficiently between different tasks or mental sets), response inhibition (capacity to suppress prepotent but inappropriate responses or resist distractions), and abstract reasoning abilities.</li>
                  <li><strong>Language:</strong> Assessing various aspects of language function, including naming ability (confrontation naming, assessing word-finding difficulties or anomia), verbal fluency (generating words within specific categories, e.g., animals, or starting with a specific letter), auditory comprehension, and expressive language skills.</li>
                  <li><strong>Visuospatial Skills:</strong> Evaluating the ability to perceive complex spatial relationships accurately, navigate environments effectively, draw or copy geometric figures precisely, and mentally assemble objects or solve visual puzzles.</li>
                  <li><strong>Attention/Concentration:</strong> Assessing different facets of attention, including ability to focus selectively, sustain attention over time (vigilance), and divide or shift attention between multiple stimuli or tasks.</li>
                  <li><strong>Processing Speed:</strong> Measuring the rapidity with which an individual can process incoming information and execute simple cognitive operations.</li>
              </ul>
              <p>
                  <strong class="block mb-1">Mechanism:</strong> Neuropsychologist administers a tailored battery comprising various standardized tests. Involving diverse formats, tests include solving visual puzzles, answering specific questions, performing challenging memory tasks (both immediate and delayed recall), drawing complex figures, and completing timed reaction tasks. Performance on each test is scored objectively according to standardized procedures, and resulting scores are then compared to established normative dataâ€”scores derived from large samples of healthy individuals matched for similar age, educational background, and sometimes other demographic factors like sex or ethnicity. Specific *pattern* of performance observed across different cognitive domains proves highly informative diagnostically. For example: Typical AD characteristically manifests with a prominent deficit in episodic memory function (specifically, marked difficulty learning and retaining newly acquired informationâ€”a pattern often referred to as an amnestic profile), frequently appearing disproportionately severe relative to other cognitive domains, particularly in the early stages of the disease <Fragment set:html={renderCitation("Bondi et al., 2017; Arvanitakis et al., 2019")} />. In contrast, other types of dementia typically exhibit distinct cognitive profiles (e.g., primary deficits in executive functions or language abilities are more characteristic of specific variants of FTD).
              </p>
              <p>
                  <strong class="block mb-1">Examples:</strong>
                  <ol class="list-decimal list-outside space-y-1 pl-5 text-xs sm:text-sm text-slate-600 dark:text-slate-400 mt-1"> {/* Adjusted contrast */}
                     <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Confirms AD Pattern):</strong> Formal neuropsychological testing reveals severe impairment on measures of delayed verbal recall (e.g., performance significantly below expectations on the California Verbal Learning Test) coupled with moderate deficits in semantic category fluency (e.g., naming animals), while basic attention and visuospatial construction skills remain relatively preserved. Supporting a clinical diagnosis of AD, this specific cognitive profile is strong evidence.</li>
                     <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Suggests Depression/Pseudodementia):</strong> Testing demonstrates markedly inconsistent effort across tasks, significantly slowed information processing speed, and mild difficulties observed across multiple cognitive domains, but notably reveals relatively intact learning and recall performance when provided with cues and structured encoding strategies. Considered alongside concurrently elevated scores on standardized depression inventoriesâ€”this pattern suggests observed cognitive symptoms may be primarily attributable to severe depression (sometimes termed pseudodementia) rather than an underlying neurodegenerative process like AD.</li>
                     <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Suggests Non-AD Dementia):</strong> Patient performs particularly poorly on tests assessing executive functions (e.g., demonstrating significant perseveration on the Wisconsin Card Sorting Test, marked difficulty on the Trail Making Test Part B) and exhibits substantial language impairments (e.g., significant word-finding difficulties on the Boston Naming Test)â€”while achieving relatively better scores on memory measures. More indicative of Frontotemporal Dementia than typical AD, this specific pattern of cognitive deficits is notable.</li>
                  </ol>
              </p>
          </div>
      </section>

      {/* == Section: Biomarker Testing == */}
       {/* This section covers tests that detect biological markers of AD pathology. */}
       <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-white to-slate-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-slate-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-0.5">
          {/* Section Heading with Icon */}
          <h2 class="mb-6 text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white mt-0 flex items-start gap-x-3">
            <span class="mt-1 shrink-0 text-violet-500 group-hover:scale-110 transition-transform duration-200 ease-in-out"><Fragment set:html={biomarkerIcon} /></span>
            Biomarker Testing (Evidence of AD Pathology)
          </h2>
           {/* Introduction to Biomarkers */}
          <p class="mb-6 text-slate-700 dark:text-slate-300 max-w-prose text-base leading-relaxed">
             <strong class="font-semibold text-slate-800 dark:text-slate-100">Biomarkers</strong> are objective, measurable biological characteristics indicating a specific disease process. For AD, they provide <i>in vivo</i> (in life) evidence of the core brain changes: <strong class="font-semibold text-slate-800 dark:text-slate-100">amyloid-beta (AÃŽÂ²) plaques</strong> and <strong class="font-semibold text-slate-800 dark:text-slate-100">phosphorylated tau (p-tau) tangles</strong>. These tests increase diagnostic certainty, especially in complex cases, guided by the <strong class="font-semibold text-slate-800 dark:text-slate-100">AT(N) framework</strong> (A=amyloid, T=tau, N=neurodegeneration) <Fragment set:html={renderCitation("Jack et al., 2018")} />. Testing is typically done in specialized centers.
          </p>
          {/* Accordion for different biomarker types */}
          <div class="space-y-4"> {/* Reduced spacing */}
            {/* CSF Biomarkers */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-violet-300 open:dark:ring-violet-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    CSF Biomarkers (A, T, N Components)
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Involving the laboratory analysis of <strong class="font-medium text-slate-800 dark:text-slate-100">cerebrospinal fluid (CSF)</strong>â€”the clear, colorless fluid circulating within and around the brain and spinal cord, serving protective and metabolic functionsâ€”this method is informative. <strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> CSF is obtained through a medical procedure known as a <strong class="font-medium text-slate-800 dark:text-slate-100">lumbar puncture (LP)</strong> (colloquially termed a spinal tap). During the procedure, a thin, sterile needle is carefully inserted between two vertebrae in the lower back (lumbar region) to collect a small sample of CSF. Generally considered safe when performed by experienced clinicians, the procedure is typically conducted on an outpatient basis. Collected CSF directly reflects the biochemical milieu within the central nervous system, providing a window into ongoing brain processes.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Interpretation:</strong> Specific proteins relevant to AD pathology are precisely quantified in the CSF sample:</p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">AÃŽÂ²42 (Amyloid-beta 42):</strong> Typically <strong class="font-semibold text-red-600 dark:text-red-400">low (â†“)</strong> in AD CSF because it's being deposited into brain plaques. ('A' marker).</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Phosphorylated Tau (p-tau):</strong> Typically <strong class="font-semibold text-emerald-600 dark:text-emerald-400">high (â†‘)</strong> in AD CSF, reflecting active tangle formation inside neurons. ('T' marker).</li> {/* Changed color */}
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Total Tau (t-tau):</strong> Typically <strong class="font-semibold text-emerald-600 dark:text-emerald-400">high (â†‘)</strong> in AD CSF, indicating the overall level of neuronal injury or death. ('N' marker).</li> {/* Changed color */}
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">AÃŽÂ²42/AÃŽÂ²40 Ratio:</strong> Often more accurate than AÃŽÂ²42 alone; typically <strong class="font-semibold text-red-600 dark:text-red-400">low (â†“)</strong> in AD. ('A' marker).</li>
                    </ul>
                    <p class="max-w-prose leading-relaxed">The combination of low AÃŽÂ²42 (or ratio) with high p-tau and t-tau is highly specific for AD pathology <Fragment set:html={renderCitation("Olsson et al., 2016")} />.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Confirms AD):</strong> A patient with progressive memory loss has CSF results showing low AÃŽÂ²42, high p-tau, and high t-tau, strongly supporting AD pathology.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Rules Out AD):</strong> A patient with cognitive symptoms has completely normal levels of AÃŽÂ²42, p-tau, and t-tau in their CSF, making AD highly unlikely.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Ambiguous/Non-AD):</strong> CSF shows normal AÃŽÂ²42 and p-tau, but markedly elevated t-tau. This suggests neuronal injury is occurring, but likely due to a non-AD cause (e.g., recent stroke, Creutzfeldt-Jakob disease).</li>
                    </ul>
                </div>
            </details>

            {/* Amyloid PET */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-violet-300 open:dark:ring-violet-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Amyloid PET (A Marker)
                 </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Positron Emission Tomography (PET) is a nuclear medicine imaging technology. For Amyloid PET, a minuscule quantity of a radioactive tracerâ€”a molecule meticulously engineered to bind with high specificity to deposited AÃŽÂ² plaquesâ€”is administered intravenously into the patient's bloodstream.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> Injected tracer circulates throughout the body, crosses the blood-brain barrier, and selectively attaches to any accumulated amyloid deposits present within the brain parenchyma. Following an appropriate uptake period (typically ranging from 30 to 90 minutes, depending on the specific tracer utilized), the patient lies comfortably within a PET scanner. Detecting the positrons emitted by the decaying radioactive tracer, the scanner facilitates imaging. Sophisticated computer algorithms then process detected signals to generate detailed cross-sectional images vividly illustrating the density and precise anatomical distribution of amyloid plaques throughout the brain.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Interpretation:</strong> A <strong class="font-medium text-slate-800 dark:text-slate-100">positive</strong> Amyloid PET scan is characterized by widespread tracer uptake observed across various cortical regions of the brain, visually confirming the presence of a significant burden of amyloid pathology (a finding highly consistent with AD). Conversely, a <strong class="font-medium text-slate-800 dark:text-slate-100">negative</strong> scan demonstrates only minimal, non-specific tracer uptake (often confined primarily to white matter regions) and renders AD considerably less likely as the cause of symptomsâ€”particularly if significant dementia symptoms are clinically present (strongly suggesting a non-amyloid driven dementia etiology) <Fragment set:html={renderCitation("Johnson et al., 2013")} />. Amyloid PET proves particularly useful in clarifying diagnoses for patients presenting with atypical clinical syndromes or for definitively confirming the presence of brain amyloidosis prior to initiating potentially costly or risky amyloid-targeting therapies.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Positive Scan):</strong> A 60-year-old individual experiencing unusually rapid cognitive decline undergoes an Amyloid PET scan, yielding a positive resultâ€”confirming underlying AD pathology as the likely driver of their symptoms, despite the atypical disease progression rate.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Negative Scan):</strong> A 75-year-old patient presenting with memory complaints but having shown normal AÃŽÂ²42 levels in their CSF analysis subsequently undergoes an Amyloid PET scan, returning a negative result. Strongly arguing against AD pathology, this finding prompts intensive investigation into alternative potential causes, such as underlying vascular dementia or severe depression.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Research Context):</strong> A cognitively normal older adult participating in an AD prevention research study undergoes an Amyloid PET scan as part of the protocol, and the scan result is positiveâ€”indicating the presence of preclinical AD (meaning amyloid accumulation has begun years before emergence of any clinical symptoms).</li>
                    </ul>
                </div>
            </details>

            {/* Tau PET */}
            <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-violet-300 open:dark:ring-violet-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Tau PET (T Marker)
                 </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Another advanced PET imaging technique, Tau PET is analogous in principle to Amyloid PET, but critically utilizes different, specifically designed radioactive tracers. Engineered to bind with high affinity and specificity to neurofibrillary tangles composed primarily of abnormal, hyperphosphorylated tau protein, tracers are key.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> A tau-specific radioactive tracer is injected intravenously, travels to the brain, selectively binds to accumulated tau tangles within neurons, and emitted positron signals are subsequently detected by the PET scanner.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Interpretation:</strong> Tau PET enables visualization of both the overall burden andâ€”importantlyâ€”the precise topographical *distribution* of tau pathology within the living brain. Unlike amyloid pathology (which can be relatively widespread even in some cognitively unimpaired older adults), anatomical location and quantitative severity of tau tangles detected by Tau PET correlate much more closely and consistently with the specific type and severity of cognitive symptoms experienced by the patient, as well as with the overall clinical stage of AD <Fragment set:html={renderCitation("Villemagne et al., 2018")} />. For instance: observing significant tau accumulation predominantly within the medial temporal lobes strongly correlates with characteristic episodic memory impairment typical of early-stage AD. While Tau PET is currently utilized more extensively within research settings, it is progressively entering clinical practice, offering valuable diagnostic and prognostic information.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Confirms AD Pattern/Stage):</strong> A patient with a clinical diagnosis of AD, supported by positive amyloid biomarker results, undergoes a Tau PET scan. Revealing significant tracer uptake concentrated primarily in the temporal and parietal cortical regions, the scan shows a pattern consistent with their presenting memory and language difficulties and confirming moderate-stage AD tau pathology.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Differentiates Tauopathy):</strong> A patient presents clinically with prominent behavioral changes highly suggestive of Frontotemporal Dementia (FTD). A Tau PET scan demonstrates tracer uptake predominantly localized to the frontal lobesâ€”supporting a diagnosis of a primary tauopathy (such as Pick's disease or Progressive Supranuclear Palsy) rather than the typical temporoparietal tau distribution characteristic of AD.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Predicts Progression):</strong> Within a research context, an individual diagnosed with Mild Cognitive Impairment (MCI) and known positive amyloid markers undergoes a Tau PET scan. Revealing early tau accumulation restricted primarily to the entorhinal cortex, the scan suggests a high probability of imminent progression from MCI to clinically manifest AD dementia.</li>
                    </ul>
                </div>
            </details>

             {/* Blood Biomarkers */}
             <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-violet-300 open:dark:ring-violet-800/60 open:shadow transition duration-300 ease-in-out">
                <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                         <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    (Emerging) Blood Biomarkers
                </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Representing a rapidly advancing frontier in AD diagnostics, blood biomarkers involve the development and validation of simple blood tests capable of detecting specific AD-related proteins circulating in the periphery.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> Highly sensitive laboratory techniques (such as sophisticated immunoassays like SIMOA or advanced mass spectrometry methods) are employed to precisely measure the concentration of specific target molecules within a patient's blood plasma or serum sample. Key molecular targets currently under intense investigation and initial clinical implementation include specific phosphorylated forms of tau protein (e.g., <strong class="font-medium text-slate-800 dark:text-slate-100">p-tau181, p-tau217, p-tau231</strong>) and the calculated <strong class="font-medium text-slate-800 dark:text-slate-100">ratio of AÃŽÂ²42 to AÃŽÂ²40</strong> concentrations in plasma.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Interpretation:</strong> Studies have demonstrated that elevated levels of specific plasma p-tau isoforms (particularly p-tau217 and p-tau231) and a decreased plasma AÃŽÂ²42/AÃŽÂ²40 ratio exhibit high accuracy in predicting the presence of underlying amyloid plaque pathology in the brain. Furthermore, elevated plasma p-tau levels also show strong correlation with the presence of brain tau tangles. Correlating remarkably well with results obtained from established gold-standard methods like PET scans and CSF analysis, blood-based measures show promise <Fragment set:html={renderCitation("Ashton et al., 2022; Karikari et al., 2020")} />.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Current Status & Future Implications:</strong> While several blood tests are beginning to achieve clinical availability (e.g., C2N Diagnostics' PrecivityAD test measuring the plasma AÃŽÂ²42/40 ratio and APOE genotype; Quest Diagnostics' AD-Detect test assessing the plasma AÃŽÂ²42/40 ratio), their primary clinical role currently is often conceptualized as an initial screening or triaging step. Effectively identifying individuals at higher risk for underlying AD pathology who would likely benefit most from undergoing more invasive or expensive confirmatory diagnostic procedures, such as CSF analysis or PET imaging, blood tests streamline diagnosis. Holding enormous potential to significantly simplify the complex AD diagnostic process, vastly improve accessibility to accurate diagnosis (particularly within primary care settings), and potentially enable earlier screening of at-risk populations, blood tests facilitate timely intervention.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Positive Screen):</strong> A primary care physician orders a plasma p-tau217 test for a patient presenting with mild but persistent memory concerns. Returning significantly elevated, the test result prompts an appropriate referral to a specialized memory clinic for probable confirmatory testing using either PET imaging or CSF analysis.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Negative Screen):</strong> A patient expressing significant worry about developing AD due to a strong family history undergoes a plasma AÃŽÂ²42/40 ratio test, yielding a result within the normal rangeâ€”substantially reducing the immediate likelihood of underlying AD pathology and providing significant reassurance.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Monitoring/Research):</strong> Blood biomarkers are utilized within a clinical trial investigating a novel therapeutic agent. Serial measurements track whether the experimental drug effectively alters levels of specific p-tau isoforms or AÃŽÂ² peptides circulating in the blood over the course of treatmentâ€”serving as a potential indicator of the drug successfully engaging its target or potentially modifying the underlying disease process.</li>
                    </ul>
                </div>
            </details>
          </div>
      </section>

       {/* == Section: Neuroimaging == */}
        {/* This section details brain imaging techniques used in diagnosis. */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-white to-slate-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-slate-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-0.5">
          {/* Section Heading with Icon */}
          <h2 class="mb-6 text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white mt-0 flex items-start gap-x-3">
            <span class="mt-1 shrink-0 text-teal-500 group-hover:scale-110 transition-transform duration-200 ease-in-out"><Fragment set:html={imagingIcon} /></span>
            Neuroimaging (Brain Structure & Function - 'N' Component)
          </h2>
           {/* Introduction to Neuroimaging */}
           <p class="mb-6 text-slate-700 dark:text-slate-300 max-w-prose text-base leading-relaxed">
             Brain imaging techniques play an indispensable, multifaceted role within the comprehensive diagnostic workup for suspected AD. Their primary purposes are fundamentally twofold: 1) definitively excluding other potential structural causes responsible for observed cognitive symptoms (such as occult brain tumors, chronic subdural hematomas resulting from falls, evidence of significant stroke, or conditions like normal pressure hydrocephalus), and 2) identifying specific, characteristic patterns of brain atrophy (regional tissue shrinkage) or demonstrably altered brain function (typically measured via metabolic activity) highly suggestive of AD or other specific neurodegenerative disease processes. Corresponding conceptually to the 'N' (Neurodegeneration) component within the established AT(N) biomarker framework, neuroimaging modalities provide crucial data.
          </p>
          {/* Accordion for imaging modalities */}
          <div class="space-y-4"> {/* Reduced spacing */}
             {/* MRI */}
             <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-teal-300 open:dark:ring-teal-800/60 open:shadow transition duration-300 ease-in-out">
                 <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                    Structural Magnetic Resonance Imaging (MRI)
                 </summary>
                 <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Magnetic Resonance Imaging (MRI) employs powerful magnetic fields and precisely timed radio wave pulses (importantly, utilizing non-ionizing radiation, unlike X-rays or CT scans) to generate exceptionally detailed, high-resolution cross-sectional images of the brain's structure. Due to its superior ability to differentiate between various soft tissues within the brain, MRI generally stands as the preferred structural imaging technique for dementia evaluation.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> Patient lies still inside the bore of a large, cylindrical superconducting magnet. Sequences of radio wave pulses are transmitted into the body and subsequently received; powerful computer systems then analyze complex signals emitted back by different brain tissues (e.g., gray matter, white matter, CSF) to reconstruct intricate, detailed anatomical pictures. Administration of intravenous contrast agents (like gadolinium-based compounds) is typically *not* required for standard dementia evaluation protocols unless a specific clinical suspicion exists for conditions like brain tumors or active inflammation.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Interpretation:</strong></p>
                    <ul class="list-disc list-outside space-y-1.5 pl-5 max-w-prose leading-relaxed">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Rule out structural lesions:</strong> MRI demonstrates excellent sensitivity for detecting various structural abnormalities causing cognitive impairment, including strokes (both acute/recent and chronic/old infarcts), primary or metastatic brain tumors, evidence of past traumatic brain injury or intracranial bleeding, signs of active inflammation or infection, and conditions such as normal pressure hydrocephalus (NPH)â€”all needing exclusion before diagnosing a primary neurodegenerative dementia like AD.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Assess atrophy patterns:</strong> In the context of AD, MRI scans frequently reveal characteristic, quantifiable patterns of regional brain volume loss (atrophy). Specifically, atrophy affecting medial temporal lobe structuresâ€”most notably involving the <strong class="font-medium text-slate-800 dark:text-slate-100">hippocampus</strong> (critically essential for forming new memories) and adjacent entorhinal cortexâ€”represents a well-established neuropathological hallmark of AD, often becoming apparent relatively early in the disease course. As AD progresses pathologically and clinically, observed atrophy typically becomes more diffuse and widespread, extending to affect parietal and frontal lobe regions as well <Fragment set:html={renderCitation("Frisoni et al., 2010")} />. Advanced quantitative MRI analysis techniques can provide precise volumetric measurements of structures like the hippocampus, allowing objective comparison to age-matched norms.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Assess vascular burden:</strong> Specific MRI sequences, such as FLAIR (Fluid-Attenuated Inversion Recovery), are highly sensitive for detecting <strong class="font-medium text-slate-800 dark:text-slate-100">white matter hyperintensities (WMH)</strong>. Often representing underlying small vessel ischemic damageâ€”a common form of vascular brain injuryâ€”WMH are significant findings. Observing an extensive burden of WMH on MRI may suggest a significant component of vascular dementia contributing to the patient's overall cognitive symptom profile (potentially indicating mixed dementia).</li>
                    </ul>
                    <p class="max-w-prose leading-relaxed">Therefore, an MRI demonstrating pronounced hippocampal atrophy in a patient presenting with significant memory loss strongly supports an AD diagnosis. Conversely, an MRI revealing a large space-occupying tumor or evidence of extensive prior stroke damage clearly points towards a different underlying etiology for cognitive symptoms.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Typical AD):</strong> An MRI scan performed on a 70-year-old individual with progressive amnesia reveals significant, bilateral atrophy of the hippocampiâ€”appearing disproportionately severe for their chronological ageâ€”alongside minimal evidence of vascular changes (WMH). Strongly supporting a clinical diagnosis of AD, this imaging finding is compelling.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Vascular Dementia):</strong> An MRI obtained for a patient exhibiting a stepwise pattern of cognitive decline accompanied by motor symptoms reveals the presence of multiple small, deep lacunar infarcts (strokes) within subcortical structures, as well as extensive confluent white matter hyperintensities throughout the brainâ€”indicative of significant underlying vascular dementia.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Tumor):</strong> An MRI performed to investigate new-onset confusion and persistent headaches reveals a large meningioma (a typically benign tumor arising from the brain's covering layers) significantly compressing the adjacent frontal lobeâ€”providing a clear structural explanation for the patient's presenting symptoms.</li>
                    </ul>
                 </div>
             </details>
             {/* FDG-PET */}
             <details class="group rounded-lg bg-slate-50 dark:bg-slate-700/40 p-4 open:ring-1 open:ring-teal-300 open:dark:ring-teal-800/60 open:shadow transition duration-300 ease-in-out">
                 <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 hover:bg-slate-100 dark:hover:bg-slate-700/60 rounded-md p-2 -m-2 transition-colors duration-200 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-800 group-open:pb-2">
                     <span class="transition-transform duration-200 ease-in-out group-open:rotate-90">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                    </span>
                     FDG-PET (Fluorodeoxyglucose PET)
                 </summary>
                  <div class="mt-4 text-sm text-slate-700 dark:text-slate-300 space-y-3">
                    <p class="max-w-prose leading-relaxed">Functioning by measuring regional brain metabolic activity, this specific type of Positron Emission Tomography (PET) scan essentially maps how actively different brain areas utilize energy. <strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Mechanism:</strong> Patient receives an intravenous injection of a radioactive tracer called <strong class="font-medium text-slate-800 dark:text-slate-100">Fluorodeoxyglucose (FDG)</strong>. FDG is structurally very similar to glucose (simple sugar)â€”the brain's primary metabolic fuel source. Highly active brain cells naturally consume more glucose (and consequently, uptake more FDG). Following an appropriate uptake period (typically 30â€“45 minutes, during which the patient rests quietly in a dimly lit room to minimize extraneous brain activation), the PET scanner detects radioactive signals emitted by the FDG tracer concentrated within brain cells. Computer processing then generates a detailed map illustrating the level of metabolic activity throughout the entire brain volume. Brain regions exhibiting significantly reduced metabolic activity (termed <strong class="font-medium text-slate-800 dark:text-slate-100">hypometabolism</strong>) appear as "cold spots" (often depicted using cooler colors like blue or green) on resulting scan imagesâ€”directly indicating reduced neuronal function or synaptic activity within those specific anatomical areas.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Purpose & Interpretation:</strong> FDG-PET provides crucial *functional* information effectively complementing *structural* information obtained from MRI scans. Directly reflecting the level of neuronal dysfunction, it importantly can often precede the development of observable, significant structural atrophy visible on MRI. In the context of typical AD, FDG-PET frequently reveals a characteristic, recognizable pattern of regional hypometabolism predominantly affecting the <strong class="font-medium text-slate-800 dark:text-slate-100">temporoparietal cortex</strong>. Reduced activity occurs in the temporal lobes (critically involved in memory formation and language processing) and the parietal lobes (essential for spatial awareness, sensory integration, and navigation) <Fragment set:html={renderCitation("Mosconi et al., 2008")} />. Posterior cingulate cortex and precuneus region are also typically hypometabolic in AD. Identifying specific topographical patterns of hypometabolism significantly aids in differentiating AD from other forms of dementia (e.g., Frontotemporal Dementia [FTD] often presents with pronounced *frontal* hypometabolism; Dementia with Lewy Bodies [DLB] may exhibit characteristic *occipital* hypometabolism). Consequently, FDG-PET can provide strong supportive evidence for an AD diagnosis, even in cases where structural MRI appears relatively normal, particularly early in the disease course. Serving as an important biomarker reflecting ongoing neurodegeneration ('N' within the ATN framework), it adds valuable data.</p>
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100 block mb-1">Examples:</strong></p>
                    <ul class="list-decimal list-outside space-y-1 pl-5 text-xs text-slate-600 dark:text-slate-400 max-w-prose leading-relaxed mt-1">
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 1 (Typical AD):</strong> An FDG-PET scan performed on a patient presenting with early but definite memory impairment and increasing navigational difficulties reveals markedly reduced metabolic activity localized to bilateral parietal and temporal cortical regions, as well as the posterior cingulate cortexâ€”strongly supporting a diagnosis of AD.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 2 (Suggests FTD):</strong> A patient presents clinically with significant personality changes and prominent executive dysfunction. Their FDG-PET scan demonstrates pronounced hypometabolism primarily affecting the frontal lobes, with relative sparing of temporoparietal regions typically affected in ADâ€”highly consistent with Frontotemporal Dementia.</li>
                        <li><strong class="font-medium text-slate-700 dark:text-slate-200">Case 3 (Normal Metabolism):</strong> Despite reporting subjective cognitive complaints, a patient undergoes an FDG-PET scan revealing entirely normal, symmetric metabolic activity throughout all cortical regionsâ€”making a significant underlying neurodegenerative process like AD considerably less likely and suggesting investigation into alternative potential causes, such as underlying anxiety, depression, medication side effects, or perhaps very early pathological changes not yet detectable by this imaging modality.</li>
                    </ul>
                  </div>
             </details>
          </div>
      </section>

    </div> {/* End Main Content Sections Container */}
</BaseLayout>

{/* Scoped styles for details/summary markers (optional enhancement) */}
<style is:global>
  /* Hides the default triangle marker for details/summary elements */
  details > summary {
    list-style: none;
  }
  details > summary::-webkit-details-marker {
    display: none;
  }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\index.astro
---
// src/pages/index.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "Welcome to CCH-MIC";
// SEO Description specific to the homepage.
const pageDescription = "Your evidence-based resource for understanding brain aging, Alzheimer's disease, and related dementias. Explore causes, diagnosis, treatments, and reliable resources.";

// --- Data ---
// Defines breadcrumb structure (only Home for the index page).
const breadcrumbs = [{ label: "Home", href: `${base}/` }];

// Defines data for the feature cards displayed on the homepage.
// Includes title, description, icon SVG, and styling classes for visual theming.
const features = [
  {
    id: "causes", // Unique identifier for the section this card links to or represents.
    title: "Causes & Risk Factors",
    description: "Dive into the underlying biology and contributing factors for Alzheimer's Disease and Related Dementias (ADRD).",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path fill-rule="evenodd" d="M4.646 4.646a.5.5 0 0 1 .708 0L10 9.293l4.646-4.647a.5.5 0 1 1 .708.708L10.707 10l4.647 4.646a.5.5 0 1 1-.708.708L10 10.707l-4.646 4.647a.5.5 0 0 1-.708-.708L9.293 10 4.646 5.354a.5.5 0 0 1 0-.708z" clip-rule="evenodd" /></svg>`, // Icon representing 'Causes/Risk'.
    // Tailwind classes defining the card's border, background gradient, and hover states.
    colorClasses: "border-red-200 dark:border-red-700/50 bg-gradient-to-br from-red-50/80 to-orange-50/80 dark:from-slate-800/80 dark:to-slate-800/70 hover:border-red-300 dark:hover:border-red-600/80",
    hoverBgGradient: "hover:bg-gradient-to-br hover:from-red-50 hover:to-orange-100 dark:hover:from-slate-800 dark:hover:to-slate-700/90",
    iconColorClass: "text-red-600 dark:text-red-400" // Specific color class for the icon SVG.
  },
  {
    id: "diagnosis",
    title: "Diagnostic Approaches",
    description: "Learn how cognitive decline and dementia are evaluated using clinical methods and advanced biomarker testing.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path d="M3.25 4A2.25 2.25 0 0 0 1 6.25v7.5A2.25 2.25 0 0 0 3.25 16h13.5A2.25 2.25 0 0 0 19 13.75v-7.5A2.25 2.25 0 0 0 16.75 4H3.25ZM10 6.5a.75.75 0 0 1 .75.75v2.5a.75.75 0 0 1-1.5 0v-2.5a.75.75 0 0 1 .75-.75ZM10 12a.75.75 0 1 1 0 1.5.75.75 0 0 1 0-1.5Z" /></svg>`, // Icon representing 'Diagnosis'.
    colorClasses: "border-cyan-200 dark:border-cyan-700/50 bg-gradient-to-br from-cyan-50/80 to-sky-50/80 dark:from-slate-800/80 dark:to-slate-800/70 hover:border-cyan-300 dark:hover:border-cyan-600/80",
    hoverBgGradient: "hover:bg-gradient-to-br hover:from-cyan-50 hover:to-sky-100 dark:hover:from-slate-800 dark:hover:to-slate-700/90",
    iconColorClass: "text-cyan-600 dark:text-cyan-400"
  },
  {
    id: "treatment",
    title: "Treatment Strategies",
    description: "Explore current medications, lifestyle interventions, emerging therapies, and management techniques for AD.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path fill-rule="evenodd" d="M8.5 4.75a.75.75 0 0 0-1.5 0v2.5h-2.5a.75.75 0 0 0 0 1.5h2.5v2.5a.75.75 0 0 0 1.5 0v-2.5h2.5a.75.75 0 0 0 0-1.5h-2.5v-2.5Z" clip-rule="evenodd" /><path fill-rule="evenodd" d="M10 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16ZM3 10a7 7 0 1 1 14 0 7 7 0 0 1-14 0Z" clip-rule="evenodd" /></svg>`, // Icon representing 'Treatment'.
    colorClasses: "border-emerald-200 dark:border-emerald-700/50 bg-gradient-to-br from-emerald-50/80 to-green-50/80 dark:from-slate-800/80 dark:to-slate-800/70 hover:border-emerald-300 dark:hover:border-emerald-600/80",
    hoverBgGradient: "hover:bg-gradient-to-br hover:from-emerald-50 hover:to-green-100 dark:hover:from-slate-800 dark:hover:to-slate-700/90",
    iconColorClass: "text-emerald-600 dark:text-emerald-400"
  },
  {
    id: "resources",
    title: "Reliable Resources",
    description: "Access links to reputable organizations offering support, education, and further information.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path d="M12.232 4.232a2.5 2.5 0 0 1 3.536 3.536l-1.225 1.224a.75.75 0 0 0 1.061 1.06l1.224-1.224a4 4 0 0 0-5.656-5.656l-3 3a4 4 0 0 0 .225 5.865.75.75 0 0 0 .977-1.138 2.5 2.5 0 0 1-.142-3.667l3-3Z" /><path d="M11.603 7.963a.75.75 0 0 0-.977 1.138 2.5 2.5 0 0 1 .142 3.667l-3 3a2.5 2.5 0 0 1-3.536-3.536l1.225-1.224a.75.75 0 0 0-1.061-1.06l-1.224 1.224a4 4 0 0 0 5.656 5.656l3-3a4 4 0 0 0-.225-5.865Z" /></svg>`, // Icon representing 'Resources'.
    colorClasses: "border-purple-200 dark:border-purple-700/50 bg-gradient-to-br from-purple-50/80 to-violet-50/80 dark:from-slate-800/80 dark:to-slate-800/70 hover:border-purple-300 dark:hover:border-purple-600/80",
    hoverBgGradient: "hover:bg-gradient-to-br hover:from-purple-50 hover:to-violet-100 dark:hover:from-slate-800 dark:hover:to-slate-700/90",
    iconColorClass: "text-purple-600 dark:text-purple-400"
  }
];
---

{/* Apply BaseLayout with homepage title, description, and breadcrumbs */}
<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs}>

    {/* Hero Section */}
    <section class="text-center relative overflow-hidden"> {/* Added padding */}
        {/* Background Gradient Layer */}
        <div class="absolute inset-0 -z-10 bg-gradient-to-br from-blue-100/60 via-white to-indigo-50/60 dark:from-slate-900 dark:via-slate-900/95 dark:to-slate-800/90 opacity-90 dark:opacity-100"></div>

        {/* Heading with animation */}
        <h1 class="mt-0 mb-4 text-4xl sm:text-5xl lg:text-6xl font-extrabold tracking-tight text-slate-900 dark:text-slate-100 opacity-0 animate-fade-in animate-slide-in-down">
            Cognitive Health & Memory Center
        </h1>
        {/* Subtitle/Description with animation */}
        <p class="text-lg sm:text-xl text-slate-700 dark:text-slate-300 max-w-3xl mx-auto mb-10 opacity-0 animate-fade-in animate-slide-in-down animation-delay-100"> {/* Increased text contrast */}
            {pageDescription}
        </p>
        {/* Call to Action Buttons with animation */}
        <div class="flex flex-col sm:flex-row justify-center gap-4">
            {/* Primary Button */}
            <a
              href={`${base}/understanding-ad/`}
              class="inline-block transform rounded-lg bg-blue-600 px-8 py-3 text-center text-lg font-semibold text-white shadow-lg motion-safe:transition-all motion-safe:duration-200 ease-in-out hover:-translate-y-1 hover:scale-[1.03] hover:bg-blue-700 hover:shadow-xl active:translate-y-0 active:scale-95 active:bg-blue-800 active:shadow-md focus:outline-none focus-visible:ring-4 focus-visible:ring-blue-300 dark:focus-visible:ring-blue-800 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-900 opacity-0 animate-fade-in animate-slide-in-up animation-delay-200"
            >
              Explore Topics
            </a>
            {/* Secondary Button */}
            <a
              href={`${base}/about/`}
              class="inline-block transform rounded-lg border-2 border-blue-600 px-8 py-3 text-center text-lg font-medium text-blue-700 motion-safe:transition-all motion-safe:duration-200 ease-in-out hover:border-blue-700 hover:bg-blue-50/70 hover:scale-[1.03] hover:-translate-y-0.5 active:translate-y-0 active:scale-95 active:bg-blue-100 focus:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:border-blue-400 dark:text-blue-300 dark:hover:bg-slate-800/70 dark:active:bg-slate-700/80 dark:focus:ring-offset-slate-900 dark:hover:border-blue-500 dark:hover:text-blue-200 opacity-0 animate-fade-in animate-slide-in-up animation-delay-300"
            >
              About Brain Health
            </a>
        </div>
    </section>

    {/* Divider */}
    <div class="my-16 h-px bg-gradient-to-r from-transparent via-slate-300 dark:via-slate-700 to-transparent opacity-0 animate-fade-in animation-delay-400"></div> {/* Increased margin */}

    {/* "What We Offer" Section */}
    <section class="mb-16"> {/* Added bottom margin */}
        <h2 class="text-center text-3xl md:text-4xl font-bold text-slate-900 dark:text-slate-100 mb-12 opacity-0 animate-fade-in animate-slide-in-down animation-delay-500">
            What We Offer
        </h2>
        {/* Grid container for feature cards */}
        <div class="grid grid-cols-1 md:grid-cols-2 gap-6 md:gap-8 max-w-5xl mx-auto">
            {/* Map over the features array to generate cards */}
            {features.map((feature, index) => (
              <div
                class:list={[
                  // Base card styling: flex column, rounded, border, padding, shadow.
                  "group flex flex-col rounded-xl border p-6 shadow-sm",
                  // Motion-aware transitions for hover effects.
                  "motion-safe:transition-all motion-safe:duration-300 motion-safe:ease-out",
                  // Hover effects: increased shadow, subtle lift and scale.
                  "hover:shadow-lg hover:-translate-y-1.5 hover:scale-[1.02]",
                  // Apply dynamic color classes for border and background gradients.
                  feature.colorClasses,
                  // Apply dynamic hover background gradient class.
                  feature.hoverBgGradient,
                  // Entry animation classes.
                  "opacity-0 animate-fade-in animate-slide-in-up"
                ]}
                style={{ animationDelay: `${index * 150 + 600}ms` }}
              >
                {/* Card Header: Icon and Title */}
                <div class="flex items-center gap-x-3 mb-3">
                   {/* Icon container with themed background and hover animation. */}
                   <span class:list={[
                       "inline-flex p-2 rounded-full bg-current/10", // Base icon background (uses text color with low opacity)
                       "motion-safe:transition-transform motion-safe:duration-300",
                       "group-hover:scale-110 group-hover:rotate-[-5deg]", // Icon animation on card hover
                       feature.iconColorClass // Applies specific text color to the icon container
                    ]}>
                       {/* Render the SVG icon markup */}
                      <Fragment set:html={feature.icon} />
                   </span>
                   {/* Card Title */}
                   <h3 class="text-xl font-semibold text-inherit mt-0 mb-0">{feature.title}</h3>
                </div>
                {/* Card Description */}
                {/* `flex-grow` allows description to push footer down if cards have uneven height. */}
                {/* Increased contrast for description text. */}
                <p class="text-sm text-slate-700 dark:text-slate-300 flex-grow leading-relaxed">
                  {feature.description}
                </p>
              </div>
            ))}
        </div>
    </section>

    {/* Enhanced Divider */}
    <div class="my-16 h-px bg-gradient-to-r from-transparent via-slate-300 dark:via-slate-700 to-transparent opacity-0 animate-fade-in animation-delay-1000"></div> {/* Increased margin */}

    {/* Disclaimer Section */}
    <section class=" opacity-0 animate-fade-in animation-delay-1100 mb-8 md:mb-12"> {/* Added bottom margin */}
        {/* Styled blockquote for the disclaimer */}
        <blockquote class="mx-auto max-w-2xl text-center p-6 rounded-lg bg-slate-100/80 dark:bg-slate-800/70 border border-slate-200 dark:border-slate-700/60 shadow-inner">
            <p class="text-base italic text-slate-600 dark:text-slate-400 leading-relaxed">
                <strong class="font-medium not-italic text-slate-700 dark:text-slate-200">Disclaimer:</strong> "This website is not a Neurology Group Website. The Website is a Project for an upper Division Undergraduate Course at USC entitled 'The Neurobiology of Aging'"
            </p>
        </blockquote>
    </section>

</BaseLayout>

{/* Global Animation Styles (Define in global.css or BaseLayout for cleaner separation) */}
<style is:global>
  @keyframes fadeIn {
    from { opacity: 0; }
    to { opacity: 1; }
  }
  @keyframes slideInDown {
    from { transform: translateY(-15px); opacity: 0; }
    to { transform: translateY(0); opacity: 1; }
  }
  @keyframes slideInUp {
    from { transform: translateY(15px); opacity: 0; }
    to { transform: translateY(0); opacity: 1; }
  }

  /* Animation utility classes */
  .animate-fade-in {
    animation: fadeIn 0.6s ease-out forwards;
  }
  .animate-slide-in-down {
    animation: slideInDown 0.6s ease-out forwards;
  }
  .animate-slide-in-up {
    animation: slideInUp 0.6s ease-out forwards;
  }

  /* Animation delay utility classes */
  .animation-delay-100 { animation-delay: 100ms; }
  .animation-delay-200 { animation-delay: 200ms; }
  .animation-delay-300 { animation-delay: 300ms; }
  .animation-delay-400 { animation-delay: 400ms; }
  .animation-delay-500 { animation-delay: 500ms; }
  .animation-delay-600 { animation-delay: 600ms; }
  /* Added intermediate delays for smoother card staggering */
  .animation-delay-750 { animation-delay: 750ms; }
  .animation-delay-900 { animation-delay: 900ms; }
  .animation-delay-1000 { animation-delay: 1000ms; }
  .animation-delay-1100 { animation-delay: 1100ms; }

  /* Ensures elements start hidden if they have an animation class */
  .opacity-0 {
    opacity: 0;
  }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\references.astro
---
// src/pages/references.astro
import BaseLayout from '../layouts/BaseLayout.astro';
const base = import.meta.env.BASE_URL;

const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "References", href: `${base}/references/` }
];

// Inline SVG for external link icon
const externalLinkIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="inline-block w-3 h-3 ml-0.5 align-baseline text-blue-500 dark:text-blue-400/80 group-hover:text-blue-700 dark:group-hover:text-blue-300 transition-colors"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 0 0 3 3.5v9A1.5 1.5 0 0 0 4.5 14h9a1.5 1.5 0 0 0 1.5-1.5v-5a.75.75 0 0 0-1.5 0v5a.5.5 0 0 1-.5.5h-9a.5.5 0 0 1-.5-.5v-9a.5.5 0 0 1 .5-.5h5a.75.75 0 0 0 0-1.5h-5ZM10 .75A.75.75 0 0 1 10.75 0h4.5A.75.75 0 0 1 16 .75v4.5a.75.75 0 0 1-1.5 0V1.56l-4.97 4.97a.75.75 0 0 1-1.06-1.06L14.44 1H10.75A.75.75 0 0 1 10 .75Z" clip-rule="evenodd" /></svg>`;
---
<BaseLayout title="References" breadcrumbs={breadcrumbs}>
  <header class="mb-1 w-full text-center">
    <h1 class="mt-0 mb-4 text-center" style="text-align: center; margin: 0 auto; width: 100%;">
      References
    </h1>
    <p class="text-center text-sm text-slate-500 dark:text-slate-400 italic" style="text-align: center; margin: 0 auto; width: 100%;">
      (Formatted using APA 7th Style)
    </p>
  </header>

    {/* Added a containing div with subtle background/border */}
    <div class="bg-white dark:bg-slate-800/50 border border-slate-200 dark:border-slate-700/50 rounded-lg p-6 md:p-8 shadow-sm">
        <dl class="space-y-6 text-sm text-slate-700 dark:text-slate-300 max-w-prose mx-auto"> {/* Centered content */}

            {/* === Start of Reference List === */}

            <div class="break-inside-avoid">
              <dt class="sr-only">Alzheimer's Association (2024)</dt>
              <dd class="leading-relaxed">
                Alzheimer's Association. (2024). 2024 Alzheimer's disease facts and figures. <em>Alzheimer's & Dementia</em>, <em>20</em>(S1). <a href="https://doi.org/10.1002/alz.13698" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1002/alz.13698</span><Fragment set:html={externalLinkIcon} /></a>
              </dd>
            </div>

            <div class="break-inside-avoid">
              <dt class="sr-only">Anstey et al. (2011)</dt>
              <dd class="leading-relaxed">
                Anstey, K. J., Cherbuin, N., Budge, M., & Young, J. (2011). Body mass index in midlife and late-life as a risk factor for dementia: A meta-analysis of prospective studies. <em>Obesity Reviews</em>, <em>12</em>(5), e159â€“e168. <a href="https://doi.org/10.1111/j.1467-789X.2010.00744.x" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1111/j.1467-789X.2010.00744.x</span><Fragment set:html={externalLinkIcon} /></a>
              </dd>
            </div>

            <div class="break-inside-avoid">
              <dt class="sr-only">Anstey et al. (2007)</dt>
              <dd class="leading-relaxed">
                Anstey, K. J., von Sanden, C., Salim, A., & O'Kearney, R. (2007). Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. <em>American Journal of Epidemiology</em>, <em>166</em>(4), 367â€“378. <a href="https://doi.org/10.1093/aje/kwm116" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1093/aje/kwm116</span><Fragment set:html={externalLinkIcon} /></a>
              </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Arnold et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H. Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., Holtzman, D. M., & Nathan, D. M. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. <em>Nature Reviews Neurology</em>, <em>14</em>(3), 168â€“181. <a href="https://doi.org/10.1038/nrneurol.2017.185" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nrneurol.2017.185</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Arevalo-Rodriguez et al. (2015)</dt>
                <dd class="leading-relaxed">
                    Arevalo-Rodriguez, I., Smailagic, N., RoquÃ© i Figuls, M., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., Pedraza, O. L., Bonfill Cosp, X., & Cullum, S. (2015). Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). <em>Cochrane Database of Systematic Reviews</em>, (3), CD010783. <a href="https://doi.org/10.1002/14651858.CD010783.pub2" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1002/14651858.CD010783.pub2</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Arvanitakis et al. (2019)</dt>
                <dd class="leading-relaxed">
                    Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019). Diagnosis and management of dementia: A review. <em>JAMA</em>, <em>322</em>(16), 1589â€“1599. <a href="https://doi.org/10.1001/jama.2019.4782" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1001/jama.2019.4782</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Ashton et al. (2022)</dt>
                <dd class="leading-relaxed">
                    Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., SuÃ¡rez-Calvet, M., ... & Blennow, K. (2022). Plasma p-tau217 predicts longitudinal brain atrophy and cognitive decline in non-demented adults. <em>Nature Medicine</em>, <em>28</em>(10), 2158â€“2168. <a href="https://doi.org/10.1038/s41591-022-01993-0" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/s41591-022-01993-0</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Baumgart et al. (2015)</dt>
                <dd class="leading-relaxed">
                    Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015). Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. <em>Alzheimer's & Dementia</em>, <em>11</em>(6), 718â€“726. <a href="https://doi.org/10.1016/j.jalz.2015.04.002" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.jalz.2015.04.002</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Bezprozvanny & Mattson (2008)</dt>
                <dd class="leading-relaxed">
                    Bezprozvanny, I., & Mattson, M. P. (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. <em>Trends in Neurosciences</em>, <em>31</em>(9), 454â€“463. <a href="https://doi.org/10.1016/j.tins.2008.06.005" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.tins.2008.06.005</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Birks (2006)</dt>
                <dd class="leading-relaxed">
                    Birks, J. S. (2006). Cholinesterase inhibitors for Alzheimer's disease. <em>Cochrane Database of Systematic Reviews</em>, (1), CD005593. <a href="https://doi.org/10.1002/14651858.CD005593" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1002/14651858.CD005593</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Bondi et al. (2017)</dt>
                <dd class="leading-relaxed">
                    Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017). Alzheimerâ€™s disease: Past, present, and future. <em>Journal of the International Neuropsychological Society</em>, <em>23</em>(9-10), 818â€“831. <a href="https://doi.org/10.1017/S135561771700100X" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1017/S135561771700100X</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Brodaty & Donkin (2009)</dt>
                <dd class="leading-relaxed">
                    Brodaty, H., & Donkin, M. (2009). Family caregivers of people with dementia. <em>Dialogues in Clinical Neuroscience</em>, <em>11</em>(2), 217â€“228. <a href="https://doi.org/10.31887/DCNS.2009.11.2/hbrodaty" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.31887/DCNS.2009.11.2/hbrodaty</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Cummings et al. (2021)</dt>
                <dd class="leading-relaxed">
                    Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021). Aducanumab: Appropriate use recommendations. <em>The Journal of Prevention of Alzheimer's Disease</em>, <em>8</em>(4), 398â€“410. <a href="https://doi.org/10.14283/jpad.2021.41" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.14283/jpad.2021.41</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Cummings et al. (2023)</dt>
                <dd class="leading-relaxed">
                    Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023). Alzheimer's disease drug development pipeline: 2023. <em>Alzheimer's & Dementia: Translational Research & Clinical Interventions</em>, <em>9</em>(2), e12385. <a href="https://doi.org/10.1002/trc2.12385" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1002/trc2.12385</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">De la Monte & Wands (2008)</dt>
                <dd class="leading-relaxed">
                    De la Monte, S. M., & Wands, J. R. (2008). Alzheimer's disease is type 3 diabetesâ€”evidence reviewed. <em>Journal of Diabetes Science and Technology</em>, <em>2</em>(6), 1101â€“1113. <a href="https://doi.org/10.1177/193229680800200619" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1177/193229680800200619</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Deckers et al. (2015)</dt>
                <dd class="leading-relaxed">
                    Deckers, K., van Boxtel, M. P., Schiepers, O. J., de Vugt, M., MuÃ±oz SÃ¡nchez, J. L., Anstey, K. J., ... & KÃ¶hler, S. (2015). Target risk factors for dementia prevention: A systematic review and Delphi consensus study on the evidence from observational studies. <em>International Journal of Geriatric Psychiatry</em>, <em>30</em>(3), 234â€“246. <a href="https://doi.org/10.1002/gps.4150" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1002/gps.4150</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Frisoni et al. (2010)</dt>
                <dd class="leading-relaxed">
                    Frisoni, G. B., Fox, N. C., Jack, C. R., Jr, Scheltens, P., & Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. <em>Nature Reviews Neurology</em>, <em>6</em>(2), 67â€“77. <a href="https://doi.org/10.1038/nrneurol.2009.215" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nrneurol.2009.215</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Galvin et al. (2006)</dt>
                <dd class="leading-relaxed">
                    Galvin, J. E., Roe, C. M., Powlishta, K. K., Coats, M. A., Muich, S. J., Grant, E., Miller, J. P., Storandt, M., & Morris, J. C. (2006). The AD8: A brief informant interview to detect dementia. <em>Neurology</em>, <em>67</em>(8), 1391â€“1397. <a href="https://doi.org/10.1212/01.wnl.0000242554.85391.1e" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1212/01.wnl.0000242554.85391.1e</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Gitlin et al. (2012)</dt>
                <dd class="leading-relaxed">
                    Gitlin, L. N., Kales, H. C., & Lyketsos, C. G. (2012). Nonpharmacologic management of behavioral symptoms in dementia. <em>JAMA</em>, <em>308</em>(19), 2020â€“2029. <a href="https://doi.org/10.1001/jama.2012.36918" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1001/jama.2012.36918</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Goedert & Spillantini (2006)</dt>
                <dd class="leading-relaxed">
                    Goedert, M., & Spillantini, M. G. (2006). A century of Alzheimer's disease. <em>Science</em>, <em>314</em>(5800), 777â€“781. <a href="https://doi.org/10.1126/science.1132814" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1126/science.1132814</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Goldman et al. (2011)</dt>
                <dd class="leading-relaxed">
                    Goldman, J. S., Hahn, S. E., Catania, J. W., LaRusse-Eckert, S., Butson, M. B., Rumbaugh, M., ... & Mayeux, R. (2011). Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. <em>Genetics in Medicine</em>, <em>13</em>(6), 597â€“605. <a href="https://doi.org/10.1097/GIM.0b013e31821d69b8" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1097/GIM.0b013e31821d69b8</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Gorelick et al. (2011)</dt>
                <dd class="leading-relaxed">
                    Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., ... & Benavente, O. (2011). Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. <em>Stroke</em>, <em>42</em>(9), 2672â€“2713. <a href="https://doi.org/10.1161/STR.0b013e3182299496" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1161/STR.0b013e3182299496</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Groot et al. (2016)</dt>
                <dd class="leading-relaxed">
                    Groot, C., Hooghiemstra, A. M., Raijmakers, P. G., van Berckel, B. N., Scheltens, P., Scherder, E. J., van der Flier, W. M., & Ossenkoppele, R. (2016). The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. <em>Ageing Research Reviews</em>, <em>25</em>, 13â€“23. <a href="https://doi.org/10.1016/j.arr.2015.11.005" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.arr.2015.11.005</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Heneka et al. (2015)</dt>
                <dd class="leading-relaxed">
                    Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., ... & Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. <em>The Lancet Neurology</em>, <em>14</em>(4), 388â€“405. <a href="https://doi.org/10.1016/S1474-4422(15)70016-5" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/S1474-4422(15)70016-5</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Iadecola (2013)</dt>
                <dd class="leading-relaxed">
                    Iadecola, C. (2013). The pathobiology of vascular dementia. <em>Neuron</em>, <em>80</em>(4), 844â€“866. <a href="https://doi.org/10.1016/j.neuron.2013.10.008" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.neuron.2013.10.008</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Jack et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Jack, C. R., Jr, Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., ... & Phelps, C. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <em>Alzheimer's & Dementia</em>, <em>14</em>(4), 535â€“562. <a href="https://doi.org/10.1016/j.jalz.2018.02.018" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.jalz.2018.02.018</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Johnson et al. (2013)</dt>
                <dd class="leading-relaxed">
                    Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., ... & Thies, W. (2013). Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimerâ€™s Association. <em>Alzheimer's & Dementia</em>, <em>9</em>(1), e1â€“e16. <a href="https://doi.org/10.1016/j.jalz.2013.01.002" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.jalz.2013.01.002</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Kales et al. (2015)</dt>
                <dd class="leading-relaxed">
                    Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015). Assessment and management of behavioral and psychological symptoms of dementia. <em>BMJ</em>, <em>350</em>, h369. <a href="https://doi.org/10.1136/bmj.h369" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1136/bmj.h369</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Kametani & Hasegawa (2018)</dt>
                <dd class="leading-relaxed">
                    Kametani, F., & Hasegawa, M. (2018). Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimerâ€™s disease. <em>Frontiers in Neuroscience</em>, <em>12</em>, 25. <a href="https://doi.org/10.3389/fnins.2018.00025" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.3389/fnins.2018.00025</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Karikari et al. (2020)</dt> {/* Assuming Karikari 2020 from diagnosis page */}
                <dd class="leading-relaxed">
                    Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., ... & Blennow, K. (2020). Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <em>The Lancet Neurology</em>, <em>19</em>(5), 422â€“433. <a href="https://doi.org/10.1016/S1474-4422(20)30071-5" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/S1474-4422(20)30071-5</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Knopman et al. (2021)</dt>
                <dd class="leading-relaxed">
                    Knopman, D. S., Amieva, H., Petersen, R. C., ChÃ©telat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021). Alzheimer disease. <em>Nature Reviews Disease Primers</em>, <em>7</em>(1), 33. <a href="https://doi.org/10.1038/s41572-021-00269-y" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/s41572-021-00269-y</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

             <div class="break-inside-avoid">
                 <dt class="sr-only">Knopman et al. (2001)</dt> {/* Added from diagnosis page */}
                 <dd class="leading-relaxed">
                     Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey-Bloom, J., Fetting, J., ... & Stevens, J. C. (2001). Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. <em>Neurology</em>, <em>56</em>(9), 1143â€“1153. <a href="https://doi.org/10.1212/wnl.56.9.1143" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1212/wnl.56.9.1143</span><Fragment set:html={externalLinkIcon} /></a>
                 </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Kuiper et al. (2015)</dt>
                <dd class="leading-relaxed">
                    Kuiper, J. S., Zuidersma, M., Oude Voshaar, R. C., Zuidema, S. U., van den Heuvel, E. R., Stolk, R. P., & Smidt, N. (2015). Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. <em>Ageing Research Reviews</em>, <em>22</em>, 39â€“57. <a href="https://doi.org/10.1016/j.arr.2015.04.006" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.arr.2015.04.006</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Kuller & Lopez (2023)</dt>
                <dd class="leading-relaxed">
                    Kuller, L. H., & Lopez, O. L. (2023). Lecanemab for Alzheimer Disease: A Critical Appraisal. <em>JAMA</em>, <em>330</em>(6), 505â€“506. <a href="https://doi.org/10.1001/jama.2023.11931" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1001/jama.2023.11931</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Larouche et al. (2019)</dt>
                <dd class="leading-relaxed">
                    Larouche, E., Hudon, C., & Goulet, S. (2019). Potential benefits of mindfulness-based interventions on cognitive functioning in persons with mild cognitive impairment or dementia: A systematic review. <em>Geriatric Nursing</em>, <em>40</em>(2), 161â€“168. <a href="https://doi.org/10.1016/j.gerinurse.2018.09.005" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.gerinurse.2018.09.005</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Lin & Beal (2006)</dt>
                <dd class="leading-relaxed">
                    Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. <em>Nature</em>, <em>443</em>(7113), 787â€“795. <a href="https://doi.org/10.1038/nature05292" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nature05292</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Liu et al. (2013)</dt>
                <dd class="leading-relaxed">
                    Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. <em>Nature Reviews Neurology</em>, <em>9</em>(2), 106â€“118. <a href="https://doi.org/10.1038/nrneurol.2012.263" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nrneurol.2012.263</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Livingston et al. (2020)</dt>
                <dd class="leading-relaxed">
                    Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., ... & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. <em>The Lancet</em>, <em>396</em>(10248), 413â€“446. <a href="https://doi.org/10.1016/S0140-6736(20)30367-6" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/S0140-6736(20)30367-6</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">McKhann et al. (2011)</dt>
                <dd class="leading-relaxed">
                    McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr, Kawas, C. H., ... & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <em>Alzheimer's & Dementia</em>, <em>7</em>(3), 263â€“269. <a href="https://doi.org/10.1016/j.jalz.2011.03.005" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.jalz.2011.03.005</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">McShane et al. (2019)</dt>
                <dd class="leading-relaxed">
                    McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., ... & Hyde, C. (2019). Memantine for dementia. <em>Cochrane Database of Systematic Reviews</em>, (3), CD003154. <a href="https://doi.org/10.1002/14651858.CD003154.pub6" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1002/14651858.CD003154.pub6</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Meng & D'Arcy (2012)</dt>
                <dd class="leading-relaxed">
                    Meng, X., & D'Arcy, C. (2012). Education and dementia: A meta-analysis of observational studies. <em>Dementia and Geriatric Cognitive Disorders</em>, <em>34</em>(5-6), 299â€“311. <a href="https://doi.org/10.1159/000345102" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1159/000345102</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Moreno-GarcÃ­a et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Moreno-GarcÃ­a, A., Kun, A., Calero, O., Medina, M., & Calero, M. (2018). An overview of the role of lipofuscin in age-related neurodegeneration. <em>Frontiers in Neuroscience</em>, <em>12</em>, 464. <a href="https://doi.org/10.3389/fnins.2018.00464" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.3389/fnins.2018.00464</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Mosconi et al. (2008)</dt>
                <dd class="leading-relaxed">
                    Mosconi, L., Pupi, A., & De Leon, M. J. (2008). Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. <em>Annals of the New York Academy of Sciences</em>, <em>1147</em>(1), 180â€“195. <a href="https://doi.org/10.1196/annals.1427.007" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1196/annals.1427.007</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Nixon (2013)</dt>
                <dd class="leading-relaxed">
                    Nixon, R. A. (2013). The role of autophagy in neurodegenerative disease. <em>Nature Medicine</em>, <em>19</em>(8), 983â€“997. <a href="https://doi.org/10.1038/nm.3232" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nm.3232</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Olsson et al. (2016)</dt>
                <dd class="leading-relaxed">
                    Olsson, B., Lautner, R., Andreasson, U., Ã–hrfelt, A., Portelius, E., Bjerke, M., ... & Blennow, K. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. <em>The Lancet Neurology</em>, <em>15</em>(7), 673â€“684. <a href="https://doi.org/10.1016/S1474-4422(16)00070-3" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/S1474-4422(16)00070-3</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Ownby et al. (2006)</dt>
                <dd class="leading-relaxed">
                    Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006). Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. <em>Archives of General Psychiatry</em>, <em>63</em>(5), 530â€“538. <a href="https://doi.org/10.1001/archpsyc.63.5.530" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1001/archpsyc.63.5.530</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Peters et al. (2019)</dt>
                <dd class="leading-relaxed">
                    Peters, R., Ee, N., Peters, J., Booth, A., Mudway, I., & Anstey, K. J. (2019). Air pollution and dementia: A systematic review. <em>Journal of Alzheimer's Disease</em>, <em>70</em>(s1), S185â€“S203. <a href="https://doi.org/10.3233/JAD-180631" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.3233/JAD-180631</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Plassman et al. (2000)</dt>
                <dd class="leading-relaxed">
                    Plassman, B. L., Havlik, R. J., Steffens, D. C., Helms, M. J., Newman, T. N., Drosdick, D., ... & Breitner, J. C. S. (2000). Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. <em>Neurology</em>, <em>55</em>(8), 1158â€“1166. <a href="https://doi.org/10.1212/WNL.55.8.1158" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1212/WNL.55.8.1158</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Prins & Scheltens (2015)</dt>
                <dd class="leading-relaxed">
                    Prins, N. D., & Scheltens, P. (2015). White matter hyperintensities, cognitive impairment and dementia: An update. <em>Nature Reviews Neurology</em>, <em>11</em>(3), 157â€“165. <a href="https://doi.org/10.1038/nrneurol.2015.10" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nrneurol.2015.10</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Scarmeas et al. (2009)</dt>
                <dd class="leading-relaxed">
                    Scarmeas, N., Luchsinger, J. A., Schupf, N., Brickman, A. M., Cosentino, S., Tang, M. X., & Stern, Y. (2009). Physical activity, diet, and risk of Alzheimer disease. <em>JAMA</em>, <em>302</em>(6), 627â€“637. <a href="https://doi.org/10.1001/jama.2009.1144" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1001/jama.2009.1144</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Scarmeas et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018). Nutrition and prevention of cognitive impairment. <em>Current Opinion in Clinical Nutrition and Metabolic Care</em>, <em>21</em>(6), 450â€“456. <a href="https://doi.org/10.1097/MCO.0000000000000505" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1097/MCO.0000000000000505</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Scheff et al. (2006)</dt> {/* Changed year to match citation */}
                <dd class="leading-relaxed">
                    Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006). Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. <em>Neurobiology of Aging</em>, <em>27</em>(10), 1372â€“1384. <a href="https://doi.org/10.1016/j.neurobiolaging.2005.09.012" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.neurobiolaging.2005.09.012</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Scheltens et al. (2021)</dt>
                <dd class="leading-relaxed">
                    Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., ChÃ©telat, G., Teunissen, C. E., ... & Zetterberg, H. (2021). Alzheimer's disease. <em>The Lancet</em>, <em>397</em>(10284), 1577â€“1590. <a href="https://doi.org/10.1016/S0140-6736(20)32205-4" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/S0140-6736(20)32205-4</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Selkoe (2002)</dt>
                <dd class="leading-relaxed">
                    Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. <em>Science</em>, <em>298</em>(5594), 789â€“791. <a href="https://doi.org/10.1126/science.1074069" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1126/science.1074069</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Selkoe & Hardy (2016)</dt>
                <dd class="leading-relaxed">
                    Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. <em>EMBO Molecular Medicine</em>, <em>8</em>(6), 595â€“608. <a href="https://doi.org/10.15252/emmm.201606210" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.15252/emmm.201606210</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Serrano-Pozo et al. (2011)</dt>
                <dd class="leading-relaxed">
                    Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. <em>Cold Spring Harbor Perspectives in Medicine</em>, <em>1</em>(1), a006189. <a href="https://doi.org/10.1101/cshperspect.a006189" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1101/cshperspect.a006189</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Shankar & Walsh (2009)</dt>
                <dd class="leading-relaxed">
                    Shankar, G. M., & Walsh, D. M. (2009). Alzheimerâ€™s disease: Synaptic dysfunction and AÎ². <em>Molecular Neurodegeneration</em>, <em>4</em>(1), 48. <a href="https://doi.org/10.1186/1750-1326-4-48" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1186/1750-1326-4-48</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Shi et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Shi, L., Chen, S. J., Ma, M. Y., Bao, Y. P., Han, Y., Wang, Y. M., ... & Li, W. (2018). Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. <em>Sleep Medicine Reviews</em>, <em>40</em>, 4â€“16. <a href="https://doi.org/10.1016/j.smrv.2017.06.010" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.smrv.2017.06.010</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Sims et al. (2023)</dt>
                <dd class="leading-relaxed">
                    Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., ... & TRAILBLAZER-ALZ 2 Investigators. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. <em>JAMA</em>, <em>330</em>(6), 512â€“527. <a href="https://doi.org/10.1001/jama.2023.13239" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1001/jama.2023.13239</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Sperling et al. (2011)</dt> {/* Corrected year from 2021 */}
                <dd class="leading-relaxed">
                    Sperling, R. A., Jack, C. R., Jr, Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., ... & Aisen, P. S. (2011). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. <em>Alzheimer's & Dementia</em>, <em>7</em>(4), 367-385. <a href="https://doi.org/10.1016/j.jalz.2011.05.2351" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1016/j.jalz.2011.05.2351</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
              <dt class="sr-only">Stephen et al. (2017)</dt>
              <dd class="leading-relaxed">
                Stephen, R., Hongisto, K., Solomon, A., & LÃ¶nnroos, E. (2017). Physical activity and Alzheimer's disease: A systematic review. <em>The Journals of Gerontology: Series A</em>, <em>72</em>(6), 733â€“739. <a href="https://doi.org/10.1093/gerona/glw251" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1093/gerona/glw251</span><Fragment set:html={externalLinkIcon} /></a>
              </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Sweeney et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018). Bloodâ€“brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. <em>Nature Reviews Neurology</em>, <em>14</em>(3), 133â€“150. <a href="https://doi.org/10.1038/nrneurol.2017.188" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nrneurol.2017.188</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Tampi et al. (2016)</dt>
                <dd class="leading-relaxed">
                    Tampi, R. R., Tampi, D. J., Balachandran, S., & Hoq, R. (2016). Antipsychotic use in dementia: A systematic review of benefits and risks from meta-analyses. <em>Therapeutic Advances in Drug Safety</em>, <em>7</em>(5), 185â€“198. <a href="https://doi.org/10.1177/2042098616658463" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1177/2042098616658463</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Uddin et al. (2018)</dt> {/* Corrected year based on PubMed */}
                <dd class="leading-relaxed">
                    Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., Bergantin, L. B., Abdel-Daim, M. M., & Stankiewicz, A. M. (2018). Autophagy and Alzheimer's disease: From molecular mechanisms to therapeutic implications. <em>Frontiers in Aging Neuroscience</em>, <em>10</em>, 4. <a href="https://doi.org/10.3389/fnagi.2018.00004" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.3389/fnagi.2018.00004</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Vagelatos & Eslick (2013)</dt>
                <dd class="leading-relaxed">
                    Vagelatos, N. T., & Eslick, G. D. (2013). Type 2 diabetes as a risk factor for cognitive impairment and dementia: A meta-analysis of longitudinal cohort studies. <em>BMC Neurology</em>, <em>13</em>(1), 162. <a href="https://doi.org/10.1186/1471-2377-13-162" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1186/1471-2377-13-162</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">van Dyck et al. (2023)</dt>
                <dd class="leading-relaxed">
                    van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimerâ€™s disease. <em>New England Journal of Medicine</em>, <em>388</em>(1), 9â€“21. <a href="https://doi.org/10.1056/NEJMoa2212948" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1056/NEJMoa2212948</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Venegas & Heneka (2017)</dt>
                <dd class="leading-relaxed">
                    Venegas, C., & Heneka, M. T. (2017). Danger-associated molecular patterns in Alzheimer's disease. <em>Journal of Leukocyte Biology</em>, <em>101</em>(1), 87â€“98. <a href="https://doi.org/10.1189/jlb.3MR0416-204R" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1189/jlb.3MR0416-204R</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Villemagne et al. (2018)</dt>
                <dd class="leading-relaxed">
                    Villemagne, V. L., DorÃ©, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2018). AÎ²-amyloid and tau imaging in dementia. <em>Cold Spring Harbor Perspectives in Medicine</em>, <em>8</em>(9), a023711. <a href="https://doi.org/10.1101/cshperspect.a023711" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1101/cshperspect.a023711</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Walker & Lue (2015)</dt>
                <dd class="leading-relaxed">
                    Walker, K. A., & Lue, L. F. (2015). The role of inflammation in Alzheimer's disease. <em>Clinical Interventions in Aging</em>, <em>10</em>, 1697â€“1707. <a href="https://doi.org/10.2147/CIA.S71280" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.2147/CIA.S71280</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Wightman et al. (2021)</dt>
                <dd class="leading-relaxed">
                    Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., ... & Posthuma, D. (2021). A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <em>Nature Genetics</em>, <em>53</em>(9), 1276â€“1282. <a href="https://doi.org/10.1038/s41588-021-00921-z" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/s41588-021-00921-z</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>

            <div class="break-inside-avoid">
                <dt class="sr-only">Zlokovic (2011)</dt>
                <dd class="leading-relaxed">
                    Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. <em>Nature Reviews Neuroscience</em>, <em>12</em>(12), 723â€“738. <a href="https://doi.org/10.1038/nrn3114" target="_blank" rel="noopener noreferrer" class="group font-normal break-words inline-flex items-center"><span>https://doi.org/10.1038/nrn3114</span><Fragment set:html={externalLinkIcon} /></a>
                </dd>
            </div>
            {/* === End of Reference List === */}

        </dl>
    </div>
</BaseLayout>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\resources.astro
---
// src/pages/resources.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "Resources & Further Learning";
// SEO Description specific to this page.
const pageDescription = "Access reliable information, caregiving support, and research updates on Alzheimer's disease and related dementias from reputable organizations like the Alzheimer's Association, NIA, FCA, and ClinicalTrials.gov.";

// --- Data ---
// Defines breadcrumb navigation structure for this page.
const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "Resources", href: `${base}/resources/` } // Current page.
];

// Date stamp for when the resource links were last verified/retrieved.
const retrievalDate = "April 24, 2025"; // TODO: Update this date when links are verified.

// Array of resource objects, structured for easy rendering and styling.
// Each object includes name, URL, description, icon SVG, and theme color classes.
const resources = [
  {
    name: "Alzheimer's Association",
    href: "https://www.alz.org",
    description: "Leading non-profit dedicated to ending Alzheimer's through research, care, support, and advocacy. Offers extensive resources including a 24/7 helpline (1-800-272-3900) and local chapters.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path fill-rule="evenodd" d="M9.69 1.147a.75.75 0 0 1 .62 0L18.75 7.25a.75.75 0 0 1 .19 1.05l-1.22 1.758a.75.75 0 0 1-1.219-.041L13.75 6.75V16.5a.75.75 0 0 1-1.5 0V6.75l-2.75 3.928a.75.75 0 0 1-1.219.041L7.06 8.3a.75.75 0 0 1 .19-1.05l8.44-6.104Zm-7.5 5.75a.75.75 0 0 0-1.38-.57l-1.64 2.93a.75.75 0 0 0 1.218 1.106l1.095-.625v8.61a.75.75 0 0 0 1.5 0v-9.39l-.883-.504Z" clip-rule="evenodd" /></svg>`,
    baseColor: "purple", // Base theme color for Tailwind classes.
    mainShade: "600",    // Primary shade (e.g., text-purple-600).
    lightShade: "200",  // Lighter shade (e.g., border-purple-200).
    darkShade: "400",    // Dark mode text shade (e.g., dark:text-purple-400).
    gradientFrom: "purple-50/80", // Background gradient start (with opacity).
    gradientTo: "violet-50/80",   // Background gradient end (with opacity).
    darkGradientFrom: "slate-800/80", // Dark mode background gradient start.
    darkGradientTo: "slate-800/90",   // Dark mode background gradient end.
    darkBorder: "purple-700/60",      // Dark mode border color.
    darkHoverBorder: "purple-600/70"  // Dark mode hover border color.
  },
  {
    name: "National Institute on Aging (NIA) ADEAR Center",
    href: "https://www.nia.nih.gov/alzheimers",
    description: "US government agency (part of NIH) providing research-based information on AD and related dementias, including fact sheets, caregiving tips, and clinical trial details.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 0 0 3 3.5v13A1.5 1.5 0 0 0 4.5 18h11a1.5 1.5 0 0 0 1.5-1.5V7.621a1.5 1.5 0 0 0-.44-1.06l-4.12-4.122A1.5 1.5 0 0 0 11.378 2H4.5Zm4.75 11.75a.75.75 0 0 0 1.5 0v-2.546l.354.353a.75.75 0 0 0 1.06-1.06l-1.75-1.75a.75.75 0 0 0-1.06 0l-1.75 1.75a.75.75 0 1 0 1.06 1.06l.354-.353v2.546Z" clip-rule="evenodd" /><path d="M13 2.25a1.25 1.25 0 0 1 1.25 1.25v2.5A1.25 1.25 0 0 1 13 7.25H9.75A1.25 1.25 0 0 1 8.5 6V3.5A1.25 1.25 0 0 1 9.75 2.25H13Z" /></svg>`,
    baseColor: "blue",
    mainShade: "600",
    lightShade: "200",
    darkShade: "400",
    gradientFrom: "blue-50/80",
    gradientTo: "sky-50/80",
    darkGradientFrom: "slate-800/80",
    darkGradientTo: "slate-800/90",
    darkBorder: "blue-800/60", // Slightly adjusted dark border
    darkHoverBorder: "blue-700/70"
  },
  {
    name: "Family Caregiver Alliance (FCA)",
    href: "https://www.caregiver.org",
    description: "A non-profit offering support, education, policy information, and resources for family caregivers, including personalized tools like CareNav and multilingual resources.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path d="M10 9a3 3 0 1 0 0-6 3 3 0 0 0 0 6ZM10 11a6 6 0 0 1 6 6H4a6 6 0 0 1 6-6Z" /></svg>`,
    baseColor: "emerald",
    mainShade: "600",
    lightShade: "200",
    darkShade: "400",
    gradientFrom: "emerald-50/80",
    gradientTo: "green-50/80",
    darkGradientFrom: "slate-800/80",
    darkGradientTo: "slate-800/90",
    darkBorder: "emerald-700/60",
    darkHoverBorder: "emerald-600/70"
  },
  {
    name: "ClinicalTrials.gov",
    href: "https://www.clinicaltrials.gov",
    description: "A comprehensive registry and results database of public and private clinical studies worldwide, searchable for Alzheimer's disease and other conditions.",
    icon: `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-6 h-6"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 0 0 3 3.5v13A1.5 1.5 0 0 0 4.5 18h11a1.5 1.5 0 0 0 1.5-1.5V7.621a1.5 1.5 0 0 0-.44-1.06l-4.12-4.122A1.5 1.5 0 0 0 11.378 2H4.5Zm6.25 4.5a.75.75 0 0 0-1.5 0v2.5h-2.5a.75.75 0 0 0 0 1.5h2.5v2.5a.75.75 0 0 0 1.5 0v-2.5h2.5a.75.75 0 0 0 0-1.5h-2.5v-2.5Z" clip-rule="evenodd" /></svg>`,
    baseColor: "cyan",
    mainShade: "600",
    lightShade: "200",
    darkShade: "400",
    gradientFrom: "cyan-50/80",
    gradientTo: "teal-50/80",
    darkGradientFrom: "slate-800/80",
    darkGradientTo: "slate-800/90",
    darkBorder: "cyan-700/60",
    darkHoverBorder: "cyan-600/70"
  }
];

// Defines SVG icon markup for external links, used within the resource card titles.
const externalLinkIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="inline-block w-3 h-3 ml-0.5 align-baseline text-current/80 group-hover:text-current transition-colors duration-150 ease-in-out"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 0 0 3 3.5v9A1.5 1.5 0 0 0 4.5 14h9a1.5 1.5 0 0 0 1.5-1.5v-5a.75.75 0 0 0-1.5 0v5a.5.5 0 0 1-.5.5h-9a.5.5 0 0 1-.5-.5v-9a.5.5 0 0 1 .5-.5h5a.75.75 0 0 0 0-1.5h-5ZM10 .75A.75.75 0 0 1 10.75 0h4.5A.75.75 0 0 1 16 .75v4.5a.75.75 0 0 1-1.5 0V1.56l-4.97 4.97a.75.75 0 0 1-1.06-1.06L14.44 1H10.75A.75.75 0 0 1 10 .75Z" clip-rule="evenodd" /></svg>`;
---

{/* Apply BaseLayout with page-specific title, description, and breadcrumbs */}
<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs}>
    {/* Page Header */}
    <header class="mb-10 md:mb-12 text-center">
      <h1 class="mt-0 mb-4">{pageTitle}</h1>
      <p class="text-lg lg:text-xl text-slate-700 dark:text-slate-300 max-w-3xl mx-auto"> {/* Increased contrast */}
          Explore these reputable organizations for reliable information, caregiving support, and the latest research on Alzheimer's disease and related dementias.
      </p>
    </header>

    {/* Grid container for resource cards */}
    <div class="grid grid-cols-1 md:grid-cols-2 gap-8 md:gap-10 lg:gap-12">
      {/* Map over the resources array to generate each card */}
      {resources.map(resource => {
        // Dynamically construct Tailwind class lists based on the resource data.
        const cardClasses = [
          "group", "relative", "flex", "flex-col", "rounded-xl", "border", "p-6", "md:py-8", "md:px-7",
          "shadow-md", "transition-all", "duration-300", "ease-in-out", "transform",
          "hover:shadow-xl", "hover:-translate-y-1.5", "hover:scale-[1.02]", // Enhanced hover
          `border-${resource.baseColor}-${resource.lightShade}`,
          `dark:border-${resource.darkBorder}`,
          `bg-gradient-to-br from-${resource.gradientFrom} to-${resource.gradientTo}`,
          `dark:from-${resource.darkGradientFrom} dark:to-${resource.darkGradientTo}`,
          `hover:border-${resource.baseColor}-300`,
          `dark:hover:border-${resource.darkHoverBorder}`,
          // Focus-within styles provide visual feedback when the link inside is focused.
          `focus-within:ring-4 focus-within:ring-${resource.baseColor}-${resource.mainShade}/30 dark:focus-within:ring-${resource.baseColor}-${resource.darkShade}/40 focus-within:ring-offset-2 dark:focus-within:ring-offset-slate-900 focus-within:outline-none focus-within:border-${resource.baseColor}-400 dark:focus-within:border-${resource.baseColor}-500`,
          "overflow-hidden"
        ];
        const iconContainerClasses = [
            "inline-flex", "p-2.5", "rounded-full", "transition-all duration-300 ease-out",
            `text-${resource.baseColor}-${resource.mainShade}`,
            `dark:text-${resource.baseColor}-${resource.darkShade}`,
            `bg-${resource.baseColor}-100/80`, // Use slightly transparent background
            `dark:bg-${resource.baseColor}-900/50`, // Adjusted dark mode background
            "group-hover:scale-110 group-hover:rotate-[-8deg] group-hover:shadow-md",
            `group-hover:bg-${resource.baseColor}-100 dark:group-hover:bg-${resource.baseColor}-900/70` // Enhanced hover background
        ];
        const titleClasses = [
            "text-xl", "font-semibold", "mb-3", "mt-0",
            `text-${resource.baseColor}-800`, // Themed title color
            `dark:text-${resource.baseColor}-100`, // High contrast dark mode title
            "transition-colors duration-200 ease-in-out",
            `group-hover:text-${resource.baseColor}-900 dark:group-hover:text-${resource.baseColor}-50` // Title color change on hover
        ];
        const linkClasses = [
            "focus:outline-none", // Focus handled by parent focus-within
            "after:absolute", "after:inset-0", "after:rounded-xl", // Stretched link technique
             // Subtle inner ring appears on focus-within for extra feedback
            `after:ring-inset after:ring-2 after:ring-transparent group-focus-within:after:ring-${resource.baseColor}-${resource.mainShade}/40 dark:group-focus-within:after:ring-${resource.baseColor}-${resource.darkShade}/50 after:transition-shadow after:duration-200`
        ];
        const descriptionClasses = [
            "text-sm", "leading-relaxed", "flex-grow", "mb-4",
            `text-slate-700`, // Consistent description color
            `dark:text-slate-300`
        ];
        const footerClasses = [
            "mt-auto", "pt-3", "border-t",
            `border-${resource.baseColor}-200/60 dark:border-slate-700/50`, // Themed border
            "text-xs", `text-slate-500 dark:text-slate-400/80`, // Subtler footer text
        ];
        // Removes default code background/padding for cleaner footer presentation.
        const codeClasses = ["font-normal", "bg-transparent dark:bg-transparent", "p-0", "border-none"];

        return (
            // Render the card container with dynamic classes
            <div class:list={cardClasses}>
              {/* Card Header: Icon and Title */}
              <div class="flex items-start gap-x-4 mb-4">
                {/* Icon Container */}
                <div class:list={iconContainerClasses}>
                  <Fragment set:html={resource.icon} />
                </div>
                {/* Title (contains the stretched link) */}
                <h2 class:list={titleClasses}>
                  <a href={resource.href} target="_blank" rel="noopener noreferrer" class:list={linkClasses}>
                    {resource.name}
                    <Fragment set:html={externalLinkIcon} /> {/* Add external icon */}
                  </a>
                </h2>
              </div>
              {/* Card Description */}
              <p class:list={descriptionClasses}>
                {resource.description}
              </p>
              {/* Card Footer with Retrieval Date */}
              <p class:list={footerClasses}>
                <code class:list={codeClasses}>[(Retrieved {retrievalDate})]</code>
              </p>
            </div>
        );
      })}
    </div>
</BaseLayout>

{/* Optional Global Styles */}
<style is:global>
    /* Ensure smooth scrolling for any potential internal page jumps */
    html {
        scroll-behavior: smooth;
    }
</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\treatment.astro
---
// src/pages/treatment.astro
import BaseLayout from '../layouts/BaseLayout.astro';
const base = import.meta.env.BASE_URL;
const pageTitle = "Alzheimer's Disease: Treatment & Management Strategies";

const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "Treatment", href: `${base}/treatment/` }
];

// Helper function to render inline citations consistently.
function renderCitation(text: string): string {
  const textString = String(text);
  // Added subtle hover effect
  return `<code class="inline-block align-baseline text-[0.7rem] font-normal not-italic bg-slate-200/70 dark:bg-slate-700/70 px-1 py-0.5 rounded mx-0.5 transition-colors duration-150 hover:bg-slate-300 dark:hover:bg-slate-600">${textString.replace(/[\[\]()]/g, '')}</code>`;
}

// SVG Icons for section headings
const symptomIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path fill-rule="evenodd" d="M11.25 5.5A1.25 1.25 0 1 0 8.75 5.5a1.25 1.25 0 0 0 2.5 0ZM10 10.5a.75.75 0 0 0-1.5 0v1.167l-1.083 1.083a.75.75 0 1 0 1.06 1.06L9.25 13.06l.001.09a.75.75 0 0 0 1.5 0l-.001-.09 1.146 1.146a.75.75 0 1 0 1.06-1.06L11.5 11.667V10.5ZM10 18a7.5 7.5 0 1 0 0-15 7.5 7.5 0 0 0 0 15ZM10 5a5 5 0 1 0 0 10 5 5 0 0 0 0-10Z" clip-rule="evenodd" /></svg>`;
const modifyIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path d="M15.98 1.804a1 1 0 0 0-1.96 0l-.148.59a.946.946 0 0 1-1.406.832l-.467-.467a1 1 0 1 0-1.414 1.414l.467.467a.946.946 0 0 1-.832 1.406l-.59.148a1 1 0 0 0 0 1.96l.59.148a.946.946 0 0 1 .832 1.406l-.467.467a1 1 0 1 0 1.414 1.414l.467-.467a.946.946 0 0 1 1.406.832l.148.59a1 1 0 0 0 1.96 0l.148-.59a.946.946 0 0 1 1.406-.832l.467.467a1 1 0 1 0 1.414-1.414l-.467-.467a.946.946 0 0 1 .832-1.406l.59-.148a1 1 0 0 0 0-1.96l-.59-.148a.946.946 0 0 1-.832-1.406l.467-.467a1 1 0 1 0-1.414-1.414l-.467.467a.946.946 0 0 1-1.406-.832l-.148-.59ZM10 6.25a3.75 3.75 0 1 0 0 7.5 3.75 3.75 0 0 0 0-7.5ZM4.02 1.804a1 1 0 0 0-1.96 0l-.148.59c-.28.04-.56.09-.832.15l-.467-.467a1 1 0 1 0-1.414 1.414l.467.467c-.06.272-.11.552-.15.832L.02 6.944a1 1 0 0 0 0 1.96l.59.148c.04.28.09.56.15.832l-.467.467a1 1 0 1 0 1.414 1.414l.467-.467c.272.06.552.11.832.15l.148.59a1 1 0 0 0 1.96 0l.148-.59c.28-.04.56-.09.832-.15l.467.467a1 1 0 1 0 1.414-1.414l-.467-.467c.06-.272.11-.552.15-.832l.59-.148a1 1 0 0 0 0-1.96l-.59-.148c-.04-.28-.09-.56-.15-.832l.467-.467a1 1 0 1 0-1.414-1.414l-.467.467c-.272-.06-.552-.11-.832-.15L4.02 1.804Z" /></svg>`;
const behaviorIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path fill-rule="evenodd" d="M18 10a8 8 0 1 1-16 0 8 8 0 0 1 16 0Zm-5.5-2.5a2.5 2.5 0 1 1-5 0 2.5 2.5 0 0 1 5 0ZM10 12a5.99 5.99 0 0 0-4.793 2.39A6.483 6.483 0 0 0 10 16.5a6.483 6.483 0 0 0 4.793-2.11A5.99 5.99 0 0 0 10 12Z" clip-rule="evenodd" /></svg>`;
const lifestyleIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path fill-rule="evenodd" d="M15.98 1.804a1 1 0 0 0-1.96 0l-.148.59a.946.946 0 0 1-1.406.832l-.467-.467a1 1 0 1 0-1.414 1.414l.467.467a.946.946 0 0 1-.832 1.406l-.59.148a1 1 0 0 0 0 1.96l.59.148a.946.946 0 0 1 .832 1.406l-.467.467a1 1 0 1 0 1.414 1.414l.467-.467a.946.946 0 0 1 1.406.832l.148.59a1 1 0 0 0 1.96 0l.148-.59a.946.946 0 0 1 1.406-.832l.467.467a1 1 0 1 0 1.414-1.414l-.467-.467a.946.946 0 0 1 .832-1.406l.59-.148a1 1 0 0 0 0-1.96l-.59-.148a.946.946 0 0 1-.832-1.406l.467-.467a1 1 0 1 0-1.414-1.414l-.467.467a.946.946 0 0 1-1.406-.832l-.148-.59Zm-6.05 9.6a.75.75 0 1 0-1.06-1.06L7 12.25V8.75a.75.75 0 0 0-1.5 0v5a.75.75 0 0 0 .75.75h5a.75.75 0 0 0 0-1.5H8.75l1.884-1.885Z" clip-rule="evenodd" /></svg>`;
const supportIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path d="M10 9a3 3 0 1 0 0-6 3 3 0 0 0 0 6ZM10 11a6 6 0 0 1 6 6H4a6 6 0 0 1 6-6Z" /></svg>`;
const planningIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path fill-rule="evenodd" d="M5.5 4.75a.75.75 0 0 1 .75-.75h.5a.75.75 0 0 1 0 1.5h-.5a.75.75 0 0 1-.75-.75ZM8.5 4a.75.75 0 0 0-.75.75v.5a.75.75 0 0 0 1.5 0v-.5A.75.75 0 0 0 8.5 4Z" clip-rule="evenodd" /><path d="M2 6.25A2.25 2.25 0 0 1 4.25 4h7.5A2.25 2.25 0 0 1 14 6.25v7.5A2.25 2.25 0 0 1 11.75 16h-7.5A2.25 2.25 0 0 1 2 13.75v-7.5ZM4.25 5.5c-.69 0-1.25.56-1.25 1.25v7.5c0 .69.56 1.25 1.25 1.25h7.5c.69 0 1.25-.56 1.25-1.25v-7.5c0-.69-.56-1.25-1.25-1.25h-7.5Z" /></svg>`;
const monitorIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path fill-rule="evenodd" d="M1 5.25A2.25 2.25 0 0 1 3.25 3h13.5A2.25 2.25 0 0 1 19 5.25v9.5A2.25 2.25 0 0 1 16.75 17H3.25A2.25 2.25 0 0 1 1 14.75v-9.5Zm1.5 0v7.5a.75.75 0 0 0 .75.75H10A.75.75 0 0 0 10 12h6.75a.75.75 0 0 0 .75-.75v-7.5a.75.75 0 0 0-.75-.75H3.25a.75.75 0 0 0-.75.75Zm14 8.25v1.75a.75.75 0 0 1-1.5 0v-1.75a.75.75 0 0 1 1.5 0Z" clip-rule="evenodd" /></svg>`;
const trialsIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 0 0 3 3.5v13A1.5 1.5 0 0 0 4.5 18h11a1.5 1.5 0 0 0 1.5-1.5V7.621a1.5 1.5 0 0 0-.44-1.06l-4.12-4.122A1.5 1.5 0 0 0 11.378 2H4.5Zm6.25 4.5a.75.75 0 0 0-1.5 0v2.5h-2.5a.75.75 0 0 0 0 1.5h2.5v2.5a.75.75 0 0 0 1.5 0v-2.5h2.5a.75.75 0 0 0 0-1.5h-2.5v-2.5Z" clip-rule="evenodd" /></svg>`;
---
<BaseLayout title={pageTitle} breadcrumbs={breadcrumbs}>
    <header class="mb-10 md:mb-12 text-center">
      {/* Added subtle gradient to title */}
      <h1 class="text-3xl md:text-4xl lg:text-5xl font-extrabold tracking-tight bg-gradient-to-r from-blue-600 to-indigo-600 dark:from-blue-400 dark:to-indigo-400 bg-clip-text text-transparent mt-0 mb-4 pb-1">{pageTitle}</h1>
      <p class="text-lg lg:text-xl text-slate-600 dark:text-slate-400 leading-relaxed max-w-3xl mx-auto">
          Currently, no definitive cure exists for Alzheimer's Disease (AD): a relentless, progressive neurodegenerative disorder invariably characterized by gradual erosion of essential cognitive functionsâ€”memory, thinking, reasoningâ€”and accompanied by profound changes in behavior and personality. Ultimately, AD culminates in a complete inability to perform even basic activities of daily living independently. However, despite the absence of a cure, a multi-faceted, highly individualized management approach can effectively address debilitating symptoms; can significantly enhance quality of life for both the person living with AD and their dedicated caregivers; and, in certain specific contexts with newer therapies, may potentially decelerate underlying disease progression. Integrating several crucial domains, a comprehensive, holistic strategy necessarily includes: targeted lifestyle modifications meticulously aimed at promoting overall brain health; specific pharmacological interventions (medications) addressing both clinical symptoms and, more recently, underlying disease pathology; emerging therapeutic approaches currently under active investigation; and robust, indispensable systems providing comprehensive caregiver support and essential education. Precise combination and relative emphasis of diverse strategies must be meticulously tailoredâ€”customized to the individual's specific stage of AD (mild, moderate, severe), overall co-existing health status, unique profile of presenting symptoms, and articulated personal values and preferences <Fragment set:html={renderCitation("Adapted from Cummings et al., 2021; Alzheimer's Association, 2024; Arvanitakis et al., 2019")} />.
      </p>
    </header>

    {/* --- Image: Management Components Diagram --- */}
    <figure class="my-12 md:my-16 group text-center">
      <img
        src={`${base}/assets/ad-treatment-summary.jpeg`}
        alt="Circular diagram: Key Components of Early-Stage Alzheimer's Management. Center circle 'Person with AD'. Surrounding elements: Medications (Symptomatic & DMTs), Healthy Lifestyle (Diet, Exercise, Sleep), Caregiver Support & Education, Monitoring & Follow-up, Advance Care Planning, Cognitive & Social Stimulation."
        class="mx-auto block max-w-full rounded-xl border border-slate-200 shadow-lg transition duration-300 ease-in-out group-hover:shadow-xl dark:border-slate-700 md:max-w-xl lg:max-w-2xl group-hover:scale-[1.03]" 
        loading="lazy" width="700" height="700"
      />
      <figcaption class="mt-4 text-xs italic text-slate-500 dark:text-slate-400 transition group-hover:text-slate-600 dark:group-hover:text-slate-300 px-4 max-w-xl mx-auto">
        <strong class="font-semibold not-italic">Fig. 1: Comprehensive Management Components for Early-Stage Alzheimer's Disease.</strong> Visually conceptualizing the requisite holistic, integrated approach, Figure 1 provides a framework. At the very center resides the individual undergoing treatment for early-stage AD. Encircling the core focus are six essential, interconnected, and dynamically interacting components:
        <ul class="list-disc list-inside text-left mt-2 space-y-0.5">
            <li><strong class="font-medium">Cognitive Stimulation</strong> (Red Segment, Brain Icon): Highlighting the fundamental necessity of consistently engaging in mentally challenging and stimulating activities (e.g., solving complex puzzles, learning novel skills or information), cognitive stimulation aims specifically to maintain existing cognitive function and potentially bolster cognitive reserve.</li>
            <li><strong class="font-medium">Medications</strong> (Orange Segment, Pills Icon): Referring specifically to pharmacological treatments, medications primarily encompass established cholinesterase inhibitors and memantine for managing cognitive and functional symptoms, potentially including newer disease-modifying therapies designed to target underlying amyloid pathology in eligible individuals.</li>
            <li><strong class="font-medium">Healthy Lifestyle</strong> (Green Segment, Dumbbell Icon): Emphasizing the critical role of consistent physical activity, adherence to beneficial nutrition patterns (e.g., brain-healthy diets like Mediterranean or MIND), ensuring adequate restorative sleep, and diligently managing vascular risk factors (like hypertension, diabetes), this component supports overall brain health and potentially slows disease progression.</li>
            <li><strong class="font-medium">Caregiver Support</strong> (Purple Segment, Heart/Hand Icon): Underscoring the absolutely critical importance of proactively providing essential resources, targeted education, and vital emotional support to family members and other individuals undertaking the demanding role of providing care, caregiver support explicitly recognizes the significant physical, emotional, and financial burdens inherent in the role.</li>
            <li><strong class="font-medium">Monitoring and Follow-Up</strong> (Blue Segment, Checklist Icon): Stressing the non-negotiable need for regular, systematic assessments conducted by healthcare professionals, monitoring and follow-up is essential. Serving to meticulously track disease progression over time, rigorously evaluate the effectiveness of implemented treatments, effectively manage any co-existing medical conditions, and appropriately adjust the comprehensive care plan as individual needs inevitably evolve, assessments are crucial.</li>
            <li><strong class="font-medium">Advance Care Planning</strong> (Pink Segment, Calendar/Document Icon): Pointing directly to the profound importance of initiating early, open discussions and completing formal documentation regarding individual future healthcare preferences, core values concerning quality of life, and formal designation of a trusted healthcare decision-maker (proxy) for a time when they may no longer be capable of making such decisions themselves, advance care planning is vital.</li>
        </ul>
         Circular arrangement implies components are not static but rather interactive and ongoing facets, continuously informing and shaping a truly comprehensive, person-centered care plan.
      </figcaption>
    </figure>
    {/* --- End Image --- */}

    {/* --- Main Sections Container --- */}
    <div class="space-y-16 md:space-y-20 lg:space-y-24"> {/* Increased spacing */}

        {/* == Symptomatic Medications Section == */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-blue-50 to-indigo-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-blue-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-1">
            <h2 class="text-2xl md:text-3xl font-semibold text-blue-900 dark:text-blue-200 mb-6 mt-0 flex items-start gap-x-3"> {/* Increased margin */}
                 <span class="mt-1 text-blue-500 shrink-0 transition-transform duration-300 group-hover:scale-110"><Fragment set:html={symptomIcon} /></span>
                 <div>
                   Symptomatic Medications
                   <span class="block text-sm font-normal text-blue-700 dark:text-blue-300">Addressing Cognitive Changes</span>
                 </div>
            </h2>
            <p class="mb-6 text-slate-600 dark:text-slate-400 max-w-prose text-base leading-relaxed">
                Specific pharmacological treatments formally approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), symptomatic medications are explicitly designed to alleviate cognitive symptoms (e.g., demonstrable memory loss, measurable attention deficits) intrinsically associated with AD. Crucially, understand that medications do *not* halt or reverse fundamental underlying neurodegenerative processes responsible for causing progressive brain cell damage and deathâ€”their primary therapeutic function is restricted to managing clinical *manifestations* of the disease, corresponding conceptually to the 'Medications' component illustrated in Figure 1, but distinct from disease-modifying agents.
            </p>
            <div class="space-y-6 text-base text-slate-700 dark:text-slate-300 max-w-prose">
                {/* Sub-section with enhanced details/summary */}
                <details class="group/details rounded-lg bg-slate-50 dark:bg-slate-700/30 p-4 open:ring-1 open:ring-black/10 open:dark:ring-white/10 open:shadow-sm transition duration-300 hover:bg-slate-100 dark:hover:bg-slate-700/50">
                    <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 transition duration-200 ease-in-out hover:text-blue-700 dark:hover:text-blue-300 focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-700 rounded-sm">
                        <span class="transition duration-300 ease-in-out group-open/details:rotate-90">
                            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                        </span>
                        Cholinesterase Inhibitors
                    </summary>
                    <div class="mt-4 pl-6 text-sm text-slate-600 dark:text-slate-400 space-y-3 leading-relaxed">
                        <p>(Specific examples include: Donepezil [marketed as AriceptÂ®], Rivastigmine [marketed as ExelonÂ® - available as capsules or a transdermal patch], Galantamine [marketed as RazadyneÂ®]): An established class of drugs, cholinesterase inhibitors represent the standard, first-line pharmacologic treatment approach for individuals diagnosed with <strong class="font-medium text-slate-700 dark:text-slate-100">mild to moderate stages of AD</strong>. (Clinical severity stagesâ€”mild, moderate, severeâ€”are classifications based primarily on observed degree of cognitive impairment and resultant impact on functional independence in daily life.)</p>
                        <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Mechanism of Action:</em> Functioning pharmacologically by specifically inhibiting the enzyme acetylcholinesterase, these drugs target acetylcholine breakdown. Acetylcholinesterase normally performs the physiological function of breaking down <strong class="font-medium text-slate-700 dark:text-slate-100">acetylcholine</strong>: a critical neurotransmitter (a chemical messenger facilitating signal transmission between nerve cells) fundamentally essential for efficient neural communication, particularly within brain circuits heavily involved in memory formation, memory consolidation, new learning processes, and sustained attention. By effectively reducing enzymatic breakdown of acetylcholine, inhibitor drugs consequently increase its ambient concentration and prolong its duration of action within the synaptic cleft (the microscopic space between communicating neurons)â€”thereby aiming to enhance cholinergic neurotransmission, known to be deficient in AD.</p>
                        <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Effect & Limitations:</em> Leading in some individuals to modest, objectively measurable, yet temporary improvements in cognitive function (manifesting, for example, as slightly better performance on standardized memory tests, potentially increased ability to focus attention, or temporary stabilization rather than continued decline in cognitive scores), pharmacological enhancement of cholinergic signaling offers limited benefit. However, therapeutic benefit derived is purely symptomatic and inherently time-limited; underlying disease process relentlessly continues to destroy cholinergic neurons, eventually rendering the drugs progressively less effective over time. Furthermore, gastrointestinal side effects are relatively common and can include nausea, vomiting, diarrhea, and loss of appetite, sometimes necessitating dose adjustments or discontinuation <Fragment set:html={renderCitation("Birks, 2006; Arvanitakis et al., 2019")} />.</p>
                        <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Example Scenarios:</em> (1) A person diagnosed with early-stage AD experiencing mild but noticeable forgetfulness might initiate treatment with Donepezilâ€”and subsequently observe a slight, temporary improvement in their ability to recall recent events or conversations, lasting perhaps for several months. (2) Another individual diagnosed with moderate AD might find initiating Rivastigmine helps maintain their ability to actively participate in conversations for a slightly longer duration compared to their pre-treatment trajectory. (3) Conversely, a different patient might experience significant, intolerable gastrointestinal side effects (e.g., severe nausea) upon starting an oral cholinesterase inhibitorâ€”requiring either discontinuation of the drug or potentially switching to an alternative formulation (e.g., the Rivastigmine transdermal patch, often reducing GI issues).</p>
                    </div>
                </details>
                {/* Sub-section for NMDA antagonist */}
                 <details class="group/details rounded-lg bg-slate-50 dark:bg-slate-700/30 p-4 open:ring-1 open:ring-black/10 open:dark:ring-white/10 open:shadow-sm transition duration-300 hover:bg-slate-100 dark:hover:bg-slate-700/50">
                     <summary class="text-lg font-semibold text-slate-800 dark:text-slate-100 cursor-pointer list-none flex items-center gap-x-2 transition duration-200 ease-in-out hover:text-blue-700 dark:hover:text-blue-300 focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-blue-500 focus-visible:ring-offset-2 dark:focus-visible:ring-offset-slate-700 rounded-sm">
                         <span class="transition duration-300 ease-in-out group-open/details:rotate-90">
                            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-4"><path fill-rule="evenodd" d="M6.22 4.22a.75.75 0 0 1 1.06 0l3.25 3.25a.75.75 0 0 1 0 1.06l-3.25 3.25a.75.75 0 0 1-1.06-1.06L8.94 8 6.22 5.28a.75.75 0 0 1 0-1.06Z" clip-rule="evenodd" /></svg>
                        </span>
                        NMDA Receptor Antagonist
                    </summary>
                     <div class="mt-4 pl-6 text-sm text-slate-600 dark:text-slate-400 space-y-3 leading-relaxed">
                         <p>(Specific example: Memantine [marketed as NamendaÂ®]): Possessing a distinct mechanism of action, Memantine is typically indicated for individuals diagnosed with <strong class="font-medium text-slate-700 dark:text-slate-100">moderate to severe stages of AD</strong>. Frequently prescribed as an adjunct therapy (meaning used concurrently *in combination with* a cholinesterase inhibitor), it can also be utilized as monotherapy (administered alone) in certain clinical situations.</p>
                         <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Mechanism of Action:</em> Memantine functions by modulating the activity of <strong class="font-medium text-slate-700 dark:text-slate-100">glutamate</strong>: another principal excitatory neurotransmitter crucially involved in fundamental learning and memory processes throughout the brain. In the context of AD, damaged or dying neurons can lead to excessive, unregulated release of glutamate into the synaptic space. Resulting in persistent overstimulation of specific glutamate receptors known as NMDA (N-methyl-D-aspartate) receptors, chronic oversupply of glutamate is detrimental. Termed excitotoxicity, the pathological state of chronic receptor overstimulation is hypothesized to contribute further to neuronal damage and dysfunction. Memantine acts pharmacologically as a low-affinity, uncompetitive antagonist of the NMDA receptor. Allowing selective blocking of pathological, continuous (tonic) activation of NMDA receptors caused by excessive ambient glutamate, while critically still permitting normal, brief (phasic) activation required for physiological learning and memory processes, this specific mode of action is key.</p>
                         <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Effect & Limitations:</em> By effectively regulating glutamate activity and mitigating excitotoxicity, Memantine aims to provide a degree of neuroprotection for remaining viable neurons and potentially improve the signal-to-noise ratio within glutamatergic neurotransmission pathways. Modestly aiding learning capacity, memory function, and overall global functioning, particularly during later stages of AD progression, modulation may offer some benefit. Any observed benefits are generally considered modest and primarily symptomatic; focus is often on stabilizing or slightly slowing the rate of decline in ability to perform basic daily functions, such as dressing or feeding oneself independently. Importantly, Memantine does *not* halt underlying progression of the disease itself. Common potential side effects associated with Memantine include dizziness, headache, confusion, and constipation <Fragment set:html={renderCitation("McShane et al., 2019; Arvanitakis et al., 2019")} />.</p>
                         <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Example Scenarios:</em> (1) An individual diagnosed with severe AD, already receiving treatment with Donepezil, might have Memantine added to their regimen specifically to help manage increasing symptoms of confusion or agitation related to advanced cognitive decline. (2) Someone clinically transitioning from moderate to severe stage AD might initiate treatment with Memantineâ€”and subsequently demonstrate a slightly slower rate of worsening in their ability to perform basic activities of daily living compared to projections based on their previous trajectory without the drug. (3) A contrasting clinical case could involve an individual experiencing intolerable dizziness upon starting Memantine, necessitating either a reduction in dosage or complete cessation of the medication.</p>
                     </div>
                 </details>
            </div>
        </section>

        {/* == Disease-Modifying Therapies Section == */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-purple-50 to-violet-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-purple-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-1">
            <h2 class="text-2xl md:text-3xl font-semibold text-purple-900 dark:text-purple-200 mb-5 mt-0 flex items-start gap-x-3">
                <span class="mt-1 text-purple-500 shrink-0 transition-transform duration-300 group-hover:scale-110"><Fragment set:html={modifyIcon} /></span>
                <div>
                    Disease-Modifying Therapies (Anti-Amyloid mAbs)
                    <span class="block text-sm font-normal text-purple-700 dark:text-purple-300">Targeting Underlying Pathology</span>
                </div>
            </h2>
            <p class="mb-6 text-slate-600 dark:text-slate-400 max-w-prose text-base leading-relaxed">
                Representing a fundamentally distinct, newer category of pharmacological treatment meticulously designed to specifically target underlying biological processes (core neuropathology) hypothesized to actively drive AD progressionâ€”rather than merely managing resultant clinical symptoms, DMTs offer a different approach. Ambitious therapeutic goal of DMTs is to demonstrably slow down the inexorable rate at which the disease worsens over time. Falling under the broad conceptual umbrella of 'Medications' (as depicted in Fig. 1), agents possess a fundamentally different mechanism of action and therapeutic objective compared to purely symptomatic treatments like cholinesterase inhibitors or memantine. Currently available DMTs approved for AD primarily target amyloid pathology accumulation within the brain.
            </p>
            <div class="space-y-4 max-w-prose text-base text-slate-700 dark:text-slate-300 leading-relaxed">
                <p>
                    <strong class="font-semibold text-slate-800 dark:text-slate-100">Lecanemab (LeqembiÂ®) & Donanemab:</strong> Specific examples of monoclonal antibodies (mAbs)â€”complex, laboratory-engineered proteins precisely designed to recognize and bind with high specificity to particular molecular targetsâ€”Lecanemab and Donanemab target amyloid. In the context of AD therapies, targets are specific forms of the amyloid-beta (AÎ²) protein. (AÎ² protein abnormally accumulates in the brains of individuals with AD, aggregating to form characteristic amyloid plaquesâ€”a defining pathological hallmark of the disease.) Having received formal regulatory approval (Lecanemab currently holds FDA approval) or being in final stages of clinical development and regulatory review (Donanemab), specific therapies are utilized within a carefully defined patient population: specifically, individuals diagnosed with <strong class="font-semibold">Mild Cognitive Impairment (MCI) due to AD</strong> (a clinical stage where cognitive changes are objectively detectable but do not yet significantly impair independent daily functioning) or those diagnosed with <strong class="font-semibold">mild-stage AD dementia</strong>. Critically, eligibility for initiating the therapies mandates definitive confirmation of existing amyloid pathology within the patient's brainâ€”a requirement typically fulfilled through either cerebrospinal fluid (CSF) analysis demonstrating the characteristic AD biomarker signature or via a positive amyloid Positron Emission Tomography (PET) scan visually confirming plaque deposition.
                </p>
                <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Mechanism of Action:</em> Administered via intravenous (IV) infusion, monoclonal antibody therapies circulate within the bloodstream. Subsequently circulating within the bloodstream, they need to effectively cross the protective blood-brain barrier to reach their target within the brain parenchyma. Once in the brain, binding with high affinity to specific conformational forms of AÎ² occurs (e.g., Lecanemab preferentially targets soluble AÎ² protofibrils, considered highly neurotoxic species; Donanemab targets a specific pyroglutamate form of AÎ² found within established plaques). Effectively 'tagging' targeted AÎ² species for subsequent clearance and removal by the brain's resident immune cells, primarily microglia, binding facilitates removal. By actively reducing overall AÎ² burden within the brain, the therapeutic aim is to consequently lessen downstream toxic effects (such as propagation of tau pathology and progressive neuronal dysfunction) and thereby demonstrably slow the otherwise relentless decline in cognitive abilities and functional independence characteristic of AD progression <Fragment set:html={renderCitation("van Dyck et al., 2023; Sims et al., 2023")} />.</p>
                <p><em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Effect & Limitations:</em> Rigorous, large-scale Phase 3 clinical trials have successfully demonstrated that anti-amyloid antibody therapies can indeed modestly slow the average rate of cognitive and functional decline (for example, Lecanemab showed a statistically significant 27% slowing of decline over an 18-month period, as measured by the primary outcome scale, the Clinical Dementia Rating-Sum of Boxes [CDR-SB]) when compared directly to placebo administration in the specifically eligible patient population. However, absolutely crucial is emphasizing that therapies do *not* halt the decline entirely, nor reverse any existing neurological damage or provide a cure for the disease. Observed effect size, while statistically significant in group analyses, remains subject to ongoing debate regarding its practical clinical meaningfulness for individual patients facing the disease. Nonetheless, therapies represent a significant, tangible advancement in the field of AD treatmentâ€”offering the first approved agents targeting underlying pathology, but are definitively not a universal solution applicable to all individuals with AD.</p>
                {/* Considerations Box - Enhanced */}
                <div class="mt-6 rounded-lg border border-amber-300 dark:border-amber-600/60 bg-amber-50 dark:bg-slate-800/80 p-5 ring-1 ring-amber-100 dark:ring-amber-900/30 shadow-md transition-shadow hover:shadow-lg">
                    <p class="text-base font-semibold text-amber-900 dark:text-amber-300 mb-3 flex items-center gap-x-1.5">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="w-5 h-5 shrink-0"><path fill-rule="evenodd" d="M8 15A7 7 0 1 0 8 1a7 7 0 0 0 0 14Zm-.75-10.25a.75.75 0 0 1 1.5 0v4a.75.75 0 0 1-1.5 0v-4Zm.75 7a.75.75 0 1 0 0-1.5.75.75 0 0 0 0 1.5Z" clip-rule="evenodd" /></svg>
                        Key Considerations & Requirements:
                    </p>
                    <ul class="list-disc list-outside ml-6 text-sm text-amber-800 dark:text-slate-300/90 leading-relaxed space-y-2">
                        <li><strong class="font-medium">Administration:</strong> Treatment necessitates regular intravenous (IV) infusionsâ€”typically administered every two weeks (Lecanemab) or every four weeks (Donanemab)â€”which must be conducted within specialized healthcare settings (such as hospital outpatient infusion centers or appropriately equipped neurology clinics). Inherently posing significant logistical challenges and time commitments for both patients and their caregivers, the requirement is demanding.</li>
                        <li><strong class="font-medium">Monitoring for ARIA:</strong> Mandatory, serial Magnetic Resonance Imaging (MRI) scans of the brain are absolutely essential for safety monitoring. Including a baseline MRI prior to initiating treatment, followed by several additional MRIs performed at specific intervals during initial months and first year of therapy, monitoring is intensive. Primary purpose of intensive monitoring is to detect potential occurrence of Amyloid-Related Imaging Abnormalities (ARIA). ARIA refers to specific radiological findings observed on MRI scans known as potential side effects associated with anti-amyloid antibody therapies. ARIA can manifest in two primary forms: ARIA-E (indicating vasogenic Edema or sulcal effusions, often reflecting temporary fluid changes across the blood-brain barrier) or ARIA-H (representing Hemosiderin deposition, suggestive of cerebral microhemorrhages or superficial siderosis [bleeding on the brain surface]). While ARIA is frequently asymptomatic and resolves spontaneously following brief interruption of medication, it may occasionally induce clinical symptoms, including headache, disorientation, dizziness, visual abnormalities, nausea, and, in rare occasions, seizures or more serious neurological disorders. Standardized protocols dictate ARIA management, typically involving temporary suspension or permanent discontinuation of antibody treatment based on radiological severity and presence or absence of clinical symptoms <Fragment set:html={renderCitation("Sperling et al., 2011")} />.</li>
                        <li><strong class="font-medium">Patient Eligibility:</strong> Strict eligibility criteria must be met for initiating the therapies. Invariably including definitive biomarker confirmation of brain amyloid pathology and a clinical diagnosis falling within specific disease stages of MCI due to AD or mild AD dementia, criteria are rigorous. Furthermore, individuals possessing certain pre-existing medical conditions (e.g., bleeding disorders, concurrent use of anticoagulant medications) or specific genetic factors (e.g., individuals homozygous for the APOE Îµ4 alleleâ€”demonstrating a significantly higher risk of developing ARIA) may require particularly careful risk-benefit assessment or may be excluded from treatment eligibility altogether.</li>
                        <li><strong class="font-medium">Cost and Access:</strong> Currently holding a very high financial cost, new medicines create obstacles; insurance coverage regulations and reimbursement criteria are constantly changing and vary greatly. Practical access to treatment may also be limited by geographical availability of specialized diagnostic facilities (required for PET scans or CSF analysis), appropriately equipped infusion centers, and neurology practices possessing necessary expertise and infrastructure to manage complex monitoring requirements associated with the treatments <Fragment set:html={renderCitation("Kuller & Lopez, 2023")} />.</li>
                    </ul>
                    <p class="text-xs text-amber-700 dark:text-slate-400 mt-3"><em class="italic">Example Scenarios:</em> (1) A 68-year-old with confirmed amyloid PET and MCI related to AD begins Lecanemab. MRIs reveal no ARIA. Over 18 months, cognitive decline is somewhat slower than usual for untreated people. (2) A 72-year-old with moderate AD develops asymptomatic ARIA-E on MRI; medication is discontinued, ARIA disappears, and treatment is carefully reintroduced. (3) A patient in a remote region lacks access to infusion facilities or MRI monitoring, making therapy difficult despite eligibility.</p>
                </div>
            </div>
        </section>

         {/* == BPSD Section == */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-orange-50 to-amber-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-orange-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-1">
             <h2 class="text-2xl md:text-3xl font-semibold text-orange-900 dark:text-orange-200 mb-5 mt-0 flex items-start gap-x-3">
                <span class="mt-1 text-orange-500 shrink-0 transition-transform duration-300 group-hover:scale-110"><Fragment set:html={behaviorIcon} /></span>
                 <div>
                    Managing Behavioral and Psychological Symptoms of Dementia (BPSD)
                     <span class="block text-sm font-normal text-orange-700 dark:text-orange-300">Improving Daily Life & Well-being</span>
                 </div>
            </h2>
            <p class="mb-6 text-slate-600 dark:text-slate-400 max-w-prose text-base leading-relaxed">
                BPSD encompass a spectrum of non-cognitive symptoms common in AD, including agitation, apathy, depression, anxiety, delusions, hallucinations, sleep disturbances, and disinhibition. Managing these is crucial for the well-being of both the person with AD and their caregivers.
            </p>
             <ol class="list-none space-y-8 text-base text-slate-700 dark:text-slate-300 max-w-prose"> {/* Increased spacing */}
                 {/* BPSD Item 1 - Enhanced */}
                <li class="group/item relative pl-10 before:content-['1'] before:absolute before:left-0 before:top-0 before:size-7 before:bg-orange-200 dark:before:bg-orange-700 before:text-orange-700 dark:before:text-orange-200 before:rounded-full before:font-bold before:flex before:items-center before:justify-center transition-transform duration-200 ease-out group-hover/item:scale-105">
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-100 mb-2 mt-0 transition-colors duration-200 ease-in-out group-hover/item:text-orange-700 dark:group-hover/item:text-orange-300">Non-pharmacological Interventions (First-Line Approach):</h3>
                     <p class="text-sm text-slate-600 dark:text-slate-400 mt-1.5 leading-relaxed space-y-2">
                        <span>Universally recommended first, this <strong class="font-medium text-slate-700 dark:text-slate-100">person-centered approach</strong> prioritizes understanding the individual and identifying the cause behind the behavior before using medication.</span>
                        <span class="block mb-1 font-semibold text-slate-700 dark:text-slate-200"><em class="italic">Core Strategies & Rationale:</em></span>
                        <ul class="list-disc list-outside pl-5 space-y-1">
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Identifying & Modifying Triggers:</strong> Systematically observe to find factors (internal like pain/infection, or external like noise/clutter/complex tasks) causing the behavior and mitigate them. BPSD often signal distress or unmet needs.</li>
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Environmental Modifications:</strong> Adjust surroundings to be safe, calm, familiar (reduce clutter/noise, use signage, familiar objects). Reduces stressors and confusion.</li>
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Structured Activities & Routine:</strong> Establish consistent daily routines and engage in activities tailored to interests/abilities (simple chores, music, reminiscence, gentle exercise). Provides structure, reduces anxiety, promotes engagement.</li>
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Sensory Engagement:</strong> Use appropriate sensory stimulation (music therapy, aromatherapy, tactile objects, pet therapy) to evoke positive emotions and reduce agitation.</li>
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Caregiver Education & Support:</strong> Equip caregivers with knowledge (communication techniques, stress management, disease progression) and access to support systems (support groups, respite care). Supported caregivers provide better care and can delay institutionalization <Fragment set:html={renderCitation("Livingston et al., 2017; Gitlin et al., 2012; Arvanitakis et al., 2019")} />.</li>
                        </ul>
                        <span class="block mb-1 font-semibold text-slate-700 dark:text-slate-200"><em class="italic">Example Scenarios:</em></span>
                        <p>(1) 'Sundowning' (late-day pacing/anxiety) minimized by recognizing fatigue/noise as triggers and adopting afternoon rest/quiet time. (2) Resistance to bathing improved by caregiver utilizing calm communication, maintaining comfort, playing music, providing easy options. (3) Apathy mitigated by engaging individual in modest, familiar tasks like washing laundry or listening to preferred music. (4) Sudden severe agitation necessitates evaluation for acute medical reasons (such UTI) initially.</p>
                    </p>
                </li>
                {/* BPSD Item 2 - Enhanced */}
                 <li class="group/item relative pl-10 before:content-['2'] before:absolute before:left-0 before:top-0 before:size-7 before:bg-orange-200 dark:before:bg-orange-700 before:text-orange-700 dark:before:text-orange-200 before:rounded-full before:font-bold before:flex before:items-center before:justify-center transition-transform duration-200 ease-out group-hover/item:scale-105">
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-100 mb-2 mt-0 transition-colors duration-200 ease-in-out group-hover/item:text-orange-700 dark:group-hover/item:text-orange-300">Pharmacological Interventions (Second-Line, Used Cautiously):</h3>
                     <p class="text-sm text-slate-600 dark:text-slate-400 mt-1.5 leading-relaxed space-y-2">
                         <span>Considered *only* when non-pharmacological approaches fail for severe, dangerous, or highly distressing symptoms. Guiding principle: <strong class="font-semibold">"start low, go slow"</strong> (lowest effective dose, titrate gradually, reassess need, shortest duration).</span>
                         <span class="block mb-1 font-semibold text-slate-700 dark:text-slate-200"><em class="italic">Potential Options & Significant Risks:</em></span>
                        <ul class="list-disc list-outside pl-5 space-y-1">
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Antidepressants (SSRIs):</strong> Often first-line for depression, anxiety, sometimes agitation (e.g., Citalopram, Sertraline). Generally better tolerated than antipsychotics in this population.</li>
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Antipsychotics:</strong> (e.g., Risperidone, Olanzapine) considered cautiously for severe agitation/aggression/psychosis unresponsive to other methods. Carry <strong class="font-semibold text-red-600 dark:text-red-400">significant risks</strong> in dementia patients (increased mortality, stroke, sedation, falls, cognitive worsening, movement problems). Benefits must clearly outweigh risks <Fragment set:html={renderCitation("Kales et al., 2015; Tampi et al., 2016; Arvanitakis et al., 2019")} />.</li>
                            <li><strong class="font-medium text-slate-700 dark:text-slate-200">Other classes:</strong> Mood stabilizers or benzodiazepines occasionally used but have significant risks (sedation, falls, dependence).</li>
                        </ul>
                        <span class="block mb-1 font-semibold text-slate-700 dark:text-slate-200"><em class="italic">Example Scenarios:</em></span>
                        <p>(1) Severe, distressing delusions/aggression unresponsive to non-drug methods might warrant a cautious trial of a low-dose antipsychotic with close monitoring. (2) Clear clinical depression alongside AD might benefit from an SSRI. (3) Using antipsychotics for mild restlessness without trying other methods first is generally inappropriate. Always attempt to taper/discontinue psychotropics when possible.</p>
                    </p>
                </li>
            </ol>
        </section>

        {/* == Lifestyle Section == */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-green-50 to-emerald-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-green-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-1">
            <h2 class="text-2xl md:text-3xl font-semibold text-green-900 dark:text-green-200 mb-5 mt-0 flex items-start gap-x-3">
                <span class="mt-1 text-green-500 shrink-0 transition-transform duration-300 group-hover:scale-110"><Fragment set:html={lifestyleIcon} /></span>
                <div>
                    Lifestyle Modifications & Brain Health
                    <span class="block text-sm font-normal text-green-700 dark:text-green-300">Supporting Overall Well-being</span>
                </div>
            </h2>
            <p class="mb-6 text-slate-600 dark:text-slate-400 max-w-prose text-base leading-relaxed">
                Lifestyle factors significantly influence brain health throughout life and can impact AD risk and progression. These strategies are fundamental to comprehensive AD management ('Healthy Lifestyle' and 'Cognitive Stimulation' in Fig. 1). While not a cure, they aim to optimize remaining function, enhance resilience, manage risk factors, and improve quality of life.
            </p>
            <div class="grid grid-cols-1 sm:grid-cols-2 gap-x-8 gap-y-6 text-sm text-slate-700 dark:text-slate-300 max-w-prose">
                {/* Lifestyle Item 1 - Enhanced */}
                <div class="group/item flex items-start gap-x-3 transition-colors duration-200 hover:text-green-800 dark:hover:text-green-300">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-5 text-green-600 dark:text-green-400 mt-0.5 shrink-0 transition-transform duration-200 group-hover/item:scale-110"><path fill-rule="evenodd" d="M13.133 4.014a.75.75 0 0 1 .413.97l-2.25 6a.75.75 0 0 1-1.392-.52l1.584-4.224a.75.75 0 0 1-.548-.858l.23-1.459a1.5 1.5 0 0 1 1.963-.88ZM6.867 4.014a.75.75 0 0 0-.413.97l2.25 6a.75.75 0 1 0 1.392-.52L8.515 5.24a.75.75 0 0 0 .548-.858l-.23-1.459a1.5 1.5 0 0 0-1.963-.88Z" clip-rule="evenodd" /></svg>
                    <div><strong class="font-semibold text-slate-800 dark:text-slate-100 block">Physical Exercise:</strong> Consistently engaging in regular physical activity, tailored to individual capabilities. <em class="block mt-1 font-semibold text-slate-700 dark:text-slate-200">Benefits:</em> Improves cerebral blood flow, promotes cardiovascular health, regulates sleep, reduces stress, elevates mood, and may stimulate neurotrophic factors supporting neuron health and plasticity <Fragment set:html={renderCitation("Groot et al., 2016")} />. <em class="block mt-1 font-semibold text-slate-700 dark:text-slate-200">Examples:</em> Brisk walks, supervised classes (chair yoga, Tai Chi), gardening, dancing, swimming (adapted as needed).</div>
                </div>
                 {/* Lifestyle Item 2 - Enhanced */}
                <div class="group/item flex items-start gap-x-3 transition-colors duration-200 hover:text-green-800 dark:hover:text-green-300">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-5 text-green-600 dark:text-green-400 mt-0.5 shrink-0 transition-transform duration-200 group-hover/item:scale-110"><path d="M5.5 3.5A1.5 1.5 0 0 1 7 2h2a1.5 1.5 0 0 1 1.5 1.5v1a.5.5 0 0 1-1 0v-1a.5.5 0 0 0-.5-.5H7a.5.5 0 0 0-.5.5v1a.5.5 0 0 1-1 0v-1ZM9.5 7a.5.5 0 0 1 .5-.5h1a.5.5 0 0 1 0 1h-1a.5.5 0 0 1-.5-.5ZM3 7.5a.5.5 0 0 0 1 0V7a.5.5 0 0 0-1 0v.5ZM6.5 11a.5.5 0 0 1 .5-.5h3a.5.5 0 0 1 0 1h-3a.5.5 0 0 1-.5-.5Z" /><path fill-rule="evenodd" d="M0 8a8 8 0 1 1 16 0A8 8 0 0 1 0 8Zm8-6.5a6.5 6.5 0 1 0 0 13 6.5 6.5 0 0 0 0-13Z" clip-rule="evenodd" /></svg>
                    <div><strong class="font-semibold text-slate-800 dark:text-slate-100 block">Healthy Diet (Nutrition):</strong> Adopting patterns like the Mediterranean or MIND diets (rich in fruits, vegetables, whole grains, fish, nuts, olive oil; limited red meat, sweets, processed foods). <em class="block mt-1 font-semibold text-slate-700 dark:text-slate-200">Benefits:</em> Provides antioxidants, anti-inflammatory compounds, vitamins, and healthy fats to combat oxidative stress, support vascular health, and maintain brain cells <Fragment set:html={renderCitation("Scarmeas et al., 2018")} />. <em class="block mt-1 font-semibold text-slate-700 dark:text-slate-200">Examples:</em> Swap processed snacks for nuts/berries, eat fatty fish (salmon) twice weekly, include leafy greens, ensure hydration. Adapt textures if needed.</div>
                 </div>
                 {/* Lifestyle Item 3 - Enhanced */}
                 <div class="group/item flex items-start gap-x-3 transition-colors duration-200 hover:text-green-800 dark:hover:text-green-300">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-5 text-green-600 dark:text-green-400 mt-0.5 shrink-0 transition-transform duration-200 group-hover/item:scale-110"><path d="M10 3.75a2.25 2.25 0 1 0-4.5 0 2.25 2.25 0 0 0 4.5 0ZM8.5 5.75a.75.75 0 0 0-1.5 0v1.5a.75.75 0 0 0 1.5 0v-1.5ZM4.375 9.75a.75.75 0 0 0 0 1.5h7.25a.75.75 0 0 0 0-1.5h-7.25Z" /></svg>
                    <div><strong class="font-semibold text-slate-800 dark:text-slate-100 block">Cognitive & Social Stimulation:</strong> Actively engaging the mind (puzzles, games, reading, learning new things) and maintaining social connections (visits, groups, conversations). <em class="block mt-1 font-semibold text-slate-700 dark:text-slate-200">Benefits:</em> May strengthen neural connections, build cognitive reserve, improve mood, and maintain functional abilities longer <Fragment set:html={renderCitation("Livingston et al., 2020")} />. Simplify activities for later stages.</div>
                 </div>
                  {/* Lifestyle Item 4 - Enhanced */}
                 <div class="group/item flex items-start gap-x-3 transition-colors duration-200 hover:text-green-800 dark:hover:text-green-300">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="size-5 text-green-600 dark:text-green-400 mt-0.5 shrink-0 transition-transform duration-200 group-hover/item:scale-110"><path fill-rule="evenodd" d="M11.444 2.688a3.01 3.01 0 0 0-4.888 0L.56 8.233a1.004 1.004 0 0 0 1.789 1.004l1.011-.562v1.443a.5.5 0 0 0 .5.5h8.278a.5.5 0 0 0 .5-.5V8.675l1.01.562a1.004 1.004 0 0 0 1.79-1.004l-5.996-5.545Zm1.023 7.013a.75.75 0 0 0-1.267-.81L8 11.918l-2.2-.314a.75.75 0 0 0-.7-.018l-2 1A.75.75 0 0 0 4 13.25V14a.5.5 0 0 0 .5.5h7a.5.5 0 0 0 .5-.5v-.75a.75.75 0 0 0-.733-.749Z" clip-rule="evenodd" /></svg>
                    <div><strong class="font-semibold text-slate-800 dark:text-slate-100 block">Adequate Sleep:</strong> Ensuring sufficient, high-quality sleep. <em class="block mt-1 font-semibold text-slate-700 dark:text-slate-200">Benefits:</em> Crucial for memory consolidation and brain waste clearance (including AÎ² via the glymphatic system). Poor sleep is linked to AÎ² accumulation <Fragment set:html={renderCitation("Shi et al., 2018")} />. Address sleep disturbances (insomnia, sleep apnea) and practice good sleep hygiene (consistent schedule, calming routine, optimized environment).</div>
                 </div>
             </div>
        </section>

       {/* == Ongoing Management & Support Section == */}
      <section class="p-6 md:p-8 rounded-xl bg-slate-100 dark:bg-slate-800/60 border border-slate-200 dark:border-slate-700/60 shadow-md">
          <h2 class="text-2xl md:text-3xl font-semibold text-slate-800 dark:text-slate-200 mb-8 mt-0 text-center">
              Ongoing Management, Support & Future Planning
          </h2>
           <div class="grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-4 gap-6 md:gap-8">
             {/* Grid Cards - Added hover effects and transition */}
             {/* Advance Care Planning Card */}
             <div class="group text-center md:text-left p-4 rounded-lg bg-white dark:bg-slate-700/50 shadow-sm hover:shadow-lg transition-all duration-300 ease-in-out hover:scale-[1.03]">
                 <div class="flex justify-center md:justify-start mb-3">
                    <span class="inline-flex p-2 rounded-full bg-indigo-100 dark:bg-indigo-900/50 text-indigo-600 dark:text-indigo-400 transition-transform duration-200 group-hover:scale-110"><Fragment set:html={planningIcon} /></span>
                 </div>
                 <h3 class="text-lg font-semibold text-slate-700 dark:text-slate-100 mb-2">Advance Care Planning (ACP)</h3>
                 <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Definition:</em> An ongoing process of communication and documentation to articulate values, goals, and preferences for future medical care, especially for when one cannot make decisions.
                 </p>
                 <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Importance & Timing:</em> Crucial to start <strong class="font-medium">early</strong> while the person with AD has decision-making capacity to ensure autonomy and reduce future family distress.
                 </p>
                  <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Key Components:</em> Reflecting on values, discussing goals of care, appointing a healthcare proxy, and documenting preferences in forms like a living will <Fragment set:html={renderCitation("NIA, 2021; Alzheimer's Association, n.d.")} />.
                 </p>
             </div>
              {/* Regular Follow-up Card */}
              <div class="group text-center md:text-left p-4 rounded-lg bg-white dark:bg-slate-700/50 shadow-sm hover:shadow-lg transition-all duration-300 ease-in-out hover:scale-[1.03]">
                <div class="flex justify-center md:justify-start mb-3">
                    <span class="inline-flex p-2 rounded-full bg-sky-100 dark:bg-sky-900/50 text-sky-600 dark:text-sky-400 transition-transform duration-200 group-hover:scale-110"><Fragment set:html={monitorIcon} /></span>
                </div>
                <h3 class="text-lg font-semibold text-slate-700 dark:text-slate-100 mb-2">Regular Follow-up</h3>
                <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Definition:</em> Scheduled, systematic, ongoing assessments by healthcare professionals to track the disease course and manage overall health.
                </p>
                 <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Purpose & Process:</em> Regular check-ins (typically every 3-6 months) serve to: (1) Track disease progression (cognitive, functional, behavioral changes). (2) Manage co-existing medical conditions. (3) Adjust treatments (evaluate effectiveness/side effects). (4) Assess safety (home environment, driving, falls). (5) Support caregivers (address concerns, provide resources) <Fragment set:html={renderCitation("Arvanitakis et al., 2019; Petersen et al., 2018")} />.
                 </p>
            </div>
             {/* Caregiver Support Card */}
             <div class="group text-center md:text-left p-4 rounded-lg bg-white dark:bg-slate-700/50 shadow-sm hover:shadow-lg transition-all duration-300 ease-in-out hover:scale-[1.03]">
                <div class="flex justify-center md:justify-start mb-3">
                    <span class="inline-flex p-2 rounded-full bg-pink-100 dark:bg-pink-900/50 text-pink-600 dark:text-pink-400 transition-transform duration-200 group-hover:scale-110"><Fragment set:html={supportIcon} /></span>
                </div>
                <h3 class="text-lg font-semibold text-slate-700 dark:text-slate-100 mb-2">Caregiver Education & Support</h3>
                <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Definition:</em> Providing knowledge, skills, resources, and emotional support to family/friends caring for someone with AD.
                </p>
                <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Critical Need:</em> Caregiving is demanding and associated with high stress, burnout, and health issues for the caregiver. Support is essential for both caregiver well-being and the quality of care provided <Fragment set:html={renderCitation("Brodaty & Donkin, 2009")} />.
                </p>
                 <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Types of Support:</em> Includes education (disease progression, symptom management), skills training (personal care, behavior management), emotional support (support groups, counseling), respite care (temporary relief), and practical assistance (navigating resources). See <a href={`${base}/resources/`} class="text-blue-600 dark:text-blue-400 hover:underline focus:outline-none focus:ring-1 focus:ring-blue-500 rounded">Resources</a>.
                 </p>
            </div>
             {/* Clinical Trials Card */}
             <div class="group text-center md:text-left p-4 rounded-lg bg-white dark:bg-slate-700/50 shadow-sm hover:shadow-lg transition-all duration-300 ease-in-out hover:scale-[1.03]">
                <div class="flex justify-center md:justify-start mb-3">
                    <span class="inline-flex p-2 rounded-full bg-emerald-100 dark:bg-emerald-900/50 text-emerald-600 dark:text-emerald-400 transition-transform duration-200 group-hover:scale-110"><Fragment set:html={trialsIcon} /></span>
                </div>
                <h3 class="text-lg font-semibold text-slate-700 dark:text-slate-100 mb-2">Clinical Trials</h3>
                <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Definition:</em> Research studies involving human volunteers to test the safety and effectiveness of new medical approaches (drugs, diagnostics, interventions).
                </p>
                 <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Role in AD:</em> Participation is essential for advancing understanding and developing better treatments. Trials explore diverse approaches targeting amyloid, tau, inflammation, and more, plus non-pharmacological strategies <Fragment set:html={renderCitation("Cummings et al., 2023")} />.
                </p>
                <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Considerations:</em> Offers potential access to cutting-edge therapies and contributes to progress, but involves risks (side effects, placebo), time commitment. Eligibility criteria apply.
                </p>
                <p class="text-sm text-slate-600 dark:text-slate-400 leading-relaxed">
                    <em class="block mb-1 font-semibold text-slate-700 dark:text-slate-200">Finding Trials:</em> Use resources like <a href="https://www.clinicaltrials.gov" target="_blank" rel="noopener noreferrer" class="text-blue-600 dark:text-blue-400 hover:underline focus:outline-none focus:ring-1 focus:ring-blue-500 rounded">ClinicalTrials.gov</a>, Alzheimer's Association, or NIA.
                </p>
            </div>
          </div>
      </section>

    </div> {/* End Main Sections Container */}
</BaseLayout>

<style>
  /* Add subtle hover/focus styles for list items if desired */
  .prose ul > li::marker, .prose ol > li::marker {
      color: var(--tw-prose-counters); /* Ensure marker color is consistent */
  }
  .dark .prose ul > li::marker, .dark .prose ol > li::marker {
     color: var(--tw-prose-invert-counters);
  }

  /* Style for details/summary */
  details summary {
    outline: none; /* Remove default outline */
  }
  details[open] > summary {
    /* Optional: subtle style when open */
     /* background-color: rgba(0,0,0,0.02); */
     /* color: inherit; /* Ensure text color doesn't change drastically */
  }
  /* Style for the number bubble in ordered lists */
  .prose ol > li::before {
      /* Additional styling for the number if needed */
  }

  /* Enhanced label styling within details */
  details em {
    font-style: normal; /* Reset italic for labels */
    display: block;
    margin-bottom: 0.25rem; /* mb-1 */
    font-weight: 600; /* font-semibold */
    color: var(--color-slate-700);
  }
  .dark details em {
    color: var(--color-slate-200);
  }

  /* Ensure paragraphs after the enhanced em labels have proper spacing */
  details em + p, details ul + p, details p + ul {
      margin-top: 0.5rem; /* Adjust as needed */
  }
  details ul {
      margin-top: 0.25rem; /* Space between label and list */
  }

</style>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\pages\understanding-ad.astro
---
// src/pages/understanding-ad.astro
// --- Imports ---
import BaseLayout from '../layouts/BaseLayout.astro';

// --- Configuration ---
const base = import.meta.env.BASE_URL; // Base URL for link construction.
const pageTitle = "Understanding Alzheimer's & Dementia";
// SEO Description specific to this page.
const pageDescription = "Demystify dementia vs. Alzheimer's disease. Explore the core biological changes (plaques, tangles, inflammation, synapse loss, vascular issues) underlying AD.";

// --- Data ---
// Defines breadcrumb navigation structure for this page.
const breadcrumbs = [
  { label: "Home", href: `${base}/` },
  { label: "Understanding AD", href: `${base}/understanding-ad/` } // Current page.
];

// --- Schema.org Data ---
// Basic Article schema for SEO.
const articleSchema = {
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": pageTitle,
  "description": pageDescription,
  "author": {
    "@type": "Person",
    "name": "Amir Tehrani" // TODO: Confirm author name
  },
  "publisher": {
    "@type": "Organization",
    "name": "CCH-MIC",
    "logo": {
      "@type": "ImageObject",
      "url": new URL(`${base}/favicon.svg`, Astro.site).toString()
    }
  },
  // "datePublished": "YYYY-MM-DD", // Optional: Add publication date
  // "dateModified": "YYYY-MM-DD", // Optional: Add last modified date
  // Representative images for the article
  "image": new URL(`${base}/assets/ad-pathology-overview.png`, Astro.site).toString()
};

/**
 * Renders text as an inline citation using styled `<code>` tags.
 * Removes surrounding brackets/parentheses for cleaner presentation.
 * Ensures citations are visually distinct but readable with high contrast.
 * @param {string} text - The citation text (e.g., "Author, Year").
 * @returns {string} HTML string for the styled citation.
 */
function renderCitation(text: string): string {
  const textString = String(text);
  // Styling uses high contrast colors and a subtle border for distinction.
  return `<code class="inline-block align-baseline text-[0.7rem] font-normal not-italic bg-slate-200/80 dark:bg-slate-700/80 text-slate-800 dark:text-slate-200 px-1.5 py-0.5 rounded-sm mx-0.5 border border-slate-300/50 dark:border-slate-600/50">${textString.replace(/[\[\]()]/g, '')}</code>`;
}

// Defines SVG icons used as visual cues for section headings.
// Accessibility attributes ensure they are ignored by screen readers.
const infoIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 transition-transform duration-300 ease-out group-hover:scale-110" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M18 10a8 8 0 1 1-16 0 8 8 0 0 1 16 0ZM9 8a1 1 0 0 1 1-1h.01a1 1 0 1 1 0 2H10a1 1 0 0 1-1-1Zm.01 3a1 1 0 1 0 0 2h.002a1 1 0 1 0 0-2h-.002Z" clip-rule="evenodd" /></svg>`;
const brainIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 transition-transform duration-300 ease-out group-hover:scale-110" role="img" aria-hidden="true"><path d="M13.5 4A1.5 1.5 0 0 0 12 5.5V10h-4V5.5A1.5 1.5 0 0 0 6.5 4h-1A1.5 1.5 0 0 0 4 5.5V10H2.75a.75.75 0 0 0 0 1.5H4v2.5A1.5 1.5 0 0 0 5.5 15.5h1.05a3.001 3.001 0 0 1 5.9 0H13.5A1.5 1.5 0 0 0 15 14v-2.5h1.25a.75.75 0 0 0 0-1.5H15V5.5A1.5 1.5 0 0 0 13.5 4h-1Z" /><path d="M8 10.75A.75.75 0 0 1 8.75 10h2.5a.75.75 0 0 1 0 1.5h-2.5A.75.75 0 0 1 8 10.75Z" /></svg>`;
const dnaIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 transition-transform duration-300 ease-out group-hover:scale-110" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M10.79 4.72a.75.75 0 0 1 1.42 0l2.5 5.25a.75.75 0 0 1-1.12 1.02l-1.91-1.273a.75.75 0 0 0-.916-.004L10 11.293l-1.684-1.586a.75.75 0 0 0-.916.004l-1.91 1.273a.75.75 0 1 1-1.12-1.02l2.5-5.25a.75.75 0 0 1 .79-.525H7a.75.75 0 0 1 .75.75v1.5h1.5a.75.75 0 0 1 .75.75v3.067l2.06-1.943a.75.75 0 0 1 .98.04Zm-3.47 7.711a.75.75 0 0 1 1.12-1.02l1.91 1.273a.75.75 0 0 0 .916.004L13 11.293l1.684 1.586a.75.75 0 0 0 .916-.004l1.91-1.273a.75.75 0 0 1 1.12 1.02l-2.5 5.25a.75.75 0 0 1-1.42 0l-1.06-2.208a.75.75 0 0 0-.98-.04L10 18.707l-1.684-1.586a.75.75 0 0 0-.98.04l-1.06 2.208a.75.75 0 1 1-1.42 0l-2.5-5.25Z" clip-rule="evenodd" /></svg>`;
const shieldIcon = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="size-6 transition-transform duration-300 ease-out group-hover:scale-110" role="img" aria-hidden="true"><path fill-rule="evenodd" d="M10 1a9 9 0 1 0 0 18 9 9 0 0 0 0-18ZM9.008 11.195l-1.416.943a.75.75 0 0 1-1.083-.807l.418-1.622a.75.75 0 0 0-.247-.708l-1.325-1.117a.75.75 0 0 1 .43-1.28l1.65-.118a.75.75 0 0 0 .654-.477l.62-1.58a.75.75 0 0 1 1.342 0l.62 1.58a.75.75 0 0 0 .655.477l1.65.118a.75.75 0 0 1 .43 1.28l-1.325 1.117a.75.75 0 0 0-.247.708l.418 1.622a.75.75 0 0 1-1.083.807l-1.416-.943a.75.75 0 0 0-.846 0Z" clip-rule="evenodd" /></svg>`;
---

<BaseLayout title={pageTitle} description={pageDescription} breadcrumbs={breadcrumbs} schema={articleSchema}>
    <header class="mb-10 md:mb-16 text-center">
      <h1 class="mt-0 mb-4 text-3xl sm:text-4xl lg:text-5xl font-extrabold tracking-tight text-slate-900 dark:text-white transition duration-300 hover:text-blue-600 dark:hover:text-blue-400">{pageTitle}</h1>
      <p class="text-lg lg:text-xl text-slate-700 dark:text-slate-300 max-w-3xl mx-auto leading-relaxed"> {/* Increased contrast */}
          Demystifying the terms and exploring the intricate biological changes occurring within the brain during normal aging versus those characterizing Alzheimer's Disease.
      </p>
    </header>

    <div class="space-y-12 md:space-y-16 lg:space-y-20">

        {/* Section: What is Dementia? */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-white to-slate-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-slate-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-1 hover:border-blue-300 dark:hover:border-blue-600/50">
            <h2 class="text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white mt-0 mb-6 flex items-start gap-x-3 transition-colors group-hover:text-blue-800 dark:group-hover:text-blue-300">
                <span class="mt-1 text-sky-500 shrink-0 transition-transform group-hover:scale-110"><Fragment set:html={infoIcon} /></span>
                What is Dementia?
            </h2>
            <div class="text-base md:text-lg leading-relaxed text-slate-700 dark:text-slate-300 space-y-5 max-w-prose">
                <p>
                    Dementia manifests not as a singular, specific disease entity; rather, it serves as a unifying <strong class="font-semibold text-slate-800 dark:text-slate-100">clinical syndrome</strong>, a designation encompassing a complex constellation of symptoms. Arising as the direct consequence of diverse underlying neuropathological disorders, symptoms progressively impair the brain's intricate structure and essential function. Fundamentally, dementia represents an <strong class="font-semibold text-slate-800 dark:text-slate-100">acquired</strong> conditionâ€”meaning it develops later in life, standing in stark contrast to congenital cognitive impairments present from birth. Defined further by its <strong class="font-semibold text-slate-800 dark:text-slate-100">persistent character</strong>, it indicates a continuous, typically inexorable deterioration, not a transient affliction, not a fluctuating state.
                </p>
                <p>
                    At the heart of dementia lies a significant, measurable decline in cognitive faculties. Constituting a spectrum of higher brain functions, faculties demand precise assessment:
                </p>
                 <ul class="list-none space-y-4 pl-0 sm:pl-4 mt-6">
                    <li class="relative pl-8 before:content-['â€¢'] before:absolute before:left-0 before:top-0.5 before:text-sky-500 before:font-bold before:text-xl before:transition-transform before:duration-200 group-hover:before:scale-110">
                        <strong class="font-semibold text-slate-800 dark:text-slate-100 block mb-0.5">Memory suffers</strong>
                        <span class="text-slate-600 dark:text-slate-400 text-sm sm:text-base">Revealing difficulty recalling recent occurrences, difficulty learning novel information, difficulty recognizing familiar faces or navigating known places.</span>
                    </li>
                    <li class="relative pl-8 before:content-['â€¢'] before:absolute before:left-0 before:top-0.5 before:text-sky-500 before:font-bold before:text-xl before:transition-transform before:duration-200 group-hover:before:scale-110">
                        <strong class="font-semibold text-slate-800 dark:text-slate-100 block mb-0.5">Language falters (Aphasia)</strong>
                         <span class="text-slate-600 dark:text-slate-400 text-sm sm:text-base">Presenting as problems finding appropriate words, problems understanding spoken discourse, problems interpreting written text, or problems formulating written expression.</span>
                    </li>
                     <li class="relative pl-8 before:content-['â€¢'] before:absolute before:left-0 before:top-0.5 before:text-sky-500 before:font-bold before:text-xl before:transition-transform before:duration-200 group-hover:before:scale-110">
                        <strong class="font-semibold text-slate-800 dark:text-slate-100 block mb-0.5">Problem-Solving & Executive Function erode</strong>
                         <span class="text-slate-600 dark:text-slate-400 text-sm sm:text-base">Marked by challenges in planning complex tasks, challenges in organizing sequential actions, challenges in logical reasoning, challenges in sound judgment, and challenges in effective multitaskingâ€”impeding the brain's critical management system.</span>
                    </li>
                     <li class="relative pl-8 before:content-['â€¢'] before:absolute before:left-0 before:top-0.5 before:text-sky-500 before:font-bold before:text-xl before:transition-transform before:duration-200 group-hover:before:scale-110">
                        <strong class="font-semibold text-slate-800 dark:text-slate-100 block mb-0.5">Visuospatial Skills diminish</strong>
                         <span class="text-slate-600 dark:text-slate-400 text-sm sm:text-base">Resulting in difficulty interpreting visual data accurately, difficulty judging spatial distances, or difficulty navigating once-familiar environments.</span>
                    </li>
                    <li class="relative pl-8 before:content-['â€¢'] before:absolute before:left-0 before:top-0.5 before:text-sky-500 before:font-bold before:text-xl before:transition-transform before:duration-200 group-hover:before:scale-110">
                        <strong class="font-semibold text-slate-800 dark:text-slate-100 block mb-0.5">Attention & Concentration weaken</strong>
                        <span class="text-slate-600 dark:text-slate-400 text-sm sm:text-base">Characterized by an inability to maintain focus, an inability to sustain attention over time, or an inability to shift between cognitive tasks efficiently.</span>
                    </li>
                </ul>
                <p class="mt-6">
                    Most importantly, a critical criterion determines the definitive threshold for a dementia diagnosis: multifaceted cognitive decline must attain a severity level where it demonstrably and significantly <strong class="font-semibold text-slate-800 dark:text-slate-100">interferes with an individual's capacity to execute routine, everyday activities independently</strong> <Fragment set:html={renderCitation("Arvanitakis et al., 2019")} />. Manifesting in tasks such as managing personal finances meticulously, preparing complete meals safely, maintaining appropriate personal hygiene, operating a vehicle competently, or sustaining established social relationships, interference signifies dementia. Absent pronounced functional impairment, observed cognitive changes might signify Mild Cognitive Impairment (MCI) or reflect normative age-related alterationsâ€”but they do not constitute dementia.
                </p>
            </div>
        </section>

        {/* Section: What is Alzheimer's Disease (AD)? */}
        <section class="group p-6 md:p-8 rounded-xl bg-gradient-to-br from-white to-slate-50 dark:from-slate-800/70 dark:to-slate-800/90 border border-slate-200 dark:border-slate-700/50 shadow-lg hover:shadow-xl transition-all duration-300 ease-in-out hover:-translate-y-1 hover:border-indigo-300 dark:hover:border-indigo-600/50">
            <h2 class="text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white mt-0 mb-6 flex items-start gap-x-3 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-300">
                 <span class="mt-1 text-indigo-500 shrink-0 transition-transform group-hover:scale-110"><Fragment set:html={brainIcon} /></span>
                 What is Alzheimer's Disease (AD)? (Detailed Definition)
            </h2>
            <div class="text-base md:text-lg leading-relaxed text-slate-700 dark:text-slate-300 space-y-4 max-w-prose">
                <p>
                    Alzheimer's Disease (AD) stands identified as the <strong class="font-semibold text-slate-800 dark:text-slate-100">most frequent specific neuropathological cause</strong> precipitating the symptom cluster known as dementia; indeed, it accounts for a substantial majority, an estimated <strong class="font-semibold text-slate-800 dark:text-slate-100">60â€“80%</strong>, of all dementia cases <Fragment set:html={renderCitation("Alzheimer's Association, 2024")} />. Unlike the broad syndrome 'dementia', AD represents a distinct, progressive neurodegenerative disease.
                </p>
                 <p>
                    <em class="text-slate-600 dark:text-slate-400">Neurodegenerative</em> signifies that the disease entails the gradual, irreversible breakdown and ultimate death of nerve cellsâ€”neurons constituting the fundamental units responsible for transmitting electrochemical information throughout the brain and nervous system. <em class="text-slate-600 dark:text-slate-400">Progressive</em> indicates that clinical symptoms intrinsically linked to neuronal loss inevitably worsen over an extended duration, typically spanning years.
                 </p>
                 <p>
                     From a precise biological standpoint, AD is definitively characterized by two primary pathological hallmarks observable within brain tissue:
                    <ol class="list-decimal list-outside pl-5 sm:pl-6 mt-4 space-y-2 text-sm md:text-base">
                        <li class="pl-2"><strong class="font-semibold text-slate-800 dark:text-slate-100">Amyloid plaque accumulation:</strong> Dense, insoluble aggregates of a protein fragment termed beta-amyloid (AÎ²) manifest, building up extracellularly, in the spaces *outside* of neurons.</li>
                        <li class="pl-2"><strong class="font-semibold text-slate-800 dark:text-slate-100">Neurofibrillary tangle (NFT) formation:</strong> Twisted intracellular fibers composed primarily of an abnormally modified form of the protein Tau appear, accumulating *inside* neurons.</li>
                    </ol>
                </p>
                <p class="mt-4">
                     While AD commands central focus here owing to its sheer prevalence, acknowledging the existence of other distinct dementia etiologies remains crucial: <strong class="font-medium text-slate-800 dark:text-slate-100">Vascular Dementia</strong> arises from compromised blood flow to the brain, frequently resulting from cerebrovascular events like strokes; <strong class="font-medium text-slate-800 dark:text-slate-100">Lewy Body Dementia</strong> is characterized by abnormal intraneuronal protein deposits named Lewy bodies; and <strong class="font-medium text-slate-800 dark:text-slate-100">Frontotemporal Dementia</strong> predominantly affects the brain's frontal and temporal lobes, inducing marked changes in personality, behavior, and language. Furthermore, increasingly recognized is that many individualsâ€”particularly those of advanced ageâ€”exhibit <strong class="font-semibold text-slate-800 dark:text-slate-100">mixed pathology</strong>. Meaning their brains concurrently display neuropathological evidence of more than one dementia-causing process, such as the simultaneous presence of AD pathology (plaques and tangles) alongside significant vascular damage <Fragment set:html={renderCitation("Scheltens et al., 2021; Knopman et al., 2021")} />.
                </p>
            </div>
        </section>

        {/* Section: Neurobiology of AD */}
        <section class="pt-8 md:pt-12">
            <h2 class="mb-10 text-center text-3xl md:text-4xl font-bold tracking-tight text-slate-900 dark:text-white">The Neurobiology of AD: A Closer Look</h2>

            {/* Image 1: AD Pathology Overview */}
            <figure class="my-10 md:my-14 group text-center transition duration-300 ease-in-out hover:scale-[1.02]">
              <img
                src={`${base}/assets/ad-pathology-overview.png`}
                alt="Diagram comparing healthy neuron (intact microtubules, stable Tau) vs AD neuron (disrupted microtubules, tangled Tau, extracellular amyloid plaques, activated microglia/astrocytes)."
                class="mx-auto block max-w-full rounded-xl border border-slate-200 shadow-lg transition-all duration-300 ease-in-out group-hover:shadow-xl dark:border-slate-700 md:max-w-xl lg:max-w-2xl group-hover:border-slate-300 dark:group-hover:border-slate-600 will-change-transform"
                loading="lazy" width="900" height="500"
              />
              <figcaption class="mt-4 text-xs italic text-slate-500 dark:text-slate-400 transition group-hover:text-slate-600 dark:group-hover:text-slate-300 px-4 max-w-xl mx-auto">
                <strong class="font-semibold not-italic">Fig. 1:</strong> Visualization of Key Pathological Hallmarks Defining Alzheimer's Disease at the Cellular Level.
              </figcaption>
            </figure>

            {/* Introductory paragraph for neurobiology */}
            <p class="leading-relaxed mb-10 md:mb-12 text-slate-700 dark:text-slate-300 max-w-prose mx-auto text-center text-base md:text-lg">
                 Understanding basic biological alterations is essential: essential not only for explaining clinical symptoms observed in individuals afflicted with AD but also essential for guiding the rational development of targeted diagnostic instruments and innovative therapeutic strategies. Initiating insidiously, damaging processes commence silently within the brain potentially decades before initial cognitive symptoms become clinically apparent. Moreover, not unfolding in isolation, pathological changes intricately interact and reciprocally influence each other, thereby generating a complex, destructive cascade of neurodegeneration:
            </p>

            {/* Grid container for detailed pathology cards */}
            <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6 md:gap-8">

                {/* Card: Amyloid Plaques */}
                <div class="group p-6 rounded-lg bg-white dark:bg-slate-800/90 border border-slate-200 dark:border-slate-700/60 shadow-md hover:shadow-lg hover:border-indigo-300 dark:hover:border-indigo-600/60 transition-all duration-300 ease-in-out flex flex-col hover:-translate-y-1">
                  <h3 class="text-xl font-semibold mb-3 text-indigo-700 dark:text-indigo-200 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-100">Amyloid Plaques (AÎ² Pathology)</h3>
                  <div class="text-sm text-slate-700 dark:text-slate-300 leading-relaxed space-y-3 grow">
                     <p>Amyloid plaques constitute one of the defining pathological signatures of AD. Composed principally of <strong class="font-medium text-slate-800 dark:text-slate-100">beta-amyloid (AÎ²)</strong> protein fragments, dense, insoluble, adhesive clumps form. Accumulating specifically in the <strong class="font-medium text-slate-800 dark:text-slate-100">extracellular</strong> milieu, plaques reside in the space *outside* of the nerve cells (neurons).</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Formation Mechanism:</strong> AÎ² fragments originate from a larger transmembrane protein known as the Amyloid Precursor Protein (APP), participating in functions related to neuronal growth and repair. Within the pathological cascade pertinent to AD, APP undergoes sequential enzymatic cleavage: first by beta-secretase (BACE1), then subsequently by gamma-secretase. Designated the 'amyloidogenic pathway', specific enzymatic processing generates AÎ² fragments of varying amino acid lengths. Notably, the AÎ²42 fragment exhibits particular propensity for aggregation and is widely considered highly neurotoxic.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Early Toxic Species:</strong> Critically, prior to coalescing into large, microscopically visible plaques, AÎ² fragments aggregate into smaller, soluble clusters termed <strong class="font-medium text-slate-800 dark:text-slate-100">AÎ² oligomers</strong>. Now recognized as the most potently toxic species, oligomers directly interfere with synaptic function by binding to neuronal receptors, thereby disrupting the precise communication process at synapsesâ€”crucial junctions where neurons transmit signals to one another. Believed to represent an early, pivotal event driving cognitive decline, synaptic dysfunction occurs substantially before widespread plaque deposition becomes evident <Fragment set:html={renderCitation("Selkoe & Hardy, 2016; Shankar & Walsh, 2009")} />.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Examples:</strong> In rare, early-onset Familial AD variants, specific mutations within genes encoding APP or components of the gamma-secretase complex (Presenilin 1 and Presenilin 2) directly lead to increased production of the aggregation-prone AÎ²42, causing rapid and extensive plaque accumulation. Conversely, in common Late-Onset AD (LOAD), underlying issues are often hypothesized to relate more significantly to impaired AÎ² clearance mechanisms rather than solely to overproduction.</p>
                  </div>
                </div>

                {/* Card: Neurofibrillary Tangles */}
                <div class="group p-6 rounded-lg bg-white dark:bg-slate-800/90 border border-slate-200 dark:border-slate-700/60 shadow-md hover:shadow-lg hover:border-indigo-300 dark:hover:border-indigo-600/60 transition-all duration-300 ease-in-out flex flex-col hover:-translate-y-1">
                  <h3 class="text-xl font-semibold mb-3 text-indigo-700 dark:text-indigo-200 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-100">Neurofibrillary Tangles (NFTs) (Tau Pathology)</h3>
                  <div class="text-sm text-slate-700 dark:text-slate-300 leading-relaxed space-y-3 grow">
                     <p>Neurofibrillary tangles (NFTs) represent the second defining pathological hallmark of AD. Identified *inside* nerve cells, they manifest visually as dense, twisted <strong class="font-medium text-slate-800 dark:text-slate-100">intracellular</strong> filaments.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Composition and Formation:</strong> NFTs are primarily constituted by an abnormally modified form of the <strong class="font-medium text-slate-800 dark:text-slate-100">Tau protein</strong>. In its healthy physiological state, Tau protein performs a vital function in stabilizing microtubules. Essential components of the neuron's internal structural support system (the cytoskeleton), microtubules function akin to railroad tracks, forming a critical intracellular transport network for conveying nutrients, neurotransmitters, and other vital cellular components along the axonâ€”the neuron's long signal-transmitting projection.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Pathological Modification (Hyperphosphorylation):</strong> Within the context of AD, Tau undergoes a detrimental process termed <strong class="font-medium text-slate-800 dark:text-slate-100">hyperphosphorylation</strong>, wherein an excessive quantity of phosphate groups chemically attach to the Tau protein molecule. Modifying Tau's three-dimensional structure, specific chemical alteration causes it to detach from microtubules and subsequently aggregate with other abnormal Tau molecules. Self-assembling into structures known as paired helical filaments, aggregates ultimately constitute the insoluble NFTs observed pathologically.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Consequences:</strong> Detachment of hyperphosphorylated Tau precipitates microtubule destabilization and eventual disintegration. Severely disrupting the neuron's internal transport system, this hinders intracellular communication and impairs the neuron's overall function and viability. Presence and burden of NFTs demonstrate a strong correlation with neuronal dysfunction; ultimately, NFT pathology contributes significantly to neuronal death <Fragment set:html={renderCitation("Goedert & Spillantini, 2006")} />. Following a predictable topographical pattern of spread through interconnected brain regions, NFT pathology's anatomical progression closely correlates with the clinical progression of symptoms observed in patients.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Examples (Other Tauopathies):</strong> While prominently featured in AD, abnormal Tau aggregation serves as the primary pathological driver in other distinct neurodegenerative conditions collectively termed 'tauopathies' (such as Progressive Supranuclear Palsy [PSP] and Corticobasal Degeneration [CBD]). Affecting different specific brain regions, each condition consequently causes distinct clinical symptom profiles. Chronic Traumatic Encephalopathy (CTE)â€”a condition linked mechanistically to repeated head traumaâ€”is also characterized neuropathologically by prominent Tau pathology.</p>
                  </div>
                </div>

                 {/* Card: Neuroinflammation */}
                 <div class="group p-6 rounded-lg bg-white dark:bg-slate-800/90 border border-slate-200 dark:border-slate-700/60 shadow-md hover:shadow-lg hover:border-indigo-300 dark:hover:border-indigo-600/60 transition-all duration-300 ease-in-out flex flex-col hover:-translate-y-1">
                   <h3 class="text-xl font-semibold mb-3 text-indigo-700 dark:text-indigo-200 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-100">Neuroinflammation</h3>
                    <div class="text-sm text-slate-700 dark:text-slate-300 leading-relaxed space-y-3 grow">
                     <p>Neuroinflammation denotes the inflammatory response occurring specifically within the brain parenchyma. While acute inflammation constitutes a normal, protective physiological response to injury or infection, in the context of AD, inflammatory processes become chronic, sustained, and ultimately detrimental.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Cellular Basis:</strong> Brain's primary resident immune cellsâ€”<strong class="font-medium text-slate-800 dark:text-slate-100">microglia</strong>â€”along with supportive glial cells called <strong class="font-medium text-slate-800 dark:text-slate-100">astrocytes</strong>, become activated in response to the presence of accumulating amyloid plaques, forming NFTs, and resultant neuronal damage. Initially, activated microglia attempt to clear AÎ² deposits but can become dysfunctional over time. Both activated microglia and astrocytes release potent signaling molecules known as <strong class="font-medium text-slate-800 dark:text-slate-100">pro-inflammatory cytokines</strong> (e.g., TNF-Î±, IL-1Î², IL-6) and various other inflammatory mediators.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Mechanism of Damage:</strong> Although initially intended as a protective mechanism, chronic glial activation transforms into a detrimental force. Sustained release of pro-inflammatory cytokines, reactive oxygen species (ROS), and other potentially toxic molecules cultivates a harmful microenvironment. Directly, the environment can inflict damage upon surrounding healthy neurons; it can impair synaptic function; it can exacerbate both amyloid and tau pathologies (thereby creating a destructive positive feedback loop); and it can contribute to the breakdown of the protective blood-brain barrier <Fragment set:html={renderCitation("Heneka et al., 2015")} />.</p>
                     <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Examples:</strong> Elevated concentrations of specific inflammatory markers are consistently detected in the cerebrospinal fluid and post-mortem brain tissue of AD patients compared to controls. Furthermore, systemic conditions involving chronic inflammation, such as certain persistent infections or autoimmune diseases (e.g., Multiple Sclerosis, which involves CNS inflammation), might influence an individual's risk for developing AD or modulate its rate of progressionâ€”underscoring the critical brain-body connection regarding inflammatory processes.</p>
                   </div>
                 </div>

                 {/* Card: Synapse Loss */}
                <div class="group p-6 rounded-lg bg-white dark:bg-slate-800/90 border border-slate-200 dark:border-slate-700/60 shadow-md hover:shadow-lg hover:border-indigo-300 dark:hover:border-indigo-600/60 transition-all duration-300 ease-in-out flex flex-col hover:-translate-y-1">
                  <h3 class="text-xl font-semibold mb-3 text-indigo-700 dark:text-indigo-200 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-100">Synapse Loss & Neurodegeneration (N)</h3>
                   <div class="text-sm text-slate-700 dark:text-slate-300 leading-relaxed space-y-3 grow">
                    <p><strong class="font-medium text-slate-800 dark:text-slate-100">Synapses</strong> represent the fundamental points of intercellular communication between neurons, facilitating the precise transmission of electrochemical signals. <strong class="font-medium text-slate-800 dark:text-slate-100">Neurodegeneration</strong> refers specifically to the progressive loss of neuronal structure and functionâ€”culminating ultimately in neuron death.</p>
                    <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Significance in AD:</strong> Loss of synapses constitutes an early and critically important feature of AD pathophysiology. Indeed, synaptic density is widely considered the <strong class="font-medium text-slate-800 dark:text-slate-100">strongest biological correlate</strong> of the cognitive decline observed clinically in patients <Fragment set:html={renderCitation("Selkoe, 2002")} />. Manifesting demonstrably well before widespread neuronal death and significant macroscopic brain shrinkage (atrophy) become readily apparent on structural brain imaging, synaptic compromise is evident early <Fragment set:html={renderCitation("Scheff et al., 2006")} />.</p>
                    <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Causes:</strong> Synapse loss in AD is driven by a confluence of multiple pathological factors: direct toxic effects exerted by AÎ² oligomers at the synaptic terminal; functional disruption caused by tau pathology propagating into synaptic compartments; and damaging consequences of the chronic neuroinflammatory microenvironment.</p>
                    <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Examples:</strong> Post-mortem studies measuring synaptic protein levels in brain tissue consistently reveal significant reductions in AD patients relative to age-matched controls. Advanced imaging techniques, such as Positron Emission Tomography (PET) scans tracking regional metabolic activity (which closely reflects aggregate synaptic function), demonstrate characteristic declines in specific brain regions profoundly affected by AD pathology. Other neurodegenerative diseases, like Frontotemporal Dementia (FTD) or Amyotrophic Lateral Sclerosis (ALS), also involve significant synapse loss and neurodegenerationâ€”however, these typically occur in distinct anatomical patterns and affect different primary brain regions, thus leading to disparate clinical presentations compared to AD.</p>
                   </div>
                </div>

                {/* Card: Vascular Dysfunction */}
                 <div class="group p-6 rounded-lg bg-white dark:bg-slate-800/90 border border-slate-200 dark:border-slate-700/60 shadow-md hover:shadow-lg hover:border-indigo-300 dark:hover:border-indigo-600/60 transition-all duration-300 ease-in-out flex flex-col hover:-translate-y-1">
                   <h3 class="text-xl font-semibold mb-3 text-indigo-700 dark:text-indigo-200 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-100">Vascular Dysfunction</h3>
                   <div class="text-sm text-slate-700 dark:text-slate-300 leading-relaxed space-y-3 grow">
                    <p>Accumulating evidence increasingly highlights the significant contribution of pathologies within the brain's intricate network of blood vessels (the cerebrovascular system) to the overall pathophysiology of AD.</p>
                    <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Manifestations:</strong> Vascular dysfunction within the AD context can encompass several distinct issues:</p>
                    <ol class="list-decimal list-outside pl-4 space-y-1 text-xs sm:text-sm">
                        <li>Reduced <strong class="font-medium text-slate-800 dark:text-slate-100">Cerebral Blood Flow (CBF)</strong>: Insufficient perfusion delivering blood to specific brain regions, thereby depriving neurons of requisite oxygen and glucose for optimal function and survival.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Blood-Brain Barrier (BBB) Breakdown</strong>: Compromise of the BBBâ€”a highly specialized layer of endothelial cells lining brain capillaries that meticulously regulates the passage of substances between the circulating blood and the brain parenchymaâ€”can occur or become "leaky" in AD. Consequently, potentially harmful blood-borne components (such as inflammatory cells or toxic proteins) infiltrate the brain tissue.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Cerebral Amyloid Angiopathy (CAA)</strong>: A specific condition characterized by the deposition of AÎ² protein aggregates within the walls of cerebral arteries and capillaries. Weakening the vessel walls, accumulation consequently increases the risk of cerebral microbleeds or larger intracerebral hemorrhages.</li>
                    </ol>
                    <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Consequences:</strong> Vascular problems exert significant detrimental effects. Reduced cerebral blood flow directly impairs neuronal function and compromises cellular energy metabolism. BBB breakdown permits the influx of toxic substances and inflammatory mediators from the periphery, thereby exacerbating local neuroinflammation. Critically, impaired vascular function (including potentially compromised perivascular lymphatic drainage pathways) hinders the brain's intrinsic ability to effectively clear metabolic waste productsâ€”including AÎ² itselfâ€”thus potentially contributing directly to plaque accumulation <Fragment set:html={renderCitation("Zlokovic, 2011; Sweeney et al., 2018")} />. Furthermore, nutrient delivery to energy-demanding neurons is also compromised.</p>
                    <p><strong class="block mb-1 font-semibold text-slate-800 dark:text-slate-100">Examples:</strong> Vascular Dementia results directly from primary cerebrovascular disease (e.g., multiple lacunar infarcts or large strategic strokes). However, cerebrovascular pathology is exceedingly common alongside AD pathology (resulting in mixed dementia), suggesting potential synergistic detrimental effects between the two processes. Established risk factors for cardiovascular disease (such as chronic hypertension, diabetes mellitus) also represent strong risk factors for developing AD, further underscoring this critical vascular link.</p>
                   </div>
                 </div>

                 {/* Card: Other Contributing Cellular Pathologies */}
                 <div class="group p-6 rounded-lg bg-white dark:bg-slate-800/90 border border-slate-200 dark:border-slate-700/60 shadow-md hover:shadow-lg hover:border-indigo-300 dark:hover:border-indigo-600/60 transition-all duration-300 ease-in-out flex flex-col hover:-translate-y-1">
                   <h3 class="text-xl font-semibold mb-3 text-indigo-700 dark:text-indigo-200 transition-colors group-hover:text-indigo-800 dark:group-hover:text-indigo-100">Other Contributing Cellular Pathologies</h3>
                   <div class="text-sm text-slate-700 dark:text-slate-300 leading-relaxed space-y-3 grow">
                    <p>Beyond the primary neuropathological hallmarks (plaques and tangles) and significant vascular contributions, other fundamental cellular processes become dysfunctional in the AD brain, contributing substantially to the overall neurodegenerative cascade:</p>
                    <ul class="list-disc list-outside pl-4 space-y-2 text-xs sm:text-sm">
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Oxidative Stress:</strong> Signifying a critical imbalance between the production of reactive oxygen species (ROS, or free radicalsâ€”highly unstable molecules that inflict damage upon cellular components) and the brain's capacity to neutralize these harmful species using its antioxidant defense systems, oxidative stress is detrimental. Mitochondria (the cell's primary energy producers) represent a major source of ROS generation; mitochondrial dysfunction is frequently observed in AD neurons. Oxidative stress inflicts damage upon cellular lipids, proteins, and DNA within neurons, thereby contributing significantly to cellular dysfunction and eventual death <Fragment set:html={renderCitation("Lin & Beal, 2006")} />.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Metabolic Dysfunction:</strong> Neurons possess exceptionally high energy demands to maintain their function. AD brains frequently exhibit reduced glucose uptake and utilization, particularly within brain regions most affected by the pathology. Linked to underlying issues such as impaired insulin signaling within the brain (sometimes conceptualized as 'Type 3 diabetes') and compromised mitochondrial function, metabolic deficit can lead ultimately to an energy deficit that jeopardizes neuronal survival and function <Fragment set:html={renderCitation("De la Monte & Wands, 2008")} />.</li>
                        <li><strong class="font-medium text-slate-800 dark:text-slate-100">Impaired Proteostasis / Autophagy:</strong> Proteostasis denotes the intricate cellular network responsible for managing protein production, correct folding, intracellular trafficking, and eventual degradation. Autophagy represents a key cellular 'waste disposal' mechanism that removes damaged organelles and aggregated proteins (including pathological species like AÎ² and abnormal Tau). In the context of AD, essential quality control systems become progressively less efficient. Leading directly to the accumulation of misfolded, potentially toxic proteins and damaged cellular components, inefficiency further stresses the neuron and contributes to its demise <Fragment set:html={renderCitation("Nixon, 2013")} />.</li>
                    </ul>
                   </div>
                 </div>

            </div> {/* End grid for pathologies */}
        </section>

        {/* Section: Risk Factors */}
        {/* Discusses factors influencing the likelihood of developing LOAD. */}
        <section class="py-8 md:py-12">
            <h2 class="mb-10 text-center text-3xl md:text-4xl font-bold tracking-tight text-slate-900 dark:text-white">Risk Factors for Late-Onset AD (LOAD)</h2>
            <p class="mb-10 md:mb-12 text-slate-700 dark:text-slate-300 max-w-prose mx-auto text-center text-base md:text-lg leading-relaxed"> {/* Increased contrast */}
                Late-Onset Alzheimer's Disease (LOAD)â€”representing the most prevalent form, typically manifesting clinically after the age of 65â€”is understood to emerge not from a singular, identifiable cause, but rather from a highly complex, lifelong interplay. Involving factors that cannot be altered (non-modifiable risks) and those related to lifestyle choices, environmental exposures, and overall health status that can potentially be influenced (modifiable risks), interplay occurs throughout life. Accumulating and interacting dynamically across an individual's entire lifespan, diverse factors contribute.
            </p>

            {/* Image 2: Risk Factors Diagram */}
            <figure class="my-10 md:my-14 group text-center transition duration-300 ease-in-out hover:scale-[1.02]">
              <img
                src={`${base}/assets/ad-risk-factors.png`}
                alt="Infographic: Dementia Risk Factors Across Lifespan. Non-Modifiable: Age, Genetics (APOE4). Modifiable (Midlife): Hearing Loss, TBI, Hypertension, Alcohol, Obesity. Modifiable (Later Life): Smoking, Depression, Isolation, Inactivity, Air Pollution, Diabetes. Early Life: Lower Education."
                class="mx-auto block max-w-full rounded-xl border border-slate-200 shadow-lg transition-all duration-300 ease-in-out group-hover:shadow-xl dark:border-slate-700 md:max-w-xl lg:max-w-2xl group-hover:border-slate-300 dark:group-hover:border-slate-600 will-change-transform"
                loading="lazy" width="850" height="450"
              />
              <figcaption class="mt-4 text-xs italic text-slate-500 dark:text-slate-400 transition group-hover:text-slate-600 dark:group-hover:text-slate-300 px-4 max-w-xl mx-auto">
                <strong class="font-semibold not-italic">Fig. 2:</strong> Key Risk Factors for Late-Onset Alzheimer's Disease (Adapted from Livingston et al., 2020), illustrating influences across the lifespan.
              </figcaption>
            </figure>

            {/* Grid for Modifiable vs Non-Modifiable Risk Factor Cards */}
            <div class="grid grid-cols-1 md:grid-cols-2 gap-8 md:gap-10 max-w-5xl mx-auto mt-12">
                {/* Card: Non-Modifiable Risk Factors */}
                <div class="group p-6 md:p-8 rounded-lg bg-white dark:bg-slate-800/90 border border-red-200 dark:border-slate-700/60 shadow-md hover:shadow-lg transition-all duration-300 ease-in-out hover:border-red-300 dark:hover:border-red-600/60 hover:-translate-y-0.5">
                    {/* Card Header */}
                    <h3 class="text-xl font-semibold text-red-800 dark:text-red-200 mb-4 border-b border-red-300 dark:border-red-700 pb-2 flex items-center gap-x-2">
                       <span class="text-red-500 transition-transform group-hover:scale-110"><Fragment set:html={dnaIcon} /></span>
                       Non-Modifiable Risk Factors
                    </h3>
                    {/* Definition List for factors */}
                    <dl class="space-y-4 text-sm"> {/* Reduced spacing */}
                        <div>
                            <dt class="font-semibold text-slate-800 dark:text-slate-100 text-base">Age:</dt>
                            <dd class="ml-0 mt-1 text-slate-700 dark:text-slate-300 leading-relaxed"> {/* Increased contrast */}
                                Representing the single greatest non-genetic risk factor for developing LOAD, age is paramount. Probability of receiving an AD diagnosis increases substantially, dramatically, with advancing chronological ageâ€”approximately doubling every five years subsequent to age 65 <Fragment set:html={renderCitation("Alzheimer's Association, 2024")} />. While the process of aging itself does not directly cause AD, various biological changes intrinsically associated with aging (e.g., increased basal inflammation, reduced cellular repair efficiency, cumulative oxidative stress) likely cultivate a more vulnerable intracerebral environment, one more susceptible to the development and progression of AD pathology.
                            </dd>
                        </div>
                        <div>
                            <dt class="font-semibold text-slate-800 dark:text-slate-100 text-base">Genetics (APOE Îµ4):</dt>
                            <dd class="ml-0 mt-1 text-slate-700 dark:text-slate-300 space-y-2 leading-relaxed">
                                <span>While numerous genes likely contribute minor effects to overall LOAD susceptibility, the Apolipoprotein E (APOE) gene represents the most significant single genetic risk factor identified specifically for LOAD. Inheriting the <strong class="font-medium text-slate-800 dark:text-slate-100">APOE Îµ4</strong> allele significantly increases risk (1 copy ~3x, 2 copies ~8-15x) and lowers the average age of onset. However, it's important to remember Îµ4 does *not* guarantee AD development.</span>
                                <ul class="list-disc list-outside pl-5 space-y-1 text-xs">
                                    <li><strong class="font-medium text-slate-700 dark:text-slate-200">APOE Îµ3:</strong> Most common, considered risk-neutral.</li>
                                    <li><strong class="font-medium text-slate-700 dark:text-slate-200">APOE Îµ2:</strong> Less common, appears protective.</li>
                                </ul>
                                <span class="block text-xs italic text-slate-500 dark:text-slate-400/80">Other genes likely play smaller roles, interacting with APOE and lifestyle <Fragment set:html={renderCitation("Liu et al., 2013; Wightman et al., 2021")} />.</span>
                            </dd>
                        </div>
                    </dl>
                </div>

                 {/* Card: Modifiable Risk Factors */}
                 <div class="group p-6 md:p-8 rounded-lg bg-white dark:bg-slate-800/90 border border-green-200 dark:border-slate-700/60 shadow-md hover:shadow-lg transition-all duration-300 ease-in-out hover:border-green-300 dark:hover:border-green-600/60 hover:-translate-y-0.5">
                     {/* Card Header */}
                     <h3 class="text-xl font-semibold text-green-800 dark:text-green-200 mb-4 border-b border-green-300 dark:border-green-700 pb-2 flex items-center gap-x-2">
                        <span class="text-green-500 transition-transform group-hover:scale-110"><Fragment set:html={shieldIcon} /></span>
                        Potentially Modifiable Risk Factors
                     </h3>
                     {/* Definition List for factors */}
                     <dl class="space-y-4 text-sm"> {/* Reduced spacing */}
                         <div>
                             <dt class="font-semibold text-slate-800 dark:text-slate-100 text-base">Cardiovascular & Metabolic Health:</dt>
                             <dd class="ml-0 mt-1 text-slate-700 dark:text-slate-300 leading-relaxed">
                                Conditions affecting the heart, vessels, and metabolism significantly increase risk, especially in midlife: <strong class="font-medium text-slate-800 dark:text-slate-100">Hypertension, High Cholesterol (LDL), Type 2 Diabetes, Midlife Obesity, Stroke History</strong>. These likely impact brain health via reduced blood flow, inflammation, and vascular damage <Fragment set:html={renderCitation("Livingston et al., 2020; Vagelatos & Eslick, 2013; Anstey et al., 2011")} />.
                             </dd>
                         </div>
                         <div>
                             <dt class="font-semibold text-slate-800 dark:text-slate-100 text-base">Lifestyle & Environmental Factors:</dt>
                             <dd class="ml-0 mt-1 text-slate-700 dark:text-slate-300 leading-relaxed">
                                Habits and exposures play a cumulative role: <strong class="font-medium text-slate-800 dark:text-slate-100">Smoking, Physical Inactivity, Unhealthy Diet, Poor Sleep, Social Isolation, Lower Education, Untreated Hearing Loss, Later-life Depression, Traumatic Brain Injury, Excessive Alcohol, Air Pollution</strong>. Modifying these can potentially reduce risk or delay onset.
                             </dd>
                              {/* Summary statistic */}
                              <span class="block mt-2 text-xs italic text-slate-500 dark:text-slate-400/80">Together, modifiable factors may account for up to 40% of dementia risk worldwide <Fragment set:html={renderCitation("Summary: Livingston et al., 2020")} />.</span>
                         </div>
                     </dl>
                 </div>
             </div>
        </section>

        {/* Section: Prevention */}
        {/* Addresses the possibility of preventing AD. */}
        <section class="py-10 md:py-14">
            <h2 class="mb-8 text-center text-2xl md:text-3xl font-semibold text-slate-900 dark:text-white">Is Alzheimer's Disease Preventable?</h2>
            {/* Styled blockquote containing the answer */}
            <blockquote class="mx-auto max-w-3xl rounded-lg border-l-4 border-emerald-500 bg-emerald-50/80 dark:bg-slate-800/80 p-6 shadow-md dark:border-emerald-400 hover:shadow-lg transition-shadow duration-300">
              {/* Main text separated into paragraphs for readability */}
              <div class="leading-relaxed text-slate-700 dark:text-slate-300 space-y-4 text-base md:text-lg">
                  <p>
                     At present, no definitive method exists, no single guaranteed intervention capable of preventing the onset of Alzheimer's Disease entirely. Profound complexity of the diseaseâ€”arising from intricate, lifelong interactions between inherent genetic predispositions (such as APOE genotype), inevitable biological processes of aging, and a multitude of diverse environmental and lifestyle influencesâ€”renders absolute prevention an elusive objective... for the time being.
                  </p>
                  <p class="font-medium text-emerald-800 dark:text-emerald-200">
                     However, substantial, compelling evidence strongly suggests proactively addressing identified modifiable risk factors throughout the lifespan represents the most effective current strategy available. While absolute prevention remains beyond reach, proactive risk reduction offers significant promise.
                  </p>
                  <p class="text-sm italic text-slate-600 dark:text-slate-400">
                     By making conscious, health-promoting lifestyle choicesâ€”choices such as meticulously maintaining cardiovascular health (actively managing blood pressure, cholesterol levels, and diabetes); engaging consistently in regular physical activity; adopting a brain-healthy dietary pattern (e.g., rich in antioxidants, omega-3 fatty acids, and phytonutrients); ensuring sufficient, high-quality sleep; remaining socially engaged and mentally active; rigorously avoiding tobacco use; limiting alcohol consumption; protecting auditory health; and effectively managing chronic stressâ€”individuals can potentially reduce their overall lifetime risk of developing dementia or, at minimum, delay its clinical onset and potentially slow its subsequent rate of progression <Fragment set:html={renderCitation("Livingston et al., 2020; Baumgart et al., 2015")} />. Focusing squarely on promoting overall brain health, a comprehensive approach actively builds resilience against the insidious pathological changes intrinsically associated with AD.
                  </p>
               </div>
            </blockquote>
        </section>

    </div> {/* End Main Content Sections Container */}
</BaseLayout>


File: C:\Users\gamin\OneDrive\Documents\GitHub\new-astro-site\src\styles\global.css
/* src/styles/global.css */

/* 1. Import Google Fonts (Keep at the very top) */
/* Ensures fonts are loaded early. */
@import url('https://fonts.googleapis.com/css2?family=Inter:wght@400..700&family=Lora:ital,wght@0,400..700;1,400..700&display=swap');

/* 2. Import Tailwind CSS v4 */
/* Includes Tailwind's base, components, and utilities. */
@import "tailwindcss";

/* 3. Define Custom Dark Mode Variant (Class-based) */
/* Enables the 'dark:' utility classes when the 'dark' class is on the <html> element. */
@custom-variant dark (&:where(.dark, .dark *));

/* 4. Define Theme Variables */
/* Centralizes font definitions for consistency. */
@theme {
  /* Font family for general UI text, prioritizing system fonts. */
  --font-sans: 'Inter', system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;
  /* Font family primarily for headings, providing a distinct typographic style. */
  --font-serif: 'Lora', Georgia, Cambria, 'Times New Roman', Times, serif;

  /* Add other custom theme variables here if needed */
  /* Example: --color-brand-primary: oklch(60% 0.2 260); */
  /* Example: --radius-custom: 10px; */
}

/* 5. Define Global Base Styles */
/* Styles applied globally to HTML elements for foundational consistency. */
@layer base {
  html {
    font-family: var(--font-sans); /* Applies the sans-serif font globally. */
    scroll-behavior: smooth; /* Enables smooth scrolling for anchor links. */
    -webkit-font-smoothing: antialiased; /* Improves font rendering on WebKit browsers. */
    -moz-osx-font-smoothing: grayscale; /* Improves font rendering on Firefox. */
    /* Base background and text colors for light and dark modes. */
    @apply bg-slate-50 text-slate-900 dark:bg-slate-900 dark:text-slate-200;
    /* Smooth transition for color changes (e.g., theme toggle). */
    @apply transition-colors duration-300 ease-in-out;
    /* Default base text size. */
    @apply text-base;
    /* Ensures smooth scrolling behavior even when focus jumps within the page. */
    @apply focus-within:scroll-smooth;
  }

  body {
    /* Ensures the body takes at least the full viewport height and enables sticky footer layout. */
    @apply flex min-h-screen flex-col;
    /* Default text size and line height for body content, enhancing readability. */
    @apply text-base leading-relaxed;
  }

  main {
    /* Allows the main content area to expand and push the footer down. */
    @apply flex-grow;
  }

  /* Headings: Consistent serif font, balanced line wrapping, defined margins. */
  h1, h2, h3, h4, h5, h6 {
    font-family: var(--font-serif); /* Applies the serif font to headings. */
    text-wrap: balance; /* Improves text wrapping for multi-line headings. */
    @apply font-bold leading-tight text-slate-900 dark:text-slate-100; /* Base heading text styling. */
    @apply mt-0; /* Resets browser default top margin for consistent spacing control. */
  }

  /* Specific heading level styling (size, margin, border). */
  h1 { @apply text-4xl sm:text-5xl lg:text-6xl border-b border-slate-300 dark:border-slate-700 pb-3 mb-8; }
  h2 { @apply text-3xl sm:text-4xl lg:text-5xl mt-12 mb-6; } /* Increased top margin for sections. */
  h3 { @apply text-2xl sm:text-3xl lg:text-4xl mt-10 mb-5; } /* Increased top margin for sub-sections. */
  h4 { @apply text-xl sm:text-2xl lg:text-3xl mt-8 mb-4; }
  h5 { @apply text-lg sm:text-xl lg:text-2xl font-semibold mt-6 mb-3; }
  h6 { @apply text-base sm:text-lg lg:text-xl font-semibold text-slate-700 dark:text-slate-300 mt-5 mb-2; } /* Adjusted contrast for h6 */

  p {
    /* Default bottom margin for paragraphs, constrained width for optimal reading length. */
    @apply mb-6 max-w-prose;
  }
  /* Removes bottom margin from the *last* child element within common containers to prevent double spacing. */
   *:where(article, section, aside, main, div, blockquote, li) > :last-child {
      @apply mb-0;
   }

  a {
    /* Base link styling with high-contrast colors and subtle underline. */
    @apply font-medium text-blue-600 dark:text-blue-400;
    @apply decoration-blue-600/60 dark:decoration-blue-400/60 underline decoration-2 underline-offset-2;
    @apply transition duration-150 ease-in-out;
    /* Enhanced hover state with higher contrast and wavy underline. */
    @apply hover:text-blue-800 dark:hover:text-blue-300 hover:decoration-current hover:decoration-wavy;
    /* Focus styles are handled globally by *:focus-visible below. */
  }

  /* List styling */
  ul, ol {
     /* Consistent bottom margin, indentation, and spacing between list items. */
     @apply list-outside mb-6 pl-5 space-y-2;
  }
  ul { @apply list-disc; } /* Default unordered list style. */
  ol { @apply list-decimal; } /* Default ordered list style. */
  li::marker {
     /* Styling for list markers (bullets/numbers). */
     @apply text-slate-500 dark:text-slate-400 font-semibold;
  }

  blockquote {
    /* Distinct styling for blockquotes: border, padding, background, text color, rounded corner. */
    @apply border-l-4 border-blue-400 dark:border-blue-600 pl-5 pr-4 py-4 my-8 italic bg-blue-50/70 dark:bg-slate-800/60 text-slate-700 dark:text-slate-300 rounded-r-lg shadow-sm;
  }

  hr {
    /* Horizontal rule styling with increased margin for separation. */
    @apply border-t border-slate-300 dark:border-slate-700 my-12;
  }

  code {
    /* Styling for inline code snippets: background, padding, font, border. High contrast text. */
    @apply bg-slate-200/80 dark:bg-slate-700/80 text-sm px-1.5 py-1 rounded font-mono break-words text-slate-800 dark:text-slate-200 border border-slate-300/50 dark:border-slate-600/50;
  }

  pre {
      /* Styling for preformatted text blocks (code blocks): dark background, padding, rounded corners, overflow handling. */
      @apply bg-slate-800 dark:bg-gray-950/70 p-4 rounded-lg overflow-x-auto text-sm leading-relaxed my-8 shadow-md border border-slate-700 dark:border-gray-700/80 backdrop-blur-sm;
  }
  pre code {
     /* Resets inline code styles within <pre> blocks for proper code highlighting. */
     /* Ensures high contrast for code within pre blocks. */
     @apply block bg-transparent p-0 rounded-none text-inherit border-none shadow-none font-mono whitespace-pre text-slate-200 dark:text-gray-300;
  }

  /* Ensures images and media elements are responsive by default. */
  img, video, svg, canvas {
      @apply max-w-full h-auto block align-middle;
  }

  /* --- Global Accessibility Focus --- */
  /* Applies a consistent, high-contrast focus ring for keyboard navigation. */
  /* Uses focus-visible to avoid showing rings on mouse clicks. */
  *:focus-visible {
     @apply outline-none ring-2 ring-offset-2 ring-blue-500 dark:ring-blue-400 ring-offset-white dark:ring-offset-slate-900 rounded-sm; /* Standard rounded focus */
  }
  /* Removes the default browser outline only when focus is *not* triggered by keyboard (i.e., likely mouse clicks). */
   *:focus:not(:focus-visible) {
      @apply outline-none;
   }
}

/* 6. Define Reusable Components */
/* Defines styles for common UI patterns. */
@layer components {
  /* Skip Link Component: Visually hidden until focused. */
  .skip-link {
    @apply sr-only;
  }
  .skip-link:focus {
    /* Styles to make the skip link visible and usable when focused. */
    @apply not-sr-only absolute top-2 left-2 z-[9999] px-4 py-2 bg-white dark:bg-slate-800 text-blue-700 dark:text-blue-300 font-semibold rounded shadow-lg;
    /* Focus ring appearance is handled by the global *:focus-visible rule. */
  }

  /* Example Card Component Style (If needed for reuse outside of specific page implementations) */
  .card {
      @apply bg-white dark:bg-slate-800 border border-slate-200 dark:border-slate-700 rounded-lg shadow-sm p-6 transition hover:shadow-md;
  }
}

/* 7. Define Custom Utilities (if needed) */
/* For highly specific, reusable utility classes not covered by Tailwind. */
@layer utilities {
  /* Example: A utility to apply text balancing. */
  /* .text-balance { text-wrap: balance; } */
}

